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ABSTRACT 
The term glioma encompasses brain tumours arising from the glial cells. Malignant 
glioma are characterised by a rapid growth rate and high capacity for invasive 
infiltration to surrounding brain tissue, hence diagnosis and treatment is difficult, and 
patient survival is poor. Aptamers are small molecular ligands composed of short 
oligonucleotides that bind to a target with high specificity and affinity. They are 
produced in vitro through a method called systematic evolution of ligands by 
exponential enrichment (SELEX).  
 
The aim of the study was to examine the binding selectivity of DNA aptamers on 
commercial glial cell lines and primary glioma tissues. RNA aptamers and their DNA 
homologues (SA44, SA43, SA56) were selected for study which showed strong binding 
affinity to the target U87MG cells as measured by flow cytometry. SA44 and SA43 
showed higher uptake and cytoplasmic localisation in U87MG and 1321N1 glioma cell 
lines compared to non-cancerous SVGP12 cells and non-glioma MCF-7 and T24 cells 
as measured by confocal microscopy. The data was confirmed quantitatively by flow 
cytometry analysis, which showed that the aptamers were able to actively internalise in 
U87MG and 1321N1 tumorigenic cells compared to the non-cancerous and non-glioma 
cell types. Histochemistry staining on paraffin embedded, formalin fixed patient tissues 
revealed that the binding selectivity was found to be significantly higher for only SA43 
aptamer (p < 0.05) in glioma tissues (grade I, II, III and IV) compared to the non-
cancerous and tissues. Aptamer SA43 also showed cell type selectivity within the tissue.  
 
The results indicate that SA43 aptamer can differentiate between glioma and non-
cancerous cells and tissues and therefore, show promise for histological diagnosis of 
glioma and targeted delivery. In the future, targeting tumour cells and tissues through 
the use of SA43 aptamer will help develop molecular imaging, targeted delivery by 
reduction of the non-specific toxicity of chemotherapy and selectively directing anti-
cancer drugs to tumour cells. 
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CHAPTER 1 INTRODUCTION 
1.1 Introduction to CNS tumours 
Oncogenesis, the development of tumour cells, involves breakdown of the control of 
normal cell growth, somatic mutations such as activation and over-expression of proto-
oncogenes (Tyagi et al., 2002), inactivation and decreased expression of tumour-
suppression genes (Maslon and Hupp, 2010; Rivlin et al., 2011) and alteration in 
mutator genes. These factors have been associated with oncogenesis of all tissues 
including those within the central nervous system (CNS). Primary CNS tumours consist 
of a varied group of neoplasms, which are derived from several different cell lineages. 
Despite major advances in surgical and clinical neuro-oncology, there are still 7000 
people in the UK diagnosed with brain cancer per year and it remains the 10
th
 most 
common cancer in men and 13
th
 in women (Ohgaki and Kleihues, 2005). Brain tumours 
derived from the intracranial tissues and meninges vary in malignancy ranging from 
benign to aggressive (Mckinney, 2004). The benign tumour can infiltrate and spread 
locally and give rise to a malignant tumour. Malignant tumours of the brain are of rare 
occurrence and account for approximately 2 % of all cancers in adults (Mckinney, 2004; 
Sehmer et al., 2014).  
During the past two decades, tremendous efforts in diagnosis and treatment have been 
made in the field of brain tumour biology with a main focus on malignant glioma and 
medulloblastoma, which are the most common CNS cancers of adults and children, 
respectively (Huse and Holland, 2010). It has been reported that, glial cells (mature 
astrocytes or oligodendrocytes) may differentiate in response to genetic mutations (refer 
to section 1.6) and undergo neoplastic transformation leading to gliomagenesis 
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(Hambardzumyan et al., 2008).  
1.2 Glioma 
The term glioma encompasses all tumours that are thought to be of glial cell origin, and 
are the most frequent brain tumour observed (Schwartzbaum et al., 2006; Ricard et al., 
2012; Sehmer et al., 2014). Glioma account for more than 80 % of the primary 
malignant brain tumours out of which, glioblastoma multiforme (GBM) is the most 
frequent type with the poorest survival rate of all the groups (Ohgaki and Kleihues, 
2005; Ricard et al., 2012). As an aggressive malignant type of cancer, glioma often 
results in deaths of the affected patients within one to two years following diagnosis 
(Ricard et al., 2012; Sehmer et al., 2014).  
 
Gliomas can arise from neural stem cells or de-differentiated mature neural cells 
(Ignatova et al., 2002; Singh et al., 2004; Hambardzumyan et al., 2008), or from 
progenitor cells (Persson et al., 2010), which transform into cancer stem cells. These 
cancer stem cells (CSCs) constitute a heterogenous group of undifferentiated neoplastic 
cells with properties such as pluripotency, tumorigenicity at low cell numbers, and 
recapitulation of phenotypic and histological characteristics of the original tumour (Lee 
et al., 2006; Hatiboglu et al., 2010). It has been postulated that glioma CSCs (gCSCs) 
play an essential role in tumour initiation, proliferation, progression, metastasis, 
recurrence and resistance to therapy (Hatiboglu et al., 2010).  
1.3 Risk factors 
The incidence of malignant brain tumour in the UK averaged for 8.1 per 100,000 males 
and 5.3 per 100,100 females every year. The overall annual incidence rate of brain 
tumours in the UK population is 6.5 per 100,000 (Mckinney, 2004; Ricard et al., 2012; 
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Sehmer et al., 2014). These statistics have remained almost constant in the past 10 
years. Eighty-six percent of these tumours have been accounted for glioma. The risk 
factors for the cause of glioma are poorly understood, which is problematic for 
developing prevention strategies. As shown in table 1, environmental factors such as 
various occupations, diet (N-nitro compounds) and environmental carcinogens have 
been reported to be involved with small increased risk for developing glioma, but 
therapeutic X- ray radiation seems to be associated with a high risk of developing 
glioma (McKinney, 2004; Ohgaki and Kleihues, 2005).  
Table 1.1 List of environmental risk factors for brain tumours investigated in 
epidemiological studies (McKinney, 2004; Ohgaki and Kleihues, 2005). 
Factors Specific aspects Evaluation of risk 
Occupations Vinyl chloride, use of rubber and 
plastic products, petroleum refining. 
Small risks but no mechanism or 
specific chemical known. 
Diet N-Nitro compounds such as 
Nitrosamide/ Nitrite/ Nitrate 
consumption, Aspartame, high intake 
of cholesterol, sodium, etc. 
Small risk of glioma. 
Ionising 
radiation 
Therapeutic X-irradiation (dose) High risk of glioma. 
Electromagnetic 
fields 
Residential and occupational 
exposure. 
Weak association and little 
consistency, but research is 
ongoing. 
Head injury Trauma No consistent evidence 
Allergy and 
immunological 
conditions 
Atopy Small risk of glioma, further 
work needed to identify 
mechanisms. 
  
Although these environmental risk factors have also been associated with glioma brain 
tumour, no conclusive evidence has been produced to date. Several familial cancer 
syndromes such as Li-Fraumeni syndrome (TP53 germline mutations), Turcot 
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syndrome (APC germline mutation), Neurofibromatosis 1 (NF1) and 2 (NF2) have also 
been reported to be associated with brain tumours (Ohgaki and Kleihues, 2005). 
1.4 Diagnostic imaging of glioma 
Brain magnetic resonance imaging (MRI) with or without contrast agents is the most 
sensitive and commonly preferred diagnosis modality of choice when a brain tumour is 
suspected, however, patients are often initially screened with a computed tomography 
(CT) x-ray scan (Grossman, 2003; Osborn et al., 2004). CT x-ray imaging of malignant 
glioma typically show an irregular isodense (abnormality with same density as reference 
structure) or hypodense (less dense than the reference structure) mass with central 
hypodensity (representing the necrotic core), vascular infiltration of the tumour and 
vasogenic oedema. Vasogenic oedema is considered an indicator of the presence of 
tumour cells invading the parenchymal vasculature and releasing vascular permeability 
factors (Grossman, 2003). With contrast agents, the lesions appear with a heterogeneous 
(non-uniform) rim of enhancement in 95 % of such cases indicating the highly 
infiltrative nature of glioma.  
Malignant glioma observed using MRI display image contrasts that are weighted to 
demonstrate different anatomical structures and presence of tumour (Figure 1.1). Each 
tissue returns to its equilibrium state after excitation by independent processes of T1 and 
T2 relaxation. Malignant glioma observed using MRI often appear as irregular lesions 
with cysts like appearance and irregular thick margins that are isointense or hypointense 
on T1-weighted images (Differences in T1 relaxation time, spin-lattice relaxation). 
Enhancement with gadolinium contrast agent shows lesions with a highly proliferative 
tumour region surrounding the central necrotic core and white matter indicating oedema 
(Provenzale et al., 2006).  
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Figure 1.1 Brain imaging of GBM. Brain imaging from a 56 year old man who 
presented with headache, nausea, left hemiparesis, and left hand paresthesis that 
developed over the course of 3 weeks. Histological diagnosis was consistent with GBM. 
Arrows indicate region showing imaging by CT scan without contrast (A), and MRI 
which included non-contrast T1W1 showing a poorly delineated mass lesion (B), 
FLAIR (fluid attenuation inversion recovery) showing areas of hypersignal extending 
beyond the areas of contrast enhancement (C), and T1 with gadolinium contrast 
heterogeneously enhancing cystic/necrotic lesion (D), (Taken from Sonabend et al., 
2010). 
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T2-weighted images (differences in T2 relaxation time, spin-spin relaxation) and fluid 
attenuation inversion recovery (FLAIR) sequences demonstrate heterogeneous 
hyperintense lesions with surrounding vasogenic oedema and are specially employed in 
the assessment of tumour recurrence (Ludemann et al., 2001). Novel promising imaging 
modalities such as perfusion MRI (information on tumour blood volume and vascular 
permeability; Barajas et al., 2009), proton MR spectroscopy (differentiate high grade 
glioma from metastases; Server et al., 2010), and positron emission tomography (PET, 
detecting glioma recurrence; Deng et al., 2013) have potential implications for 
diagnosis of glioma.  
1.5 The WHO based classification of glioma 
The tumours of the CNS have been differentiated and classified according World Health 
Organisation (WHO) (Louis et al., 2007) with emphasis on morphological and 
immunohistochemical features including molecular pathogenesis such as cellularity, 
mitotic activity, microvascular proliferation and necrosis (Table 1.2). According to the 
classification, gliomas are categorised according to their grade, cell type, and location of 
the tumour. These include astrocytic tumours, namely, WHO classification grades I and 
II (astrocytoma), III (anaplastic astrocytoma) and IV (glioblastoma multiforme or 
GBM); oligodedrogliomas; ependymomas and mixed gliomas (Louis et al., 2007). 
Grade I gliomas generally behave in a benign fashion and also can be circumscribed, 
whereas grade II-IV gliomas can diffusely infiltrate throughout the brain. The most 
frequent primary intracranial tumours diagnosed are diffuse gliomas comprised of 
astrocytic, oligodendroglial and ependymal lesions. The process of tumour progression 
from lower grade to higher grade is accompanied by the accumulation of genetic 
alterations resulting in heterogeneity at the histologic, biologic, and molecular levels.
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Table 1.2 Histological classification of diffuse gliomas and their overall survival 
(Louis et al., 2007; Ricard et al., 2014).  
Phenotype  Grading  Median 
survival 
(years) Differentiation  Cell density Mitotic 
activity  
Necrosis Microvascular 
proliferation  
Astrocytoma 
Grade 
II 
Fibrillary neoplastic 
astrocytes  
Well 
differentiated 
Moderate  Generally 
absent 
Absent Absent 
 
6-8 
Grade 
III 
Fibrillary neoplastic 
astrocytes 
Regional or 
diffuse anaplasia  
Regionally 
or diffusely 
increased  
Present Absent  Absent 
 
3 
Grade 
IV 
Pleomorphic astrocytic 
tumour cells  
Poor High Marked  Present Prominent 1-2 
Oligodendroglioma  
Grade 
II 
Monomorphic cells, 
uniform round nuclei 
Well 
differentiated 
 
Moderate Absent or 
occasion-
al mitosis 
Absent or 
not clearly 
visible 
Not prominent  12 
Grade 
III 
Monomorphic cells, 
uniform round nuclei 
Regional or 
diffuse anaplasia  
 
Increased  Usually 
prominent 
Possible Often 
prominent  
3- >10 
Mixed oligoastrocytoma  
Grade 
II 
Neoplastic glial cells 
with astrocytic or 
oligodendroglial 
phenotypes  
Well 
differentiated 
 
Moderate No or low  Absent Absent 
 
6 
Grade 
III 
Neoplastic glial cells 
with astrocytic or 
oligodendroglial 
phenotypes  
Anaplasia High High Absent 
(if present: 
GBMO) 
Might be 
present  
3 
GBMO- glioblastoma with oligodendroglial component  
 
 
Glioblastoma multiforme (GBM; WHO grade IV tumour) is the most malignant form of 
cerebral gliomas and accounts for approximately 50 % of such tumours (Louis et al., 
2007; Jung et al., 2007). GBM can occur as a high-grade lesion arising de novo from the 
glial cells (also known as primary GBM) representing more than 90 % cases of GBM 
cases (Zulch, 1986; Ohgaki and Kleihues, 2007). GBM can develop from a lower-grade 
precursor lesion, such as WHO grade II astrocytoma and WHO grade III anaplastic 
Chapter 1                                                                                                                      Introduction 
 
 
 
23 
astrocytoma (also known as secondary or progressive GBM) (Kleihues and Ohgaki 
1999; Jung et al., 2007). GBM can occur in all age groups, however, it is commonly 
observed in adults above 50 years in age. With optimal treatment, the overall five years 
survival of patients diagnosed with glioma in UK is approximately 1.2 % and the 
median survival is 12-14.5 months (Stupp et al., 2009; Sonabend et al., 2010; Sehmer et 
al., 2014). These incidence rates have remained constant over time during the last 
decade and also throughout all regions in UK. Factors affecting the survival changes 
include age, where younger groups fare better; gender, where males are more prone to 
develop glioma; and location and extent of tumour resection (Wen et al., 2008; Van 
Meir et al., 2010). A defining feature of GBM is poorly defined tumour border, which 
often results in incomplete resection of tumour and hence poor survival due to tumour 
recurrence (Van Meir et al., 2010).  
1.5.1 Limitations with current histological diagnosis 
Implementation of the WHO classification criteria plays a key role in the diagnosis 
glioma, however, classification is mostly based on subjective criteria and is variable 
among pathologists. This variability has also resulted to ambiguous diagnosis for some 
patients (van den Bent, 2010). In addition, the inability to anticipate individual patient 
outcome based solely on WHO classification has led to considerable research trying to 
understand the pathogenesis of glioma and to determine relevant prognostic biomarkers 
in terms of molecular alterations to accurately distinguish different grades of glioma 
(van den Bent, 2010; Ricard et al., 2014). Past studies have discussed the further 
characterisation of tumours by molecular and genetic markers, which can act as useful 
prognostic indicators for tumour therapy (Davis and McCarthy, 2001; Wrensch et al., 
2002; McKinney, 2004). 
Chapter 1                                                                                                                      Introduction 
 
 
 
24 
1.6 Advances in diagnosis of glioma 
The mechanisms underlying gliomagenesis have been ambiguous, but in recent years, 
considerable progress has been made in understanding the molecular genesis of 
gliomas. At the forefront of such development, the identification of 1p/19q codeletion 
and mutations involving the isocitrate dehydrogenase genes (IDH1 and/or IDH2) in 
specific tumour types has played a key role in classifying gliomas.  
 
For example, tumours that contain unbalanced reciprocal chromosomal translocation of 
19p to 1q have been associated with an oligodendroglial phenotype. Similarly, tumours 
that contain whole deletion of 1p in [t(1; 19)(q10; p10)] along with TP53 mutations 
have been associated with astrocytic phenotype (Idbaih et al., 2005; de Groot, 2013; 
Ricard et al., 2014). IDH1 and/or IDH2 mutations have been frequently identified in 
more than two-thirds of low-grade gliomas and anaplastic gliomas and also in 
secondary GBM, however, these mutations have been rarely identified (<10 %) in 
primary GBMs (Figure 1.2). In such cases, mutant IDH enzyme is unable to perform its 
normal activity in tricarboxylic acid  TCA  cycle to convert isocitrate into α-
ketoglutarate  αKG , which is responsible for DNA and histone demethylation. Instead, 
the mutant IDH enzyme acquires the ability to reduce αKG to oncometabolite 2-
hydroxyglutarate and not NADPH, which results in depletion of intermediates in TCA 
cycle. This leads to epigenetic alterations and induces hypoxia that affects gene 
expression thereby resulting in inhibition of cellular differentiation and promotion of 
angiogenesis and neoplastic growth (Cohen et al., 2013; Schaap et al., 2013; Ricard et 
al., 2014).  
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Figure 1.2 IDH1 immunohistochemistry using IMab-1 antibody (x 100). a Diffuse 
astrocytoma, b anaplastic astrocytoma, c anaplastic oligoastrocytoma, d secondary 
glioblastoma, e primary glioblastoma. Note that IDH1 expression was not seen in grade 
IV primary glioblastomas (Taken from Takano et al., 2011). 
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Primary GBM cases (> 90 % cases of all GBM) mainly affect elderly patients, and are 
genetically characterized by phosphate and tensin homolog (PTEN) mutations, EGFR 
amplification and p16
INK4A
 deletion (Figure 1.3). Secondary GBM (5 % cases) manifest 
mainly in younger patients and are often characterized by TP53 mutations with frequent 
G:C to A:T transitions at CpG (cytosine and guanine nucleotide in the linear sequence) 
sites. During progression to GBM, additional mutations occur; including, loss of 
heterozygosity (LOH) on chromosome 10q (10q25-qter) in both primary and secondary 
GBM (Ohgaki and Kleihues, 2007; Kakkar et al., 2011 Raudino et al., 2013). 
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Figure 1.3 Molecular and genetic characterization and pathways to primary and 
secondary GBMs at population level. *Frequency in genetic alterations differed 
significantly between primary and secondary GBMs (Ohkagi and Khlehieus, 2007; 
Raudino et al., 2013).  
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1.7 Establishment of tumour cell models 
Use of in vitro cell lines as a model for glioma has been an essential mainstay for 
studying glioma biology and response to therapy (Wang et al., 2005; Higgins et al., 
2010; Mullins et al., 2013). Advances in cell-based assay techniques have facilitated the 
progress and understanding of the cellular and molecular processes involved in tumour 
initiation and progression (Laerum et al., 2009). Cell culture has also been one of the 
fundamental tools for identification of novel therapeutic targets and high throughput 
screening of new chemical entities for desired pharmacological properties in drug 
design and development (Wang et al., 2005;  reslin and O‟Driscoll, 2013    
 
Cell culture models can be derived from primary human cells or immortalised human 
cell lines. Primary cultures are cells that have been isolated from human tissue 
resections, which may be further sub-cultured to form short-term cell lines with a finite 
replicative potential (Wang et al., 2005). Immortalised cell lines have an infinite 
replicative potential, induced following exposure of cells to viruses such as monkey 
simian virus 40 (SV40) T antigen. An advantage of human immortalised cell lines is the 
ease of growth and maintenance and the consistency and reproducibility of the results 
obtained from a single cell type (Schindler, 1969; Wang et al., 2005; Mullins et al., 
2013). A number of human malignant glioma cell lines were first developed by Poten 
and Westermark in the mid-1960s and 1970s and since then, a large number of well 
characterised cell lines for the major categories of brain tumours have been developed 
(Westermark, 1973; Poten, 1978; Masters and Palsson, 1999).  
1.7.1 Applications of glioma cell lines to model human gliomas 
Applications of GBM cell lines to model human gliomas have provided new 
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fundamental insight into potential and novel targets for therapeutics in cancer research. 
GBM cell lines have been used as a simple model system for glioma and have helped in 
finding new diagnostic and therapeutic modalities for these tumours. Various glioma 
derived cell lines such as 1321N1, U87MG, U251MG, GOS-3, TB10, LN-18, LN-229, 
T98G, and A172 have different malignant phenotypes and distinct genetic backgrounds. 
For example, U87MG (wild-type p53) and T98G (mutant p53) cell lines are both highly 
malignant and share similar altered cellular pathways, however, differ in the potential to 
form tumours in nude mice, with U87MG being highly tumorigenic in vivo (Cerchia et 
al., 2009; Ramao et al., 2012). U87MG also harbour higher levels of ErbB2 and 
phosphorylated extracellular signal- regulated protein kinase (ERK) than T98G (Cerchia 
et al., 2009). The glioma cell culture models are more valuable to pharmaceutical 
scientists for evaluating new chemical entities as potential targets (Wang et al., 2005; 
Mullins et al., 2013).  
1.7.2 Applications of pathological tissues to model human glioma 
One of the common procedures for cancer detection relies on the examination of tissue 
from biopsies, which are fixed under chemical conditions to preserve the integrity and 
antigenicity of tumour samples for later use. An important assay in examining cancer 
tissues is immunostaining, which can provide valuable diagnostic information for 
determination of malignancy. From fixed tissue, cancers have been categorised, 
subtyped and features enumerated to help elucidate the differences that exist between 
them. Several glioma related studies have used human tissue specimens as the primary 
source of investigational material for studying various prognostic markers involved in 
glioma (Dong et al., 2005; Kalinina et al., 2010; Sipayya et al., 2012). They offer 
advantages over cell lines because they are more representative of the diagnosed 
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condition, not having undergone numerous passages and are reflective of the in vivo 
condition.  
1.8 Current treatment strategies for malignant glioma 
The treatment of glioma, especially GBM remains difficult because no contemporary 
treatments have been curative (Preusser et al., 2011). Multiple challenges for treating 
glioma persist because of the tumour heterogeneity, tumour location in the region where 
it is beyond the reach of local control, and rapid tumour relapse. While overall mortality 
rates remain high, recent work in the management of glioma combined with clinical 
trials are leading to more promising and tailored therapeutic approaches. Currently 
management of glioma is carried out in three modalities including surgery, 
radiotherapy, and chemotherapy.  
1.8.1 Surgery 
The aim of brain tumour surgery is to maximise the removal of neoplastic tissue and 
minimise collateral damage to surrounding normal brain as well as vascular structures. 
Studies on glioma resection based on functional neuroimaging (MR imaging and 
magnetoencephalography), functional brain mapping and monitoring (fibre-tracking 
technique) (Mikuni and Miyamoto, 2010); and other functional neurosurgery methods 
such as neuro-navigation (Panciani et al., 2012) and awake surgery (Yordanova et al., 
2011) are being reviewed to gain better treatment outcome. Combining these methods 
will allow safe and effective resection and may result in successful treatment. 
Conventional fluorophores and chromophore dyes have been used to identify tumour 
margins and have improved the extent of resection. Several studies also demonstrated 
that fluorescence imaging could be used to facilitate radical resection of glioblastoma 
during surgery (Laws et al., 2003; Stummer et al., 2006; Zhou et al., 2009). The 
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discovery of photodynamic therapy  PDT  during 1980‟s involved the excitation of 
porphyrin derivatives to allow selective destruction of a tumour by means of apoptosis 
induced by cytochrome C. Photosensitisers such as 5-aminofluoresceinalbumin and 
mono-L-aspartyl chlorine have been used extensively in research. Stummer et al., 
(2006) assessed the effect of fluorescence-guided resection with photosensitiser 5- 
aminolevulinic acid (5-ALA) on surgical radicality and demonstrated that intraoperative 
fluorescence imaging facilitated gross total resection and improved the prognosis of 
patients. Surgical treatment has therefore remained an important tool for the 
management of patients with GBM, however, complete surgical resection still continues 
to be the goal to reduce severe neurological, regional and systemic complications 
(Reardon and Wen, 2006; Lassen et al., 2012; Wong et al., 2012). 
1.8.2 Radiotherapy 
Radiotherapy, an ionising radiation mainly affects rapidly dividing cells and is 
administered in short doses (fractions) to allow normal tissue to recover while rapidly 
dividing cells suffer an irreparable damage to DNA, cellular organelles and membranes 
thereby inducing cell death. Currently, the standard care for patients with newly 
diagnosed GBM includes maximal safe resection of the tumour followed by adjuvant 
radiotherapy (typical therapeutic dose of 60 Gy in 30 fractions) combined with 
chemotherapy (Stupp et al., 2005; Mikuni and Miyamoto, 2010). The use of intensity-
modulated and focal radiotherapy techniques has been increasingly preferred, however, 
because of the infiltrative diffusive nature of malignant glioma, there is currently a 
limited defined role for stereotactic radiosurgery or brachytherapy as first-line of 
treatment (Tsao et al., 2005).  
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1.8.3 Chemotherapy 
Several chemotherapetuic drugs including, tamoxifen (Brandes et al., 1999), 
temozolomide (MacDonald, 2001; Strik et al., 2008; Taal et al., 2012), platinoids 
(Jeremic et al., 1992; Francesconi et al., 2010), topoisomerase inhibitors such as 
etoposide and irinotecan (Santisteban et al., 2009), and procarbizine and vincristine 
(Schmidt et al., 2006) are currently employed for the treatment option for glioma, with 
temozolomide paying special attention.  
 
Temozolomide (TMZ), an alkylating agent is currently the most primarily used 
chemotherapeutic drug, given its ability to penetrate the blood brain-barrier and its 
acceptable toxicity profile. Analysis of patients with a tumour displaying promoter 
methylation of the DNA repair enzyme O
6
-methylguanine-DNA methyltransferase 
(MGMT) were most likely to have better prognosis with the addition of temozolomide 
to radiotherapy due to silencing of the DNA repair gene (Hegi et al., 2005). GBM 
tumours carrying a non-methylated promotor (40-55 % of cases) responded poorly to 
TMZ dose (Hegi et al., 2005; Sadones et al., 2009), due to the functional MGMT 
enzyme repairing TMZ induced damage.  
 
Carmustine or bis-chloroethlynitrosourea (BCNU) implants are biodegradable wafers 
implanted into the resected tumour area at surgery with the aim of improved 
chemotherapeutic targeting and passing the blood brain barrier (BBB). The 
biodegradable discs, Gliadel, infused with carmustine were approved by FDA in 2002. 
Though approved for treatment, the National Institute of Clinical health Excellence 
(NICE) appraisal noted no overall improvement in treatment response between patients 
treated with carmustine implants and patients treated with placebo at tumour resection 
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(Macbeth, 2007). The mean survival gain was however, observed for patients who had 
greater than 90 % tumour resection. NICE has therefore approved the use of carmustine 
implants in the conditional basis of greater than 90 % tumour resection, which is often 
unachievable in higher grade glioma due to the infiltrative nature (Macbeth, 2007). 
Moreover, carmustine wafers have also shown adverse effects in patients such as 
increased rates cerebrospinal fluid (CSF) leak and increased intracranial pressure 
secondary to oedema and mass effect (Gutenberg et al., 2013).   
1.9 Novel chemotherapeutics and issues identified while targeting and 
treating glioma 
The progress in genomics has provided the means for identification of novel targets and 
has enhanced progress in drug development and therapeutic regimes Molecular 
targeting has been one of the novel approaches in the diagnosis of glioma as mentioned 
above. This approach is based on identifying a population of glioma cancer cells, which 
may express a unique receptor or antigen to be used as a targeting molecule for 
therapeutic purposes (Licha and Olbrich, 2005). 
 
A large number of inhibitory agents targeting receptor tyrosine kinases such as 
epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor 
(VEGFR) and platelet derived growth factor receptor (PDGFR) along with transduction 
pathways inhibitors directed towards mTOR, PI3K, and histone deacetylase (HDAC) 
have also been evaluated in patients; however, the response rates have been variable and 
unpredictable (Table 1.3). Previous studies have identified a new mutant receptor of 
epidermal growth factor receptor (EGFR) known as EGFRvIII, which contains a unique 
polypeptide sequence with deletion of 269 amino acids and was expressed on several 
Chapter 1                                                                                                                      Introduction 
 
 
 
34 
malignant cells including GBM, but absent in non-cancerous healthy cells (Wickstrand 
et al., 1995; Nash et al., 2001; Sampson et al., 2009). Although this initially appeared to 
be a unique marker of GBM, it was subsequently found that only 30 % of GBMs 
overexpressed EGFRvIII (Johnson et al., 2012).  
 
Table 1.3 Selected agents tested in recurrent GBM.  
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Over expression of the receptors for Interleukin (IL)- 4R and IL-13R on various human 
brain tumour cells have also been identified (Debenski et al., 1999). Studies on glioma 
found IL 13R2 was also highly expressed by GBM tumours. Interestingly, this receptor 
was found to be absent in normal brain tissues and therefore represented as a tumour-
specific antigen for GBM, which may prove useful for diagnosis and imaging for 
patients with glioma (Debinski et al., 1999; Mintz et al., 2000; Nash et al., 2001). These 
markers may potentially act as tumour associated targets (Kawakami et al., 2002; Joshi 
et al., 2003). This finding offered a novel approach to target malignant glial cells while 
sparing normal cells; however, the over-expression of the IL was not consistent due to 
the inherent heterogeneity of GBM (Liu et al., 2003). 
 
Vascular endothelial growth factor (VEGF) is a highly specific mitogen for vascular 
endothelial cells and induces endothelial cell proliferation, promotes cell migration, and 
inhibits apoptosis. The binding of VEGF to its receptor on blood vessels, promotes the 
proliferation, migration and survival and permeability of endothelial cells which forms 
building blocks of new vascular network for a malignant tumour (Ferrara et al., 2003). 
Several studies have demonstrated the prevalence of VEGF expression and its isoforms 
and therefore have served as an important mediator of intense angiogenesis, which is a 
characteristic of glioblastoma (Oka et al., 2007; Takano et al., 2010; Xu et al., 2013). A 
recent study demonstrated that VEGF is mainly expressed on the cell surface and also 
internalised in the early endosome compartment of the cytoplasm of the CD133
+
 human 
glioma stem-like cells (GSCs) (Hamerlik et al., 2012). 
 
Bevacizumab (Avastin), an anti-VEGF inhibitor (FDA approved, 2009), has been 
studied in combination with radiotherapy and chemotherapy for potential use in 
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treatment of recurrent malignant glioma (Figure 1.4). It was also reported that 
combining bevacizumab with radiotherapy/temozolomide demonstrated improved 
quality of life, diminished steroid requirement, and statistically significant improvement 
in progression free survival (PFS) but not overall survival (Cloughsey et al., 2006; 
Gilbert et al., 2014). The results were encouraging, however, there is not enough 
available clinical trial data that provide convincing evidence that such combination 
therapy is superior to a single agent approach (Zhang et al., 2012; Gilbert et al., 2014). 
Moreover, prolonged treatment with bevacizumab has potential for serious adverse 
effects, with moderate survival benefit (Friedman et al., 2009; Reardon et al., 2012; 
Gilbert et al., 2014).  
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Figure 1.4 Brain MRI image (FLAIR, axial plane) of a 44 years old man with 
recurrent GBM. Note significant amount of tumour associated vasogenic oedema 
(arrows) and the midline shift (shift of the brain past its centre line). After treatment 
with bevacizumab, midline shift was resolved and amount of oedema significantly 
decreased leading to clinical improvement (Taken from Mrugala, 2013).  
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1.10 Future approaches towards targeting and treating glioma 
Several studies have demonstrated that current therapies are limited by ineffective early 
diagnosis, insufficient drug concentrations reaching the tumour, drug toxicity, and poor 
therapeutic monitoring. There have been several cases, especially in diffusely invasive 
brain tumours, where a significant amount of residual tumour persists even after total 
resection (Albayrak et al., 2004; Doherty, 2010). In addition, several aspects such as 
size of the therapeutic molecule, lipophilicity, presence of active efflux pumps and most 
importantly, integrity of the blood-brain barrier that is typically damaged by the 
invasive GBM have a great impact on drug access to CNS tumours (Neuwelt et al., 
2011). Major improvements in molecular imaging in a non-invasive manner are 
required to help with the early detection of disease and to help achieve gross total 
resection, and hence improve the outcome for the patient. 
 
The rapid development of novel technologies for molecular diagnostics and tumour-
targeted therapy has enabled the development of highly specific ligands for targeting 
cell surface or internalised molecules that are expressed differently in tumour cells and 
tissue (Cerchia and Franciscis, 2010; Yu et al., 2011, Yu et al., 2012). Recent advances 
in studying intercellular and intracellular biochemical process has significant impact on 
cell imaging and drug delivery (Cibiel et al., 2011; Esposito et al., 2014). Novel 
technologies including single molecular imaging, fluorescence resonant energy transfer 
(FRET) and gene regulation have greatly contributed to our understanding towards 
cellular functions and drug delivery (Xing et al., 2012). The intrinsic heterogeneity in 
human tumours has meant there is a need for targeting ligands that can help in the 
identification of tumour specific signatures. The goal of targeted therapy is to improve 
diagnostics, predicted therapeutic response and as a result, a decline in unnecessary 
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treatment of unresponsive oncological patients.  
 
Targeted drug delivery for cancer demands a ligand which can specifically carry the 
drug to cancer cells. A number of biological delivery systems have been used to 
selectively transport imaging probes to tumour cells with monoclonal antibodies 
receiving significant attention in the literature for more than three decades (Scott et al., 
2012). The anibody-drug conjugate (ADC) field have been developed for targeted 
delivery of potent anti-cancer drugs with the aim to deliver the cytotoxic drug to the 
target tumour cells and therefore passing the morbidity common to conventional 
chemotherapy. ADC consists of an antibody (or antibody fragment) linked to a 
biological active cytotoxic payload or drug  Three such ADC‟s received FDA approval 
including Gemtuzumab ozogamicin (Mylotarg
®
) (2001), Brentuximab vadotin 
(Adcetris
®, 
2011) marketed by Seattle Genetics, and trastuzumab emtansine (Kadcyla, 
2013) marketed by Genentech and Roche for the treatment of acute myelogenous 
leukemia, Hodgkin‟s Lymphoma and Her2+ metastatic breast cancer, respectively.  
 
Despite advances in this area, ADC still carry a number of limitations such as cancer 
cell specificity, tumour penetration, product heterogeneity, conjugation chemistry and 
manufacturing issues. For example, Gemtuzumab ozogamicin (Mylotag), FDA 
approved in 2001 for the treatment of patients with acute myelogenous leukemia was 
withdrawn from the market in June 2010 due to its significant side effects and 
negligible improvement in clinical benefit. Such limitations restrict the use of antibodies 
as drug carriers. By defining the advantages and disadvantages of ADC, it should be 
possible to develop a more rational approach to the application of targeted drug delivery 
strategies and develop therapies that are more effective for cancer patients.  
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The adoption of a new class of oligonucleotide- based molecular recognition elements 
have recently emerged as a rival of antibody based methods, serving an ever-increasing 
demand for versatility in the biomedical field.  
1.11 Historical review of aptamers 
Aptamers are short single stranded DNA or RNA oligonucleotides, and could be ideal 
targeting agents for cancer. The DNA or RNA oligonucleotides were termed as 
“aptamers” with etymology stemming from the Greek word “aptus” meaning “to fit” 
(Shangguan et al., 2008; Cibiel et al., 2011; Meyer et al., 2011). The highly defined 
three-dimensional structure of aptamers helps them to bind to their targeted molecules 
with nanomolar affinities and high specificity (Cerchia et al., 2009; Bayrac et al., 2011; 
Kong and Byun, 2013). Aptamers were discovered in the early 1990‟s  Ellington and 
Szostak, 1990), and were found to bind to a range of targets from small organic 
compounds (Mannironi et al., 1997), peptides (Nieuwlandt et al., 1995), amino acids 
(Geiger et al., 1996), proteins (Lupold et al., 2002) and cells (Cerchia et al., 2009). The 
speciality of aptamers is the small size, low immunogenicity, and low molecular weight 
(5-25 kDa), which correspond to binding affinity to targets in the low nanomolar to 
picomolar range. The specificity of aptamer – target binding was such that aptamers 
were shown to discriminate between closely related isoforms or different 
conformational states of the same targeted molecule (Cibiel et al., 2011; Liu et al., 
2013).  
 
Since their discovery, numerous aptamers have been engineered against various 
molecular targets and have been shown to exhibit inhibitory and modulatory activity 
towards their targets (Refer to section 1.16) (Keefe et al., 2010; Cibiel et al., 2011; Liu 
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et al., 2013). Some of the key features of aptamers include, functional immobilisation 
on various substrates, long-term chemical stability by chemical modification of bases, 
uniform labelling, for instance with biotin or fluorescence reporters, and the ability to 
recover native active conformation after denaturation.  
1.12 Secondary and tertiary structure of aptamers 
Aptamers are known to bind to target molecules on single stranded regions known as a 
„bulge‟ or „loop‟ which contribute to the spatial structure of binding (Hermann and 
Patel, 2000; Nery et al., 2009; Cibiel et al., 2011). Moreover, the overall structure is 
dominated by base pairings that are similar to those observed in the DNA double helix 
formation. The nucleotide sequence in an oligonucleotide chain allows Watson and 
Crick base pairing (guanine to cytosine, adenine to thymine/ uracil) as the single strand 
is folded back on itself. The folding pattern of such base pairing is known as the 
secondary structure of the aptamer (Figure 1.5, Klussmann, 2006; Bayrac et al., 2011).  
Ideally, an approximate knowledge of the aptamer secondary structure is required to 
understand and optimise the aptamer binding interactions with the target. The molecular 
recognition of aptamers results from intermolecular interactions such as stacking of 
aromatic rings, electrostatic and van der Waals interactions, or hydrogen bonding with a 
target compound (Hermann and Patel, 2000). 
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Figure 1.5 Secondary and tertiary structure depictions of aptamers. 
a) Secondary structure of a RNA aptamer showing coloured loops due to unpaired 
nucleotides and kinks due to mismatched bases (base pairs are indicated by „–„   The 
Watson-Crick interactions between aptamer and its ligand (circled) are depicted with 
dashed lines. b) Tertiary structure of the same RNA aptamer showing the binding site 
(red) where unbound bases in the loops binds to the target molecule. c) Exploded view 
of the binding site showing hydrogen bonding with the target molecule (red). (Taken 
from Klussmann, 2006).  
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The formation of unique three – dimensional structure by aptamers is mainly due to 
changing intramolecular base pairing, having a combination of stems, loops, 
quadraplexes, pseudoknots, bulges, and hairpins. Such unique properties of the 
aptamers justify them to be valuable for diagnostics, purification process, target 
validation, drug discovery, and therapeutic interventions (Cerchia and Franciscis, 2010; 
Esposito et al., 2011; Cibiel et al., 2011, Mencin et al., 2013).  
1.13 Generation of aptamers 
Over the past few years, considerable efforts have been made to improve the isolation 
and selection process for aptamers. The development of the Systemic Evolution of 
Ligands by Exponential enrichment (SELEX) process (first implemented at NascaCell 
IP Munic, Germany) in 1990 by Ellington and Szostak, significantly accelerated the 
generation of aptamers with a capacity of recognizing virtually any class of target 
molecules with high affinity and specificity. Since then several SELEX methods have 
been designed as the targets to generate aptamers conveniently and easily (Ellington and 
Szostak, 1990; Jayasena, 1999; Cerchia et al., 2009; Ababneh et al., 2013). During 
SELEX, general selection and amplification processes of nucleic acids are performed 
until the target interacting sequences dominate the population (Figure 1.6). A library of 
nucleic acid (DNA or RNA) molecules is incubated with the target and the non-binding 
sequences are partitioned away. The sequences with high affinity for the target are 
eluted and re-amplified by RT-PCR and transcription process to yield an enriched pool 
of molecules that bind to the protein of interest. Several rounds of selection (15-25) with 
increasingly stringent condition and amplification are performed to obtain high affinity 
target specific aptamers followed by cloning, sequencing, and characterization. 
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Figure 1.6 General scheme of cell-SELEX procedure.  
Aptamers can be obtained through an iterative selection process known as SELEX 
(systematic evolution of ligands by exponential enrichment) by using single-stranded 
DNA or RNA. An initial pool of 10
14
-10
15
 random oligonucleotide strands is subjected 
to binding with the target tumour cells. Unbound oligonucleotides are discarded and 
RT-PCR is performed to amplify the target-bound oligonucleotides. The target bound 
oligonucleotides are then subjected to counter-selection using control (non-cancerous) 
cells This time the unbound sequences are collected and amplified. This selection 
process is repeated 15-25 times using amplified oligonucleotides as a new pool. This 
way, aptamers having high specificity and affinity are screened. Diverse molecules can 
be the target of the SELEX, including metal ion, protein, and organic compound (Taken 
from Marolt et al., 2000). 
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During the selection process, the sequence diversity of oligonucleotide library is 
remarkably reduced and the overall affinity of the selected sequences increases in each 
successive SELEX. Once knowledge of particular aptamer sequence is elucidated, 
production can be easy and rapid via enzymatic in vitro transcription or chemical 
synthesis. Also, recent advances in selection processes and more detailed analysis of 
delivering nucleic acids to target cells and tissues should speed the process of drug 
development (Lee et al., 2006; Cerchia et al., 2009). Researchers have also developed 
in vivo SELEX, where instead of using in vitro cell-culture system, the whole 
experimental animal is used for aptamer generation (Mi et al., 2010; Cheng et al., 
2013).  
1.14 Aptamers versus antibodies 
Aptamers can provide an excellent alternative to antibodies as aptamers have high 
affinity and sensitivity, very low detection limits and no problems with batch-to-batch 
variation (Baldrich et al., 2004). Many experiments have compared aptamers and 
antibody based assays and has proven that aptamers show more accurate and specific 
results compared to antibodies (Blank et al., 2001; Zeng et al., 2010). Aptamers have 
also been used in ELISA- like assays and flow cytometry (Blank et al., 2001). The time 
required for the generation of aptamers is comparatively shorter than that to obtain 
monoclonal or polyclonal antibodies. To date, antibody-based assays have also been 
developed for in vivo applications but, in most cases, antibodies have failed to reach 
expected adequate sensitivity because of the toxicity profile in vivo (Descotes, 2009).  
 
The use of aptamers is currently limited to parenteral administration but has proven to 
be useful in animal models as mentioned in the previous sections. Aptamers have been 
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proven to address such requirements because of their small size and polyanionic nature, 
which help them to accumulate at the tumour site and show rapid blood clearance 
minimising their residence in liver and kidney. As a result of the small size (figure 1.7) 
and similarity to endogenous molecules, aptamers are thought to be poor antigens. In 
addition, aptamers include faster excretion than antibodies due to the small size and 
susceptibility to serum degradation when unmodified aptamers are used, however, this 
can be overcome by modifying the structure and adding stabilising groups (Refer to 
section 1.15). Clinical studies have confirmed that aptamers are thermally stable, have 
an unlimited shelf life, non-toxic and non-immunogenic molecules and so their 
applications have far exceeded the limitations (Table 1.4). 
 
 
Figure 1.7 Size comparison of an antibody and an aptamer (Taken from Lee et al., 
2006). 
Chapter 1                                                                                                                      Introduction 
 
 
 
47 
Table 1.4 Properties of aptamers versus antibodies (Blank et al., 2001; Proske et al., 2005; Lee 
et al., 2006).  
 
 Aptamers Antibodies 
Size (figure 1.7) Small, MW: 8-12 kDa Large, MW: 150 kDa 
Selection 
procedure 
The whole selection is a chemical 
process carried out in vitro and 
can therefore target any protein. 
 
The selection requires a biological 
system and therefore is difficult to 
raise antibodies to toxins or non- 
immunogenic targets which is not 
tolerated by animal. 
Working 
conditions 
Can select for ligands under a 
variety of conditions for in vitro 
diagnostics. 
Limited to physiologic conditions for 
optimizing antibodies for 
diagnostics. 
Activity Consistent activity regardless of 
batch synthesis. 
Activity of antibodies varies from 
batch to batch. 
Modifications Wide variety of chemical 
modifications to molecule for 
diverse functions 
Limited modifications of molecule 
Shelf-life Unlimited shelf- life Limited shelf-life 
Immunogenicity No evidence of immunogenicity  Significant immunogenicity 
 
1.15 Modification of oligonucleotide aptamers to improve their 
function 
One of the ultimate goals during aptamer selection is the biostability in clinical 
application; however, unmodified oligonucleotides per se are unstable in biological 
fluids due to enzymatic degradation or a short half-life (Gold, 1995; Dupont et al., 
2010). RNA aptamers are capable of forming a greater variety of spatial structures as 
compared with DNA aptamers, as a result of the presence of 2‟-OH groups. RNA 
aptamers are however, more sensitive to the action of cell nucleases and therefore, 
various strategies have been established to increase the serum stability by the 
introduction and modification of additional protective group (Wang et al., 2011; 
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Shigdar et al., 2013). One common chemical modifications involved are substitutions of 
the 2‟- hydroxyl group of the pyrimidine nucleotides with 2‟- fluoro or 2‟- amino 
although, 2‟- fluoro RNAs appear superior to 2‟- amino RNAs in terms of target 
affinity. Such modifications can improve the half – life considerably (Figure 1.8) 
(Esposito et al., 2011). Phosphate and base modification are also used for this purpose. 
LNA has been designed to structurally protect 2‟ site offering stability  In addition, 
amino, thiol and carboxyl are introduced to strengthen the oligonucleotide backbone. 
 
 
Figure 1.8 Modifications employed to improve the function and pharmacokinetic 
profile of aptamers. Such modifications can assist in stabilising the nucleic acids 
against enzymatic hydrolysis and renal filtration.  
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Recently, Pieve and his group performed a study on aptamers to improve the stability 
and provide resistance to nuclease degradation. They used 99mTc labelled anti-MUC 1 
(cell-surface mucin glycoprotein) aptamers (AptA and AptB) and conjugated with 
MAG2 and also modified their 3‟ end with an inverted thymidine. Such modification 
showed accumulation of the aptamer in the target tumour site along with reduced blood 
clearance (Pieve et al., 2009). 
 
Several authors have also conjugated polyethylene glycol (PEG) with aptamers to 
enhance the bioavailability and pharmacokinetic properties and increase the half-life of 
aptamers in vivo (Boomer et al., 2005; Guo et al., 2011). Aptamer anti-PDGF was 
conjugated with 40 kDa PEG to slow down the renal clearance thereby allowing the 
aptamer more time to perform its function (Floege, 1999). Similarly, Healy et al. (2004) 
conjugated an aptamer with 20 and 40 kDa PEG to increase its half-life in circulation.  
 
Due to the small size and presence of high covalent bond between the aptamers and 
targets, aptamers have a high detection range and thus reduce the number of false- 
positive signals. Aptamers are chemically synthesised, and therefore, modification can 
be performed at either 5‟ or 3‟- with any fluorescent dye or a chemical group or biotin 
using simple phosphoramidite chemistry without interfering with the aptamer binding to 
its target (Blank et al., 2001; Sefah et al., 2009; Jimenez et al., 2012).  
1.16 Applications of aptamers 
Aptamers are very effective tools owing to their easily modified chemical structure, 
specificity, non-immunogenicity, non-toxicity and wide range of targets and therefore, 
can be the ideal candidates for clinical application such as molecular imaging, target 
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diagnosis, cell detection, drug delivery, and therapeutic intervention.  
1.16.1 Aptamer based molecular imaging 
Along with in vitro imaging, aptamers have been successfully employed for in vivo 
imaging, thus providing many potential applications in biomedicine. These imaging 
systems can be categorised according to their energy source (photons, positrons, X-rays, 
or sound waves), their spatial resolution (macroscopic or microscopic), or to the type of 
information that can be obtained (anatomical, cellular or molecular). Imaging 
technologies such as optical imaging, stereotactic navigation and intraoperative MRI, 
CT (computed tomography), PET (positron emission tomography), and SPECT (single 
photon emission computed tomography) have shown promising approaches to improve 
the extent of resection (Doherty, 2010).  
1.16.1.1 Optical imaging 
Optical methods such as confocal imaging, multiphoton imaging, microscopic imaging 
and near-infrared imaging have been adapted for current cancer research (Laws et al., 
2003; Sefah et al., 2010; Lin et al., 2014) These optical methods represent tissue-
specific imaging and monitoring the progression of disease by utilizing new non-
invasive imaging modalities, radioligands and contrast agents. Aptamer based optical 
imaging is a cost effective imaging technique that typically uses fluorescent or 
bioluminescent probes and can be categorised as a direct targeting probes that is able to 
be activated (Hong et al., 2011). Several studies have been performed where simply 
conjugating a fluorescent molecule to the aptamer has proved to be a convenient way to 
image cellular target by fluorescence (Shi et al., 2010; Cui et al., 2011; Zhang et al., 
2012; Song et al., 2013).  
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The use of aptamers as in vivo imaging probe was studied by Hicke et al., (2006). In 
this publication, an aptamer generated against tenascin C (TTA1) was labelled with 
rhodamine red and 99mTc (radioisotope) to study uptake and biodistribution in 
glioblastoma (U251) and breast cancer (MDA-MB-436) cells by confocal microscopy 
and in vivo imaging, respectively. After intravenous injection, the aptamer showed 
accumulation in the tumour site within 10 min and by diffusion throughout tumour in 3 
h followed by rapid renal and hepatic clearance from the circulatory system (Hicke et 
al., 2006). The results were promising, and therefore encouraged the researchers to 
perform several more in vivo studies. 
1.16.1.3 MRI 
An approach by Dua et al., (2011) was carried out to test the potential of RNA aptamer 
A10 against prostate cancer in tumour imaging. The study was performed by 
conjugating the A10 aptamer with a thermally cross-linked super paramagnetic iron 
oxide nanoparticle (TCL-SPION). This nanoparticle is often used as a contrast agent in 
MRI imaging and has low systemic toxicity. In this study, the A10 aptamer allowed 
TCL-SPION to bind specifically to prostate cancer cells expressing prostrate specific 
membrane antigen (PSMA) thus enhancing the potential for tumour imaging 
capabilities of TCL-SPION to be localised to the prostate tumour (Dua et al., 2011). A 
multimodality-imaging probe based on the AS1411 aptamer was evaluated by Hwang et 
al., (2010). The biodistribution was studied by intravenously administering rhodamine 
labelled magnetic fluorescent nanoparticle conjugated to gallium-67 (67Ga) and 
nucleolin aptamer AS1411 into tumour bearing nude mice. The conjugates accumulated 
at the tumour site and also showed rapid blood clearance as observed by planar 
scintigraphic images and MRI (Hwang et al., 2010). 
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1.16.1.4 PET 
PET, a widely used molecular imaging modality measures the signal originated from the 
radioactive decay of neutron-deficient radioisotopes such as 
11
C, 
15
O, 
64
Cu and 
18
F that 
are intravenously injected into the body. PET imaging application was studied using 
64
Cu-labelled A10-3.2 PSMA specific RNA aptamer to enable radiolabeling for in vivo 
imaging of tumours (Rockey et al., 2011). In this study, the choice of chelators and 
radiolabeling parameters such as pH, temperature and aqueous conditions were 
investigated and found to be favourable for the development of 
64
Cu-labelled RNA-
based targeted agents for potential PET imaging. 
1.16.1.5 SPECT 
SPECT is a relatively new imaging technique similar to PET, however, the 
radionuclides used are Xenon-133, Technetium- 99 (99mTc), and Iodine-123 which 
have longer decay times than those used in PET. A study performed by Pieve et al., 
(2009) reported conjugation of radioactive substances to aptamers and antibodies 
showed quick distribution and rapid tumour uptake of the residual radioactive aptamers 
followed by clearance from the blood stream. This radionucleotide conjugation not only 
allowed for superior tumour imaging, but also decreased toxicity to healthy tissues that 
was often seen with radioactively labelled antibodies due to the slow clearance from the 
body. An example of the use of aptamers for in vivo imaging using SPECT was 
published by Charlton et al., (1997) where, aptamers that were generated against 
activated neutrophil elastase, NX21909, a marker for inflammation in rats, were 
conjugated with 99mTc, a metastable radioactive tracer. The results were compared 
with a negative control and the antibody counterpart, showing rapid clearance of the 
aptamer-radioactive tracer conjugate from circulation and higher signal-to-background 
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ratio.  
1.16.2 Aptamers for target identification 
The high binding affinity of aptamers to a target enables detection of cancer cells, 
resulting in early and sensitive diagnosis. Highly specific aptamers have been selected 
against a wide range of intracellular and extracellular targets such as tenascin-C (Hicke 
et al., 2001), IFN-γ-inducible CXCL10 chemokine (Marro et al., 2005), nucleolin 
(Hwang et al., 2010) or human epidermal growth factor receptor -3 (HER3) (Tan et al., 
2013). Table 1.5 lists some promising aptamers widely studied with the targets and 
clinical applications. 
Table 1.5 Promising aptamers involved in diagnostic imaging and treatment of 
various diseases.  
Name Nucleotide Target Clinical applications Reference 
TTA1 RNA Tenascin C Imaging (SPECT) Hicke et al., 2006 
AptA, 
AptB 
DNA Mucin Imaging (SPECT/ 
Optical) 
Pieve et al., 2009; 
Savla et al., 2011 
AS1411 DNA Nucleolin Imaging 
(MRI/SPECT/Optical) 
Hwang et al., 2010 
Kuo et al., 2014 
A10, 
A10-3, 
A10-3.2 
RNA PSMA Prostate cancer 
therapy 
Farokhzad et al., 
2006; Dhar et al., 
2008 
gp120 
aptamer 
RNA gp120 HIV therapy Neff et al., 2011 
CD30  RNA CD30 Imaging lymphoma  Zeng et al., 2010 
  
A new strategy for exploiting aptamers in the analysis of proteins and small molecules 
was developed by Yamamoto and Kumar in 2000, and was called aptamer beacons. 
Aptamers beacons produce fluorescent signals upon target binding and structural 
rearrangement (Yamamoto and Kumar, 2000). Vicens et al., (2005) described these 
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molecular beacon aptamer as a high affinity synthetic DNA probe, which could detect 
the target in as little as 10 nanogram of platelet-derived growth factor (PDGF) per 
microgram of serum proteins from cell culture media.  
 
Multiplexed aptamer-based proteomics has emerged as a potentially powerful analytical 
and quantification tool, which could complement mass-spectrometry (MS) based 
approaches for the purpose of drug and biomarker discovery. Using such technology, 
several thousands of proteins can be simultaneously measured and profiled with high 
accuracy from a tiny amount of serum or plasma, thus becoming an attractive technique 
for biomarker and clinical purposes. Shuangguan et al., (2008) utilised T-cell acute 
lymphoblastic leukaemia (T-ALL) and identified a biomarker, PTK7 (protein tyrosine 
kinase 7), through cell SELEX and MS.  
1.16.3 Aptamer as therapeutics - clinical trials of aptamers in medicine 
Angiogenesis is a crucial process in growth, development, and wound healing of tissue; 
however, it can also contribute to diseases such as tumour growth, cancer progression, 
and macular degeneration. In such cases, anti-angiogenic aptamers have shown to 
prevent or delay such unwanted neovascularisation (Eugene et al., 2006). Since 2005, 
aptamer technology has achieved a breakthrough in the therapeutic application field 
when an aptamer drug Macugen (Pegaptanib) was developed for treatment of neo-
vascular age related macular degeneration, a disease of the eye (FDA, 2004). The target 
for this anti-angiogenic aptamer was VEGF-165, (figure 1.9), which is a homodimeric 
protein and the most abundant VEGF isoform that regulates vascular permeability 
(Eugene et al., 2006; Ferrara et al., 2006). Table 1.6 lists few of the current aptamers, 
which are being tested in clinical trials. 
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Figure 1.9 Pegaptanib structure and target binding. a Sequence and predicted 
secondary structure of pegaptanib with chemical modifications  2′-O-methylated purines 
are shown in red, 2′-fluorine-modified pyrimidines are shown in blue and unmodified 
ribonucleotides are shown in black. The site of attachment of a 40-kDa polyethylene 
glycol moiety is shown. b Model showing interaction between the 55-amino-acid 
heparin-binding domain of vascular endothelial growth factor (VEGF)165 and 
pegaptanib. The interaction between cysteine-137 of VEGF-165 (cysteine-27 of the 
heparin-binding domain) and uridine-14 of the aptamer is indicated in red. (Taken from 
Eugene et al., 2006).  
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Table 1.6 Current therapeutic aptamers in various stages of clinical development. 
Name Nucleotide Target Condition Phase 
Pegaptanib RNA VEGF Macular Degeneration FDA approved 
AS1411 DNA Nucleolin Acute Myeloid Leukemia Phase II 
NU172 DNA Thrombin Heart disease Phase II 
NOX-E36 RNA CCL2 Type 2 Diabetes Mellitus  Phase I 
E10030 DNA PDGF Age-related macular 
degeneration 
Phase II 
  
The most advanced aptamer on the potential treatment of cancer is AS1411, a guanine 
rich aptamer previously known as AGRO100, developed by Antisoma (London, UK). 
AS1411 binds nucleolin on the cell surface and is able to internalise into the cancer 
cells. The therapeutic benefit of AS1411 is presumably attributed to interfere with 
intracellular pathways by disruption of nuclear factor kappa    NFκ ) signalling 
thereby inducing apoptosis (Bates et al., 2009). AS1411 had also shown positive 
responses in patients with advanced solid tumours (including three renal and two 
pancreatic cancer cases) without adverse side effects (Laber et al., 2005). In addition, in 
randomised phase II clinical trials, a 10 mg/kg/day or 40 mg/kg/day dose of AS1411 
combined with high dose cytarabine (chemotherapeutic drug for acute myeloid 
leukaemia and Hodgkin lymphoma) was well tolerated and showed better efficacy and 
outcome with primary refractory or relapsed acute myeloid leukaemia (Stuart et al., 
2009). Other aptamers under clinical evaluation include NU172 targeting thrombin 
(Waters et al., 2009), NOX-A12 and NOX-E36 targeting chemokine ligand 12 (CCL12) 
(Darisipudi et al., 2011), and E10030 targeting PDGF (Keefe et al., 2010). 
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1.16.4 Aptamer conjugates for targeted drug delivery 
To date, a large number of anti-cancer drugs have been approved by the Food and Drug 
Administration (FDA), however, most of them are not molecularly targeted which has 
caused significant toxicity and side effects. Successful delivery of anti-cancer drugs 
demands optimisation of many aspects including encapsulation, targeting, delivery, and 
controlled release. In addition, combining specific targeting and controlled drug release 
should be able to deliver sufficient doses of cytotoxic drugs to tumour cells over an 
extended period of time without significantly affecting the surrounding non-cancerous 
healthy tissues. Aptamers can potentially alterate and satisfy the aforementioned 
problems and challenges by use as recognition moieties and guide a variety of 
therapeutics to target diseased sites. Several aptamers have been selected against 
various cancer cell lines and have also demonstrated their targeted anti-tumour activity 
alone (Eugene et al., 2006), or coupled with toxins (Chu et al., 2006), siRNA (Liu and 
Gao, 2013), microRNA (Esposito et al., 2014) chemotherapeutic drugs (Chen et al., 
2011), and metal oxides (Yigit et al., 2008) with several characteristics attractive for 
their use in imaging and drug delivery probes.  
 
As an example, Chen et al., (2011) developed a smart functional nanostructure (SMN) 
composed of aptamer (scg8) and pegylated porous hollow magnetic nanoparticles 
(PHMNP) encapsulating doxorubicin (DOX), a commonly used anthracycline drug. 
This SMN worked as an imaging agent for MRI and was also shown to internalise by 
endocytosis into the target CEM (human T-cell lymphoblast) tumour cells (high 
expression of PTK7) resulting in inhibition of target cell proliferation. Hu et al., (2012) 
developed an 86 base DNA aptamer (MA3) targeting MUC1 protein (overexpressed in 
adenocarcinoma and breast cancer cells) as a ligand for carrying DOX to cancer cells. 
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The aptamer-DOX conjugate was capable of carrying DOX to MUC1-positive tumour 
cells, while significant reduction in drug uptake and toxicity was observed in MUC1- 
negative cells.  
 
Aptamers for intracellular targets have also been shown to regulate cellular functions 
causing cell death or proliferation, however, such aptamers have limited use due to low 
bioavailability and this becomes even more challenging when aptamers need to be 
delivered into cells in vivo. To characterise the biological effect of aptamers, Zamay et 
al., (2013) attempted to inject the mixture of a natural polysaccharide product 
arabinogalactan (AG) as a carrier and aptamer NAS-24 intraperitonealy for 5 days into 
mice with adenocarcinoma. Coupled with AG, aptamer NAS-24 was delivered into the 
cytoplasm and caused apoptosis in Ehrlich ascites adenocarcinoma cells in vitro and in 
vivo leading to greater suppression of tumour growth compared to administration of free 
AG or the aptamer alone. Vimentin, which is over-expressed in tumour cells, was found 
to be the most probable protein target (Zamay et al., 2013).  
 
Micro-RNAs (mi-RNAs) play an important role in regulating multiple pathways 
integral to disease development and progression. There are however insufficient means 
for specific delivery of miRNAs to target tissues, therefore, researchers attempted to 
utilise aptamers as carriers for cell-targeted delivery by conjugating let-7g miRNA 
involved in tumour suppressor function with the established GL21.T aptamer that binds 
to and antagonises the oncogenic receptor tyrosine kinase Axl. Experiments performed 
in a xenograft model of lung adenocarcinoma showed reduced tumour growth using this 
multifunctional conjugate (Esposito et al., 2014).  
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1.17 Aptamers and glioma 
The use of aptamers in studying glioma is currently evolving. Research scientists have 
developed a series of aptamers via whole-cell SELEX that can bind to U87MG human 
glioma cell line. The GMT8 aptamer was shown to have highest binding affinity for 
U87MG cells compared to cell lines of other origin including MCF-7, CEM, RAMOS, 
HT29 and HBE-135 (Bayrac et al., 2011). This GMT8 aptamer may be effective in 
improving drug accumulation in GBM cells enhancing tumour penetration for GBM 
targeting therapy (Gao et al., 2012
b
).  
 
Cerchia et al., (2009) reported a differential cell-SELEX using target U87MG cells, 
yielding aptamers that selectively bind to the tumorigenic glioma cell lines (Cerchia et 
al., 2009). The nuclease-resistant RNA aptamers were developed through the cell-
SELEX process and the aptamers were capable of binding at high affinity to the target 
U87MG cells compared to the non-tumorigenic T98G cells. Likewise, aptamers such as 
GBM128 and GBM131 (Kang et al., 2012) and apt 32 (Tan et al., 2013) have been 
developed to target glioma cells. Chen et al., (2008) demonstrated a new biosensing 
technique where a GBI-10 aptamer was conjugated to the quantum dot (QD) surface to 
construct a new kind of fluorescent QD labelled aptamer (QD-apt) nanoprobe. This 
nanoprobe was found to recognise the tenascin-C (overexpressed in glioma) on the 
surface of human glioma cells (Chen et al., 2008).  
Many chemotherapy regimes fail because of the limited blood-brain barrier (BBB) 
penetration and poor glioma targeting of the chemotherapeutics leading to unfavourable 
toxicity profiles (Serwer and James, 2012; Liu et al., 2012). Effective treatment for 
brain glioma needs to conquer two barriers: the BBB and the brain-glioma barrier. Dual 
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targeting delivery systems were developed to conquer these two barriers and presented 
promising results (Gao et al., 2012
a
; Yan et al., 2012). These systems utilised AS1411 
aptamer (glioma targeting ligand) and TGN peptide modified nanoparticles (AsTNPs, 
BBB targeting ligand) for precisely targeting glioma. It was demonstrated that the 
conjugation of both AS1411 and AsTNPs could effectively target brain glioma and 
improve survival of glioma bearing mice (Gao et al., 2012
a
).  
1.18 Scope for the present study 
Malignant glioma remains a challenging disease to treat. Despite recent advances in 
understanding the molecular heterogeneity of the disease and development in drug 
based multimodality therapy, customised therapy for GBM remains challenging (Wen 
and Kesari, 2008; Stupp et al., 2010). Aptamers contribute a very promising and unique 
technology for the in vitro and in vivo imaging of live cells and tissues, with a 
potentially bright future in clinical diagnostics and therapeutics for malignant glioma. 
Considerable effort in developing novel aptamers against various cancers to improve 
specificity of drug delivery and targeting and to reduce adverse drug reactions due to 
cytotoxicity of healthy cells is on going. The use of aptamers for the treatment of 
glioma could be ideal, as not only could aptamers improve delivery of drugs across the 
BBB, but also healthy brain cells could be spared and maximal resection and targeted 
treatment of this diffuse cancer would hopefully minimise recurrence and increase life 
expectancy.  
 
One of the major challenges for targeting drug delivery is to be able to direct the 
binding of the targeting aptamers to tumour cells instead of normal healthy cells. 
Aptamers (GL44 RNA, GL43 RNA and GL56 RNA) were adapted from Cerhcia et al., 
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(2009) and modified by truncating the primer sequences from both ends. The aptamer 
sequences were studied for evaluation of their cellular localisation, uptake process, 
binding selectivity, and toxicity behaviour on glioma cells. From the literature, it was 
also identified there was a gap in the potential use of the aptamers for glioma diagnosis. 
To date, there have only been a few reports on the use of aptamers for the recognition of 
fixed clinical tissues (Li et al., 2009; Zeng et al., 2010; Han et al., 2014; Lu et al., 
2014), with only one report for selectively recognising glioma tissues (Kang et al., 
2012). To explore the potential use of the aptamers for disease diagnosis, histochemistry 
was performed to screen the aptamers on various glioma, meningiomas and non-
cancerous brain tissue sections 
1.19 Aims and Objectives 
1.19.1 Main Aim 
The main aim of the study was to determine the potential of the aptamers to selectively 
target glioma cells and tissues. 
1.19.2 Objectives 
 To evaluate the binding affinity of shortened aptamers (SA44 RNA, SA43 RNA 
and SA56 RNA) towards the target U87MG cells. 
 To study the cellular localisation and binding selectivity of shortened aptamer 
sequences (SA44 RNA, SA43 RNA and SA56 RNA) for selective glioma 
targeting.  
 To determine the difference in the binding affinity and selectivity of the selected 
DNA homolog sequences of the RNA aptamers towards the target glioma cells. 
 To evaluate the internalisation and uptake process and toxicity behaviour of the 
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selected DNA aptamers on glioma cells and to compare with non-cancerous and 
non-glioma cells.  
 To explore the potential use of the selected DNA aptamers for disease diagnosis 
by screening the aptamers on various pathological glioma, meningiomas and 
non-cancerous brain tissue sections. 
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CHAPTER 2 MATERIALS AND METHODS 
2.1 Cell lines 
Cell culture experiments were carried out using different grades of human glioma cell 
lines including 1321N1 (malignant astrocytoma, sub-clone of grade IV U118MG, 
tumorigenic in vivo), U87MG (grade IV glioblastoma, tumorigenic in vivo), T98G 
(glioblastoma, non-tumorigenic in vivo) and non-cancerous foetal astrocytes SVGP12. 
The cell lines were obtained from the European Collection of Cell Cultures (ECACC, 
England, UK) and American Type Culture Collection (ATCC, Middlesex, UK). Two 
other non-glioma cell lines were also utilised for the study including MCF-7 (breast 
cancer) and T24 (bladder cancer), kindly donated by Royal Preston Hospital, UK and 
University of Leeds, UK respectively (Appendix 1).  
2.1.1 Materials 
All media and supplements including DMEM, EMEM, FBS, L-glutamine, Sodium 
pyruvate solution, non-essential amino acid (NEAA) and penicillin/streptomycin 
(pen/strep) were obtained from scientific laboratory supplies (SLS), Lonza, Nottingham, 
UK (Appendix 2). Cell culture reagents including trypsin and DMSO were purchased 
from SLS, Lonza, Nottingham, UK. PBS and ethanol were purchased from Fisher 
scientific, Leicestershire, UK. All plasticware including tissue culture flasks, well plates 
with lids, centrifuge tubes, serological pipettes, unplugged pasteur pipettes, eppendorf 
tubes, syringes and membrane filters were purchased from Fisher scientific, 
Leicestershire, UK. Coverslips for confocal microscopy were purchased from Harvard 
apparatus, Kent, UK. All other chemicals were purchased from Sigma-Aldrich Ltd 
(Butterworth, UK) unless mentioned otherwise. Primary antibodies GFAP, VEGF and 
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beta actin were purchased from ABCAM, Cambridge, UK and secondary antibodies 
were purchased from Invitrogen, Paisley, UK. 
2.1.2 Media and supplements 
The media and supplements that were used for each cell line were in accordance with 
the recommendations of ECACC and ATCC. The media preparations were carried out 
under aseptic conditions by the addition of required supplements as recommended by 
the suppliers (Appendix 1). Both DMEM and EMEM were supplied in 500 ml bottles, 
to which 50 ml of FBS and 5 ml of L-glutamine (200 mM) were aseptically added to 
achieve a final concentration of 10 % FBS and 2 mM L-glutamine, respectively. 
Sodium pyruvate (5 mM) and NEAA (5 mM) solution were added as supplements in 
EMEM media. The prepared media were stored at 4 °C for up to 4 weeks. All cell lines 
were routinely grown in 75 cm
2 
or 25 cm
2
 tissue culture flasks and maintained in a 37 
°C humidified incubator supplied with 5 % CO2, 95 % O2. For all the experiments in the 
study, each of the cell lines were harvested when they reached 70-80 % confluence and 
were used between passages 5-25. 
2.1.3 Routine cell culture and maintenance 
When the monolayer of cells reached 70-80 % confluency, cells were subcultured. The 
media was aspirated and the cells were washed with 0.1 M PBS, pH 7.4 to remove any 
traces of serum. The cells were detached by incubation with 0.25 % trypsin diluted in 
0.1 M PBS, pH 7.4 for 2 minutes at 37 °C in a humidified incubator supplied with 5 % 
CO2, 95 % O2. After trypsin treatment, the flask was tapped gently and viewed under 
the inverted light microscope to ensure the detachment of cells. Media was then added 
to neutralise the trypsin reaction and mixed well to obtain homogenous and evenly 
distributed cell suspension. The cells were seeded at the ratio of 1:4 to each fresh flask.  
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2.2 Growth and biological characteristics of cells lines used in the study 
2.2.1 Growth kinetics of cell lines 
Growth curves were generated to evaluate the growth kinetics of the cultured cell lines 
such as their lag time, population doubling time (exponential phase) and saturation 
density. This assessment was done using the trypan blue exclusion method. Viable cells 
with intact membrane excluded trypan blue and cells stained blue were classified as 
dead cells. Cells at a density of 6 x 10
4
 cells/ml were then seeded into T25 flasks and 
incubated at 37 °C supplied with 5 % CO2, 95 % O2. At defined time points between 2 
and 10 days, cells were trypsinised and resuspended in media prior to a 1:1 dilution of 
cell suspension and trypan blue. The number of viable cells were counted using a 
haemocytometer and light microscope (x10 magnification).  
2.2.2 Data analysis 
The average viable cell count per square (n=5 squares) was multiplied by the 
haemocytometer factor (10
4
) and the dilution factor (x 2) to give number of viable cells/ 
mL. The experiment was performed in triplicate and cell count verses time was plotted 
to study growth kinetics. Accordingly, the lag, exponential and plateau phase of cell 
growth were determined. The growth curve also aided in determining the seeding 
density for each of the flat bottom 12, 24 and 96-well plate used on each day of the 
experiment using equation 1 stated below. The surface area and plating volume for each 
culture dish is given in table 2.1.  
 
Equation 1 
Where: C1 = initial concentration of cells per flask; V1 = initial volume of medium with 
cells per flask; C2 = final concentration of cells needed per well; and V2 = final volume 
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of plating medium with cells per well.  
Table 2.1 Surface-area and plating volume in each culture dish used in the study 
 
 
2.3 Characterisation of cell lines using Immunocytochemistry assay 
The cell lines used in the study were characterised using specific markers to confirm the 
maintenance of the biological features of the cell lines. This was carried out using 
antibodies to Human leukocyte antigen (HLA; Santacruz biotechnology, Middlesex, 
UK) as a human cell marker, glial fibrilliary acidic protein as a glial cell marker and 
vascular endothelial growth factor as a tumour cell marker. Primary antibodies were 
detected using Alexa fluor 488 secondary antibodies including goat anti-mouse and goat 
anti-rabbit. Isotype controls against each primary antibody such as mouse IgG and 
rabbit IgG were used to show that the labelling was specifically due to the primary 
antibody and to assess the level of background non-specific staining in the assay. 
Positive controls were included to the confirm immunocytochemistry method by use of 
beta actin primary antibody and the goat anti-mouse secondary antibody. Detailed 
information regarding the primary and secondary antibodies with their working 
concentration diluted in 0.1 M PBS (pH 7.4) is mentioned in Table 2.2. 
Culture dish 
 
Surface area per well 
(cm2) 
 
Volume of plating medium 
(ml) 
 
T25 
 
25 
 
5 
 
T75 
 
75 
 
10 
 
12-well plate 
 
3.8 
 
1 
 
24-well plate 
 
2 
 
1 
 
96-well plate 
 
0.36 
 
0.1 
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Table 2.2 Antibodies used in the study and their working concentrations. 
Protein Antibody Type Final 
concentration 
Isotype control 
 
Beta 
Actin 
 
Primary Mouse monoclonal to 
Beta actin 
150 µg/ml  
 
Mouse IgG Secondary Goat anti- mouse IgG 20 µg/ml 
 
 
GFAP 
 
Primary 
 
Rabbit polyclonal to 
GFAP 
4 µg/ml  
 
Rabbit IgG Secondary 
 
Goat anti- rabbit IgG 
 
20 µg/ml 
 
 
VEGF 
 
Primary 
 
Mouse monoclonal to 
VEGF 
10 µg/ml  
 
Mouse IgG Secondary 
 
Goat anti- mouse IgG 
 
20 µg/ml 
 
 
HLA 
 
Primary 
 
Mouse monoclonal to 
HLA 
4 µg/ml  
 
Mouse IgG Secondary 
 
Goat anti- mouse IgG 
 
20 µg/ml 
  
2.3.1 Cell fixation 
Glial cell lines (1321N1, U87MG, T98G and SVGP12), breast cancer cell line (MCF-
7), and bladder cancer cell line (T24) were plated on 12 mm coverslips in a 24-well 
plate at a seeding density of 3 x 10
4
 cells/ well in media specified in section 2.1.2 and 
incubated in a 37 °C humidified incubator supplied with 5 % CO2, 95 % O2 and were 
allowed to attach and grow for 36 hours. Post attachment, the cells were washed and 
fixed with 4 % paraformaldehyde (PFA; Sigma, UK) for 15 minutes at room 
temperature. The cells were rinsed three times with 0.1 M PBS (pH 7.4) for 10 minutes 
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followed by treatment with 0.01 % triton X-100 (Fisher Scientific, Leicestershire, UK) 
diluted in 0.1 M PBS (pH 7.4) for 5 minutes to permeabilise the cells. The cells were 
rinsed three times with 0.1 M PBS (pH 7.4) for 10 minutes and were ready for the 
staining experiments.  
2.3.2 Cell staining and visualisation 
The fixed permeabilised cells were incubated with the 10 % blocking serum (goat 
serum) dissolved in 0.1 M PBS (pH 7.4) for 1 hour at room temperature. The cells were 
washed with 0.1 M PBS (pH 7.4) for 5 minutes and incubated with the primary 
antibodies for 1 hour at room temperature. The cells were then washed with 0.1 M PBS 
(pH 7.4) for 10 minutes and incubated with the respective secondary antibodies in the 
dark for 1 hour at room temperature. Post treatment with primary and secondary 
antibody, the cells were washed three times with 0.1 M PBS, pH 7.4 for 10 minutes and 
counterstained with VECTASHIELD
®
 mounting medium with propydium iodide (PI) 
(1.5 µg/ml) (Vector laboratories, Peterbourough, UK). The cells were visualised under 
40 x using a Zeiss LSM510 confocal microscope (Zeiss LSM, Germany) equipped with 
appropriate filters sets for the detection of expression of various markers using FITC 
signal (excitation: 488 nm; emission: band pass filter 505-530 nm; detector gain: 897; 
amplifier offset: -0.06; amplifier gain: 1). The experiment was performed on three 
independent occasions and was analysed using in-built Zeiss LSM image browser. 
2.4 Oligonucleotide synthesis and labelling 
Aptamers  oligonucleotides  were conjugated at the 5‟ end with Cy3 for confocal 
microscopy (section 2.6) and flow cytometry analysis (sections 2.5 and 2.7) and with 
biotin for histochemistry (sections 2.9 and 2.10) by Integrated DNA technologies (IDT, 
Glasgow, UK). Primary sequences of the single stranded RNA aptamers and their DNA 
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homologs are given in the table 2.3. Biotin labelled oligonucleotides were synthesised 
in desalted form, whereas the Cy3 labelled oligonucleotides were HPLC purified. 
Table 2.3 Primary sequences of aptamers used in the study.  
Test aptamer  Sequence 5’ to 3’ Sugar 5’ label Reference 
SA44 RNA ACG UUA CUC UUG CAA CAC 
CCA AAC UUU AAU AGC CUC 
UUA UAG UUC 
Ribose Cy3 Cerchia et 
al., 2009 
SA43 RNA ACG UUA CUC UUG CAA CAC 
AAA CUU UAA UAG CCU CUU 
AUA GUU C 
Ribose Cy3 Cerchia et 
al., 2009 
SA56 RNA UGA UUU UGC AGC ACU UCU 
UGU UAU CUU AAC GAA CUG 
UUG AUG A 
Ribose Cy3 Cerchia et 
al., 2009 
SA44 DNA ACG TTA CTC TTG CAA CAC 
CCA AAC TTT AAT AGC CTC 
TTA TAG TTC 
Deoxyribose Cy3/ Biotin Cerchia et 
al., 2009 
SA43 DNA ACG TTA CTC TTG CAA CAC 
AAA CTT TAA TAG CCT CTT 
ATA GTT C 
Deoxyribose Cy3/ Biotin Cerchia et 
al., 2009 
SA56 DNA TGA TTT TGC AGC ACT TCT 
TGT TAT CTT AAC GAA CTG 
TTG ATG A 
Deoxyribose Biotin Cerchia et 
al., 2009 
SAN1 DNA GGA AAA TTA TAC CCT CCA 
TTA AAT CCA CCA TTA CCA 
CAC CCU TTA 
Deoxyribose Cy3/ Biotin In-house 
SAN2 DNA CCG TTA ATT AGG CCC TTA 
AAT GGC ATA AAA TTT GAA 
AGG GAA T 
Deoxyribose Cy3/ Biotin In-house 
  
2.5 Determining the binding affinity of the aptamers to the target 
U87MG cells by flow cytometry 
Live U87MG cells were seeded in 12-well plate at a seeding density of 4 x 10
4 
cells/ 
well in complete media specified in section 2.1.2 and were allowed to attach and grow 
for 36 hours at 37 ºC in a 5 % CO2 humidified incubator. The binding affinity of the test 
aptamers SA44, SA43 and SA56 was determined by incubating live adherent U87MG 
cells with varying concentrations (0.5 nM – 200 nM) of the Cy3 labelled aptamers in 
media for 90 mins at 37 ºC in a 5 % CO2 humidified incubator. This experiment also 
determined the effect of different concentrations of the selected aptamers on cells and 
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also aided in selecting a standard optimal concentration of each aptamer for determining 
their uptake on other cell lines. Untreated cells were incubated with complete growth 
medium alone. Post incubation, the cells were washed three times with 0.1 M PBS (pH 
7.4) and detached using 0.25 % trypsin for 2 minutes. The suspended cells were 
transferred to an eppendorf tube and centrifuged at 224 x g for 5 minutes to remove the 
supernatant that contained unbound aptamer. The cells were then resuspended in PBS 
(0.26 ml, ideal volume for measuring at least 10000 events) for flow cytometry analysis. 
Fluorescence analysis was performed on BD FACSAria flow cytometer (BD 
Biosciences, San Jose, CA, USA) using phycoerythrin (PE) was detected at an 
excitation at 488 nm and emission at 578 nm where 10,000 events were collected for 
each sample. The mean fluorescent intensity (MFI) was determined using in-built FACS 
Diva version 4.1.2 software (BD biosciences). All the experiments for the binding assay 
were performed at least three times.  
 
For calculation of the equilibrium dissociation constant (Kd) of the aptamers and 
U87MG cell interaction, the average MFI value of cells was plotted against the 
fluorescently labelled aptamer concentration and a curve fitted using non-linear 
regression analysis (Graphpad Prism, Graphpad software, Inc, La Jolla, USA). 
Accordingly, the Kd value was obtained for each aptamer using the one site-specific 
binding equation (Equation 2) (Sefah et al., 2010). 
 
 
Equation 2 
Where: Bmax = maximum binding sites; Captamer  = concentration of aptamer; Kd = 
dissociation constant (binding affinity).  
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2.6 Cellular uptake and localisation of aptamers by confocal 
microscopy 
All Cy3 labelled RNA and DNA aptamers were screened on various growing cell lines 
and confocal imaging was used to obtain three dimensional (3D) images and z-stacks to 
determine whether aptamer uptake or binding was selective and where the aptamer 
loacalised. The two steps involved were (a) determining the optimum standard 
concentration of each Cy3-labelled aptamer using the target U87MG cell line and (b) 
using the standard concentration of each aptamer on 1321N1, U87MG, SVGP12, T98G, 
T24 and MCF-7 cell lines to determine their binding selectivity.  
 
Glioma cells (1321N1, U87MG, T98G), non-cancerous glial cells (SVGP12), breast 
cancer cells (MCF-7), and bladder cancer cells (T24) were plated on coverslips (12 mm) 
in 24 well plates at a seeding density of 3 x 10
4
 cells/ well in media specified in section 
2.1.2 and allowed to grow for 36 hours. Post attachment, the following experiments 
(sections 2.6.1 – 2.6.2) were performed to study the uptake of aptamers by the cells.  
2.6.1 Determining the optimum standard concentration for each Cy3-labelled 
aptamer using the target U87MG cells 
Live U87MG cells were incubated with varying concentrations (5 nM, 20 nM, 40 nM, 
80 nM and 100 nM) of the Cy3 labelled aptamers SA44, SA43 and SA56 in media as 
previously specified in section 2.1.2 for 90 minutes at 37 ºC in a 5 % CO2 humidified 
incubator Untreated cells were incubated with complete growth medium alone. Post 
incubation, the cells were washed three times with 0.1 M PBS (pH 7.4) to remove any 
unbound aptamer. Cells were fixed with 4 % PFA for 15 minutes at room temperature. 
After fixing, the cells were washed thrice with 0.1 M PBS, pH 7.4 and counter-stained 
using VECTASHIELD® mounting medium with DAPI (1.5 µg/ml) (Vector 
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laboratories, Peterbourough, UK) in the dark to stain the nucleus. The cells were then 
visualised under 40 X magnification using a Zeiss LSM510 confocal microscope (Zeiss 
LSM, Germany) equipped with appropriate filter sets for the detection of Cy3 dye 
fluorescence (Excitation: 543; emission: long pass filter 560 or band pass filter 560-615; 
amplifier gain: 1; detector gain: 927; amplifier offset: - 0.06).  
 
The images of aptamer uptake to the cells were acquired under 40 X oil immersion 
objective in z- stack mode with independent slice thickness determined by the software. 
3D reconstruction with 64 projections of various z-stacks was then performed using 
Zeiss LSM image browser software. For all the staining experiments, cellular 
localisation was further confirmed by overlaying the fluorescence images (single plane 
image from the middle of Z-stack) with the nuclear DAPI stain. The experiments were 
performed at least three independent times and the fluorescence images reported in the 
study are representative of at least three captured images per experiment. 
2.6.2 Assessing the uptake of the aptamers on live glial and non-glial cells 
Live 1321N1, U87MG, T98G, SVGP12, MCF-7, and T24 cells were incubated with 
suitable standard concentrations of the selected Cy3 labelled aptamers SA44, SA43, 
SA56 along with random sequenced aptamers in growth medium supplemented with 
FBS for 90 minutes at 37 ºC in a 5 % CO2 humidified incubator. Untreated cells were 
incubated with complete growth medium alone. Post incubation, the cells were washed 
three times with 0.1 M PBS (pH 7.4) to remove the unbound aptamer followed by the 
same treatment as mentioned in the section 2.6.1. The experiments were performed in 
triplicate and were analysed using same settings on Zeiss LSM image browser as 
mentioned in the section 2.6.1. 
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2.7 Cellular uptake and internalisation of aptamers by flow cytometry 
Aptamer uptake and internalisation on live cells was also assessed quantitatively by 
flow cytometry. Glioma cells (1321N1, U87MG, T98G), non-cancerous glial cells 
(SVGP12), breast cancer cells (MCF-7), and bladder cancer cells (T24) were seeded in 
12-well plate at a seeding density of 4 x 10
4
 cells/ well in complete media specified in 
section 2.1.2 and were allowed to attach and grow for 36 hours at 37 ºC in a 5 % CO2 
humidified incubator. Post attachment, the following experiments (sections 2.7.1- 2.7.3) 
were performed to analyse the aptamer uptake and internalisation by the live cells. 
2.7.1 Assessing the aptamer uptake on live glial and non-glial cells 
Live 1321N1, U87MG, T98G, SVGP12, MCF-7, and T24 cells were used for the study. 
The binding selectivity of SA44, SA43, SA56 along with random sequence aptamers 
was determined by incubating the cells with suitable standard concentration of the 
aptamers at 37 °C (5 % CO2) for 90 minutes. Untreated cells were incubated with 
complete growth medium alone. The cells were washed with 0.1 M PBS (pH 7.4) 
followed by the same protocol for flow cytometry analysis as mentioned in the section 
2.5. The mean fluorescent intensity (MFI) was determined using FACS Diva version 
4.12 software. The binding assay experiments were analysed using windows multiple 
document interface (Win MDI) software (version 2.9) to determine the uptake of each 
aptamer on various cell types. The software creates single or dual-parameter histograms 
as frequency distribution based on the mean fluorescent intensity (MFI) for each 
sample. Evident peak shift compared to cells with no aptamers corresponded to an 
increase in the fluorescent signal which indicated increase in uptake and selectivity of 
the aptamers on the cells.  
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2.7.1.1 Data analysis 
To determine the binding selectivity and affinity for each aptamer on all cell lines, 
statistical analysis was performed on the MFI values using IBM SPSS statistics v20 
software (IBM SPSS Statistics for Windows, Version 20.0, Armonk, NY). All MFI 
values of the untreated cells obtained from FACS Diva software were initially 
subtracted from the MFI values obtained from aptamer treated cells. Thereafter, the 
MFI of the random aptamer was subtracted from the MFI of the lead aptamers. A 
Shapiro-Wilk‟s test  p > 0.05) (Shapiro & Wilk, 1965; Razali & Wah, 2011), an 
inspection of skewness and kurtosis measures and standard errors, and a visual 
inspection of their histograms, normal Q-Q pots and box plots was performed on the 
average MFI values from three individual experiments of each aptamer to test the 
normal distribution of the data. Statistical significance of differences in the means of 
average MFI values of each shortened aptamer between individual cell groups was then 
determined by using a one-way ANOVA (Ruxton and Beauchamp, 2008) followed by 
post hoc Bonferroni test (Ruxton and Beauchamp, 2008). The significant statistical 
difference was defined according to p value less than 0.05. 
2.7.2 Effect of temperature on aptamer binding to the cells 
Live 1321N1, U87MG, and SVGP12 cells were used for the study. Cells were separated 
into two groups for the experiments and incubated with each aptamer (100 nM) at 4 °C 
and 37 °C simultaneously for 90 minutes. After incubation, cells were washed thrice 
with 0.1 M PBS, pH 7.4 following the same protocol for flow cytometry analysis in the 
section 2.7.1. The binding assay experiments were repeated at least three times and 
were analysed using WinMDI 2.9 software as mentioned in the section 2.7.1. Statistical 
significance of differences in the means of average MFI values of each shortened 
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aptamer between individual cell groups treated at 4 °C and 37 °C was then determined 
by using two-way ANOVA followed by Bonferroni post-hoc test (Ruxton and 
Beauchamp, 2008). 
2.7.3 Effect of protease trypsin on aptamer binding to the cells 
To determine whether the entry of the lead aptamers was mediated through the cell 
surface receptors or through a different mechanism other than receptor-mediated 
pathway, cells were treated with trypsin protease before the aptamer treatment. The 
experiment also provided an idea about the nature of the aptamer target, whether it was 
mainly membrane bound or was intercellular. Live 1321N1, U87MG, and SVGP12 
cells were used for the study and were separated into two groups for the experiments. 
One group was treated initially with aptamer and then trypsinised to remove any cell 
surface bound aptamers (similar experiment as mentioned in 2.7.1 and 2.7.2). Second 
group was initially incubated with 0.25 % trypsin at 37 °C (5 % CO2) for 10 minutes to 
remove the cell surface receptors. Media with FBS was then added to inhibit the 
protease activity. The cell suspension was then transferred to an eppendorf tube and 
centrifuged (MSE Microcentaur, DJB labcare) at 224 x g for 5 minutes. Each cell pellet 
was then resuspended with 500 μl complete growth media containing 100 nM aptamer 
and incubated for 90 minutes at 37 °C. Post treatment, the cells were washed and 
centrifuged at 224 x g three times to remove any unbound aptamer and taken for flow 
cytometry analysis. The binding assay experiments were repeated at least three times 
and were analysed using WinMDI 2.9 software (Section 2.7.1). Statistical significance 
of differences in the means of average MFI values between individual cell groups 
treated with aptamer before and after trypsin treatment was then determined by using 
two-way ANOVA followed by Bonferroni post-hoc test (Ruxton and Beauchamp, 
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2008).  
2.8 Effect of aptamers on cell viability 
The effect of aptamers on cell viability was tested using the Presto blue assay. Presto 
blue reagent is a resazurin based solution that functions as cell viability indicator by 
using the reducing power of living cells to quantitatively measure the proliferation of 
cells (Boncler et al., 2013). Briefly, 2 x 10
3 
cells/ well of 1321N1, U87MG, and 
SVGP12 cells were seeded in 96-well plates and incubated at 37 °C (5 % CO2) for 24 h. 
Cells were treated with four different concentrations (20 nM, 100 nM, 500 nM and 1000 
nM) of biotinylated DNA aptamers SA44 and SA43 for 24, 48 and 72 hours. Cisplatin 
diluted in media  10 μM  was used as a positive control  To evaluate the cell viability 
following 24, 48 and 72 hours treatment, 10 μl of presto blue was added to each well 
and incubated for 1 hour at 37 °C. The assay was read using a TECAN genios pro 
multifunctional microplate reader (Tecan, Austria; software version 4.53) with 
excitation and emission wavelength of 535 nm and 612 nm respectively. Cell viability 
was expressed in percentage relative to control untreated cells grown in media.  
2.9 Aptamer binding on fixed cells 
To determine the ability of the aptamers to bind to the targets of fixed cells, cells were 
treated with biotin labelled DNA aptamers post fixation.  
2.9.1 Fixation and permeabilisation 
1321N1 (glioma cells) and SVGP12 (non-cancerous cells) were seeded on coverslips in 
24 well plates at a seeding density of 3 x 10
4 
cells/ well in media previously detailed in 
section 2.1.2, and allowed to grow for 36 hours. Post attachment, the cells were washed 
three times and incubated with 4 % PFA for 15 minutes at room temperature. The cells 
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were then washed with 0.1 M PBS (pH 7.4) and permeabilised using 0.1 % Triton X- 
100 (diluted in PBS) for 5 minutes. Post permeabilisation, the cells were washed three 
times with 0.1 M PBS (pH 7.4) and incubated with 10 % biotin-blocking solution 
(Vector laboratories, UK) for 30 minutes at room temperature to mask the endogenous 
biotin binding.  
2.9.2 Aptamer labelling and imaging 
The cells were then incubated with 100 nM concentration of each biotin labelled DNA 
aptamers for 60 minutes at room temperature. The cells were washed three times with 
0.1 M PBS, pH 7.4 and incubated with VECTASTAIN
®
 avidin biotin complex (ABC) 
reagent (Vector laboratories, Peterbourough, UK) for 30 minutes at room temperature. 
Untreated cells were incubated with 0.1 M PBS (pH 7.4) alone followed by ABC 
reagent treatment. After three washes with 0.1 M PBS, pH 7.4, the cells were treated 
with 250 µl of 3,3-diaminobenzidine (DAB) peroxidase substrate solution (Vector 
laboratories, Peterbourough, UK) at room temperature for 5 minutes. Counterstaining of 
the cell nuclei was performed with 250 µl Mayer‟s haematoxylin solution for 5 minutes. 
The cells were then rinsed with distilled water and dehydrated through an increasing 
series of ethanol washes (70 %, 90 % and 100 % twice for 2 minutes each). The 
coverslips were then placed into histoclear (Fisher scientific, UK) for 1 min and then 
mounted in DPX (distrene dibutyl- phatalate xylene) mounting medium. The treated 
cells were then examined using a Nikon light microscope under 40 X magnification 
equipped with digital eclipse camera system and screen, and analysed for their binding 
selectivity on fixed cells.  
2.10 Aptamer binding selectivity to patient tissue samples 
The study also involved screening of the biotin labelled DNA aptamers SA44, SA43, 
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SA56, and random aptamer on patient serial tissue sections from the Brain Tumour 
North West (BTNW) bank. Different grades of glioma including grade I, grade II, grade 
III, grade IV glioblastoma, meningioma (grade II, grade III), and non-cancerous brain 
tissues were included in the study. The demographic details including the diagnosis and 
the tumour type for all the different patients used in the study are mentioned in appendix 
4. Ethical approval and informed consent was obtained by the ethics committee for the 
use of above mentioned patients tissue sections.  
2.10.1 Dewaxing of paraffin embedded sections 
Each excised tumour tissue sample and non-tumour portion were formalin-fixed and 
serially sectioned  4 μm  by pathologists Katherine Ashton and Dr Tim Dawson from 
the Royal Preston hospital. These paraffin-embedded tissue slides were deparaffinised 
with two changes of histoclear (Fisher scientific, UK), 15 minutes each and rehydrated 
through graded ethanol washes (100 %, 90 % and 70 %), 5 minutes each. 
Deparaffinised tissue slides were then rinsed in distilled water.  
2.10.2 Antigen retrieval 
Antigen retrieval involved immersing the slides in 0.01 M citrate buffer at 97 ºC for 20 
minutes. The sections were allowed to stand at room temperature for 30 minutes to cool. 
The sections were rinsed in 0.1 M PBS, pH 7.4 twice for 2 minutes each.  
2.10.3 Aptamer labelling and imaging 
To mask endogenous biotin binding, sections were treated with biotin-blocking solution 
(Vector laboratories, UK) for 30 minutes and then washed three times with 0.1 M PBS, 
pH 7.4. The tissue slides were incubated with 100 nM biotin labelled DNA aptamers for 
60 minutes at room temperature. The slides were washed three times with 0.1 M PBS, 
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pH 7.4 for 5 minutes. The slides were then incubated with VECTASTAIN
®
 ABC 
reagent for 30 minutes at room temperature. After three washes with 0.1 M PBS, pH 
7.4, the tissues sections were treated with 200 µl of DAB peroxidase substrate solution 
for 5 mins at room temperature for colour development. Counterstaining of the cell 
nuclei in tissue sections was performed with Mayer‟s haematoxylin solution for 5 
minutes. The slides were then rinsed with distilled water and dehydrated through 
increasing series of ethanol washes (70 %, 90 % and 100 % two times for 2 minutes 
each). The sections were then placed into xylene for 5 minutes and then mounted in 
DPX mounting medium (Sigma, UK). The sections were then imaged and captured 
using bright field microscopy using Nikon microscope equipped with digital eclipse 
camera system (Nikon, UK) and analysed for the binding selectivity using a protocol 
mentioned below (Sections 2.10.4 and 2.10.5). 
2.10.4 Schematic explanation of the protocol for immuno-scoring 
A defined protocol was applied to analyse and count the cells stained with each DNA 
aptamer in the tissue sections. This protocol is based on that applied by Leake et al., 
(2000) and is NEQAS approved for the scoring of BRCA1 positive cells in breast 
tumour tissue sections. The aptamers showed distinctive and remarkable staining in the 
tissue sections, which assisted in scoring them according to their staining intensity 
(Figure 2.1). 
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Figure 2.1 Representative images from tumour tissues showing differential 
staining intensities with the studied DNA aptamers. All scale bars, 200 μm  
 
A blind study without knowing the grades of tissues was then performed to be unbiased 
and therefore more accurate in analysing the binding results. The binding of the 
aptamers on tissue sections was identified by carefully examining each tissue section 
under 10 X and 40 X magnification. For accuracy, 10 different fields were selected per 
tissue section and counted. Initially, an intensity score was assigned, which represented 
the average staining intensity score of positive stained cells (Table 2.4). Thereafter, 
proportion score intensity was assigned, which represented the estimated proportion of 
positive stained tumour cells. The intensity and the proportion scores were then added 
together to obtain a total score, which ranged from 0 to 8. A total score of 3 or below 
was considered as negligible binding. 
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Table 2.4 Suggested scoring system (Leake et al., 2000).  
Score for staining intensity  Score for proportion intensity 
0= no staining 
1= weak staining 
2= intermediate/ moderate staining 
3= intense/ strong staining 
0= no staining 
1= <1% cell staining 
2= 1-10% cell staining 
3= 11-33% cell staining 
4= 34-66% cell staining 
5= 67-100% cell staining 
 
 
2.10.5 Data analysis 
To identify a clinically meaningful cut point for defining positive binding of aptamers to 
the cells on tissue sections, the results were examined on a scatter plot. A statistical test 
using one-way ANOVA followed by Bonfferoni post hoc test was applied to compare 
the overall mean binding scores for each aptamer on all glioma and meningioma tissues 
versus the non-cancerous tissues. Comparison of binding selectivity between the control 
(non-cancerous) group and tumour groups (grade I, grade II, grade III, grade IV, and 
meningioma  were further analysed by Fishers‟ exact test  Graph Pad Prism software, 
La Jolla, USA) using a 2 x 2 contingency table. A value of p < 0.05 was considered to 
indicate a statistically significant differences of each aptamer between the non-
cancerous and cancerous group. Morphological characteristics and cell type selectivity 
for each aptamer within each tissue sections was also analysed carefully using 40 X 
objective lens. 
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CHAPTER 3 GROWTH AND BIOLOGICAL CHARACTERISTICS 
OF CELL CULTURE MODELS 
3.1 Introduction 
Characterisation of the glioma cell lines is critical for the evidence of astrocytic 
differentiation and has been one of the most common parameters used for preliminary 
assessment in cell culture. Extensive cell culture may lead to problems such as cross-
contamination in which a contaminant is another cell line or a micro-organism without 
handler‟s knowledge  Capes-Davis et al., 2010). It was therefore essential to verify that 
the represented cell lines selected have a well-defined origin and growth. 
Immunological approaches have been one of the best methods for the evidence of the 
biological characteristics of the cell lines (Higgins et al., 2010; Kamphuis et al., 2012). 
This chapter aimed to determine the growth rate for each cell line to understand the 
growth pattern and ascertain appropriate seeding density for the downstream 
experiments. In addition, the chapter aimed to confirm the biological characteristics 
(glial and human origin, and cancerous) of each cell line using immonucytochemistry. 
3.2 Results 
3.2.1 Growth curves 
Growth curves were generated to evaluate the growth kinetics of the cultured glial 
(1321N1, U87MG, SVGP12 and T98G) and non-glial (T24 and MCF-7) cell lines used 
in the study. This assessment was done using trypan blue exclusion microscopy 
(Section 2.2). From the results shown in figure 3.1, it was evident that the 1321N1, 
T98G, T24 and MCF-7 cells proliferate more rapidly than SVGP12 and U87MG cells. 
All the cell lines exhibited a lag phase between days 1 and 2, an exponential growth 
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phase between the 3
rd
 and the 7
th
 day and reached the plateau or decline phase 
thereafter. The population doubling time was 36 - 48 hours for all the cell lines.  
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Figure 3.1 The growth kinetics of cultured glial and non-glial cell lines used for the 
study. A Growth curve for glial cells 1321N1, U87MG, SVGP12, and T98G. B Growth 
curve for non-glial cells T24 and MCF-7. Each time point represents the average value 
of triplicates from three independent experiments and error bars represent standard error 
mean (S.E.M).  
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3.2.2 Immuno-cytochemical characterisation of various cell lines using specific 
markers  
1321N1, U87MG, T98G (glioma), SVGP12 (non-cancerous), T24 (bladder cancer), and 
MCF-7 (breast cancer) cells were characterised using a panel of antibodies raised 
against HLA-I, GFAP and VEGF to confirm the maintenance of biological features 
(Section 2.3). The antigens chosen to define the origin of the cell lines used in the study 
here were HLA-I to ensure the cells were human origin, GFAP to confirm glial origin 
for glial cells, and VEGF to confirm the cancerous nature of the tumour cells. C2C12 
(mouse mycoblast cell line, ATCC, UK) was used as a negative control to ensure the 
cells used for the study were human origin and was characterised using HLA-I 
antibody.  
 
Immunocytochemical analysis of GFAP expression on the cell lines demonstrated that 
1321N1, U87MG, SVGP12 and T98G cells were positive. Expression of GFAP was 
localised in the cytoplasm. In contrast, T24 and MCF-7 cells, and all isotype controls 
did not show staining above background levels (Figures 3.2 - 3.4). Similarly, all cell 
lines expect C2C12 showed positive expression of human cell marker HLA-I. 
Moreover, all cancerous cells including glial and non-glial expressed positive staining 
for VEGF marker, expect for weak to negligible staining on non-cancerous SVGP12 
cells.  
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Figure 3.2 Expression of HLA-I, GFAP and VEGF antigens (green) in cultured 
1321N1 and U87MG cells. A, B, and C represent expression of HLA-I, GFAP and 
VEGF counterstained with PI (nuclear stain) respectively, in 1321N1 cells. A’, B’, and 
C’ represent isotype controls against HLA-I, GFAP and VEGF counterstained with PI 
respectively, in 1321N1 cells. Similarly, D, E, and F represent expression of HLA-I, 
GFAP and VEGF counterstained with PI respectively, in U87MG cells. D‟, E‟, and F‟ 
represent isotype controls against HLA-I, GFAP and VEGF counterstained with PI 
respectively, in U87MG cells  Scale bar = 20 μm   
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Figure 3.3 Expression of HLA-I, GFAP and VEGF antigens (green) in cultured 
SVGP12 and T98G cells. A, B, and C represent positive expression of HLA-I, GFAP 
and negligible expression of VEGF counterstained with PI (nuclear stain) respectively, 
in SVGP12 cells. A’, B‟, and C‟ represent isotype controls against HLA-I, GFAP and 
VEGF counterstained with PI respectively, in SVGP12 cells. Similarly, D, E, and F 
represent expression of HLA-I, GFAP and VEGF counterstained with PI respectively, 
in T98G cells. D’, E’, and F’ represent isotype controls against HLA-I, GFAP and 
VEGF counterstained with PI respectively, in T98G cells  Scale bar = 20 μm  
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Figure 3.4 Expression of HLA, VEGF, and GFAP antigens (green) in cultured 
MCF-7, T24, and C2C12 cells. A and B represent positive expression of HLA-I in 
MCF-7 and T24, respectively. C represents negligible expression of HLA 
counterstained with DAPI (nuclear stain) in C2C12 cells. A’, B’ and C’ represent 
isotype controls against HLA-I counterstained with PI respectively, in MCF-7, T24 and 
C2C12 cells, respectively. D and E represent positive expression of VEGF 
counterstained with PI respectively, in MCF-7 and T24 cells, respectively. D’ and E’ 
represent isotype controls against VEGF counterstained with PI respectively, in MCF-7 
and T24 cells, respectively. F and G represent negligible expression of GFAP 
counterstained with PI respectively, in MCF-7 and T24 cells, respectively. F’ and G’ 
represent isotype controls against GFAP counterstained with PI respectively, in MCF-7 
and T24 cells, respectively  Scale bar = 20 μm   
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3.3 Discussion 
High heterogeneity in phenotypic and growth characteristics has been well identified 
between different glioma cell lines developing the need to study and confirm both the 
growth rate and biological characteristics of the individual cell line before screening and 
testing of various novel molecules (Mullins et al., 2013). The characterisation of the 
glial and non-glial cell lines consisted of evaluating the proliferative capacity of cells 
using growth curve analysis and identification of biological features of the cell lines 
using glial, human and tumour specific markers.  
 
Growth kinetic studies using trypan blue exclusion microscopy were useful in 
determining the cell density along with growth characteristics such as lag time, 
population doubling time (exponential phase) and saturation density of a cell line 
(Mather and Roberts, 1998; Li et al., 2010; Assanga et al., 2013). This assay also 
distinguished between viable and nonviable cells, based on the ability of cells with an 
intact plasma membrane (live cells) to exclude trypan blue while those cells that stained 
blue had impaired membrane integrity and were classified as non-viable cells, possibly 
undergoing necrosis or possible advanced apoptosis (Li et al., 2010
a
; Assanga et al., 
2013). All the cell lines exhibited a lag phase between day 1 and day 2 which indicated 
the cells were adapting to culture conditions and ready to divide. An exponential growth 
phase was observed between the 3
rd
 and the 7
th 
day, which indicated maximum cell 
proliferative activity, hence maximum cellular function. The cells reached the plateau or 
decline phase thereafter, indicating that cell proliferation slowed due to cell population 
becoming over-confluent ultimately leading to cell death at this stage which was due to 
the natural path of the cellular cycle (Raaphorst et al., 2004; Bai et al., 2012; 
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Darzynkiewicz, 2012).  
The next aim was to confirm the maintenance of the biological features of the original 
tumour and also to ensure that the cell lines had a well-defined human and glial origin. 
The cell lines were characterised for their expression of HLA-I, GFAP and VEGF to 
confirm that the cell lines were of human and glial origin and cancerous. These were 
compared to the respective isotype controls to measure the level of non-specific 
background signal caused by primary antibodies, based on the cell type.  
 
HLA-I expression was observed on all human derived cells except C2C12 cells (animal 
derived), which suggested that the cells used in the study were of human origin. The 
results were in accordance with other related study where HLA marker was used to 
confirm human origin of human derived cells (Belkin et al., 2013). GFAP expression 
was also observed on all glial cell lines confirming the glial origin. This was 
comparable to other studies, which reported that all astroglial cells, neural stem cells 
along with astroglial tumours such as astrocytoma and GBM characteristically express 
GFAP as their major filament protein (Abaza et al., 1998; Doetsch, 2003; Brahmachari 
et al., 2006; Kamphuis et al., 2012). Non-cancerous astrocytes characteristically express 
glial fibrillary acidic protein (GFAP) as their major filament protein, but cells derived 
from malignant astrocytoma show less evidence of astrocytic differentiation and usually 
do not express this antigen after prolonged culture in vitro (Sultana et al., 1998; Zhou 
and Skalli, 2000; Darling 2005). The GFAP expression was similar in all the glial cells, 
which suggested and verified that both non-cancerous and glioma cell cultures used in 
the study highly express GFAP as their filament protein and show high evidence of 
astrocytic differentiation. The prevalence of VEGF expression and isoforms has served 
as an important mediator of intense angiogenesis which is a characteristic of 
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glioblastoma. VEGF is normally expressed in healthy cells but over-expressed in the 
tumour cells predicting glioma aggressiveness (Leon et al., 1996; Oka et al., 2007; 
Takano et al., 2010; Hamerlik et al., 2012). In this study, VEGF was expressed in all 
tumour cells but weak to negligible expression was identified in non-cancerous 
SVGP12 cells. The results were comparable to other studies which demonstrated 
increased expression of VEGF in malignant glioma tissues compared to non-cancerous 
tissues with both ELISA and immunohistochemistry (Ferrara et al., 2003; Takano et al., 
2010; Hamerlik et al., 2012; Xu et al., 2013).  
 
Overall, characterisation of the cell lines confirmed that they had well defined origin 
and also depicted a defined proliferative growth rate. This data thereby confirmed 
suitability of the cell lines for the downstream experiments in determining the binding 
selectivity of aptamers using various techniques for targeting glioma.  
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CHAPTER 4 BINDING ANALYSIS OF SHORTENED RNA AND 
DNA APTAMERS 
4.1 Introduction 
A key step in the identification and selection of aptamers is the evaluation of the 
aptamer binding affinity for the target molecules. Aptamers can be quite large (typical 
length between 80-200 nucleotides) including the primer regions but only specific 
nucleotides in the loop and bulge region are likely to be responsible for binding, thus it 
is possible to remove non-essential portions or primer regions whilst retaining 
specificity. Three out of eight aptamers from Cerchia et al., (2009) publication (GL44, 
GL43, and GL56) were selected for the study as they had the lowest Kd (dissociation 
constant) and thus higher binding affinity towards U87MG cells (Cerchia et al., 2009). 
These aptamers were identified through the standard SELEX process and comprised of 
91 nucleotides (nt) for GL44, and 89 nt for GL43 and GL56 including the fixed primer 
sites of 23 nt on each side. The fixed primer sequences thus comprised of approximately 
50 % of the full sequences and therefore, may have an impact on binding and 
penetration into the cells.  
 
Generally, not all the nucleotides are necessary for target binding. Aptamer sequences 
can be optimised primarily towards the binding to targets by truncating few nucleotides 
within the aptamer sequence based on the secondary structure (Dey et al., 2005; Simons 
et al., 2012) or by simply deleting the primer sites from both ends (Jimenez et al., 
2012). Computational methods have suggested that aptamers with fixed primer 
sequences do not significantly influence the secondary structure and binding to the 
target (Cowperthwaite and Ellington, 2008). Other studies however, have reported 
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problems such as large numbers of false-positive binding sequences during selection 
process and also non-specific binding of the aptamers with primer sequences 
(Stoltenburg et al., 2007; Pan and Clawson, 2009). Jimenez et al., (2012) screened 
DNA aptamers sequences without primers and reported higher binding affinity and 
selectivity for lung adenocarcinoma cells. The study therefore hypothesised that 
removal of primer sites may improve the binding affinity towards the target and may 
result in high penetration into the target cells because of the smaller size. For the study 
here, the three aptamers were truncated at the primer ends and were subsequently 
renamed as shortened aptamers (SA44, SA43, and SA56).  
 
The knowledge of functional secondary structures can have a significant impact on 
aptamer engineering for optimising desired properties and thereby modifying aptamer 
function (Refer to section 1.12 for more details) (Rockey et al., 2011
a
; Fisher et al., 
2008). Studies based on aptamers and targets have also revealed complex folding 
structure where negative “Gibbs free energy”  ΔG) values plays a critical role for a 
successful aptamer sequence to function (Fischer et al., 2008). This is typically 
predicted using in silico modelling techniques such as M-fold. The shortened aptamers 
were primarily characterised by evaluating the predicted secondary structures using M-
Fold and binding affinity to the glioma cell line was compared with the aptamers 
published by Cerchia et al., (2009) M-Fold predicted potential lowest free energy 
structures that can be generated from the primary sequence taking hairpin loops and 
other structural formations into account (Zuker, 2003). The binding selectivity and 
localisation of the shortened RNA aptamers for glioma cells and their DNA homologues 
were then analysed using confocal microscopy and confirmed by flow cytometry. For 
binding experiments, random nucleotide sequences (SAN1 DNA and SAN2 DNA) were 
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used as negative controls. The nucleotide composition length of the test and control 
aptamers were the same, however, due to the random primary sequence of the control 
aptamers, it was hypothesised that they would not fold into the exact secondary 
structure as the test DNA aptamers reported, and therefore will not show binding and 
selectivity to the target cells. 
4.2 Results 
4.2.1 Characterisation of published and shortened RNA aptamers 
One (GL43 and GL56) or two (GL44) secondary structures were predicted per aptamer 
by the M-Fold program. All three aptamers (GL44, GL43 and GL56) also showed 
complex two - dimensional (2D) secondary structures, including four defined conserved 
stem-loop structures. The primer regions from the predicted secondary GL44 and GL43 
aptamer differed by the presence of two cytosines (cyt42 and cyt43) at the 42
nd
 and 43
rd 
position in GL44 but not GL43, this however, did not alter affinity for the target cells 
(Figure 4.1). Truncating the primer ends from both the sides resulted in shorter base 
sequences and new predicted secondary structure with low free energies. A similar 
structure of a stem-bulge-stem-loop was predicted for the shortened aptamers SA44 and 
SA43 with similar Gibb‟s free energy  Figure 4 2   These stem-loop structures of 
aptamers are likely to play fundamental role in binding to a target molecule.  
 
Aptamer-target complexes often reveal low dissociation constants that range from 
nanomolar to picomolar levels (Tombelli et al., 2005; Cerhcia et al., 2009). As 
mentioned in section 4.1, Cerchia et al., demonstrated that GL44 RNA, GL43 RNA and 
GL56 RNA showed higher binding affinity and specificity for the target U87MG cells 
(Cerchia et al., 2009). The next approach was therefore to identify if the shortened 
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aptamers had similar binding capability to target U87MG cells (Refer to section 2.5). 
Binding curves were plotted using the average mean fluorescence intensity (MFI) of 
Cy3 labelled aptamers against various aptamer concentrations from three independent 
experiments (Figure 4.3). The binding assay showed that the shortened aptamers could 
strongly bind to target cells in the nanomolar range. Comparison of the Kd for the 
shortened aptamers showed that SA44 RNA and SA43 RNA bound with higher affinity 
(15.7 ± 3.43 nM and 13.89 ± 5.7 nM) than SA56 RNA (41.48 ± 16.96 nM) to U87MG 
cells with their Kd values in nanomolar range. Comparison of maximum binding sites 
(Bmax) for the shortened aptamers showed that SA56 RNA had higher maximum 
binding capacity as indicated by the higher MFI (1571 ± 201.3) compared to SA44 
RNA (460.2 ± 64.21) and SA43 RNA (303.8 ± 20.47) for U87MG cells. The shortened 
aptamers SA44 RNA and SA43 RNA also showed almost three times decrease in their 
Kd values indicating their higher binding affinity to U87MG compared to the GL44 (38 
± 3 nM) and GL43 RNA (44 ± 4 nM) (Cerchia et al., 2009).  
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Figure 4.1 Primary sequence and secondary structure of the selected published 
aptamers with high binding affinity for U87MG cells and lowest free energies. 
From left to right, primary sequences showing 91 base length and 89 base length for 
selected single stranded RNA aptamers GL44 RNA, and GL43 RNA and GL56 RNA 
aptamers, respectively (Cerchia et al., 2009). Note the difference in the sequences GL44 
RNA and GL43 RNA with the presence of two cytosines (cyt42 and cyt43) in GL44 
RNA which is absent in GL43 RNA (red). Sequences in bold were truncated to form 
new shortened aptamers. Predicted folding with lowest free energies of published 
aptamers using M-fold software (Zuker, 2003). Binding affinity (Kd) values for target 
U87MG cells is also shown (Cerchia et al., 2009). Dashes between nucleotides indicate 
Watson-Crick base pairs. All three aptamers showed complex 2D secondary structures, 
including four defined conserved stem-loop structures. 
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Figure 4.2 Primary sequences and predicted secondary structures of shortened 
aptamers SA44 RNA, SA43 RNA, and SA56 with lowest free energies. From left to 
right, primary sequences showing 45 base length and 43 base length for shortened 
single stranded RNA aptamers SA44 RNA, and SA43 RNA and SA56 RNA aptamers, 
respectively from Cerchia et al., (2009) publication. Note the difference in the 
sequences SA44 RNA and SA43 RNA with the presence of two cytosines (cyt19 and 
cyt20) in SA44 RNA which is absent in SA43 RNA (red). Predicted folding with lowest 
free energies of shortened single stranded RNA aptamers using M-fold software (Zuker, 
2003). Dashes between nucleotides indicate Watson-Crick base pairing.  
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Figure 4.3 Determination of binding affinity (Kd) of the shortened aptamers SA44 
RNA, SA43 RNA, and SA56 RNA to the target U87MG cells. Aptamers were 
incubated with live U87MG cells and analysed by flow cytometry. The average mean 
fluorescence intensity (MFI) of the cells was plotted against varying concentrations of 
the Cy3 labeled aptamers (0.5 – 200 nM) and analysed using non-linear regression 
analysis. (A) Binding curve of aptamer SA44 RNA, (B) binding curve of aptamer SA43 
RNA, and (C) binding curve of aptamer SA56 RNA on U87MG cells (n = 3). 
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4.2.2 Concentration dependent binding study of shortened aptamers in live 
U87MG cells 
The binding assay results in section 4.2.1 also helped to determine the optimum 
concentration of each shortened Cy3-labelled aptamer for binding live U87MG cells. 
This was accomplished using flow cytometry to measure the aptamer concentration at 
which Kd values started reaching saturation point. The mean fluorescence intensity 
(MFI) values of the Cy3 labelled aptamers bound to the live U87MG cells increased 
with an increasing aptamer concentration until reaching the plateau phase at 100 nM 
after 90 min incubation (Figure 4.3), hence this concentration was chosen for further 
analysis.  
 
Confocal microscopy was used to confirm the concentration dependent uptake and to 
determine the localisation of the aptamers in U87MG cells. Live U87MG cells were 
incubated with Cy3- labelled aptamers with increasing concentrations ranging from 5 
nM to 100 nM for 90 min at 37 °C and then analysed using confocal microscopy 
(Section 2.6.1). Untreated cells were incubated with complete growth medium alone. 
Figures 4.4, 4.5, and 4.6 represent middle section single plane images of the Z- axis for 
the Cy3 labelled SA44 RNA, SA43 RNA, and SA56 RNA aptamers with live U87MG 
cells, respectively. The results from Z stacks imaging indicated that the uptake was 
concentration dependent with lower uptake on lower concentrations and higher uptake 
at higher concentrations. Negligible uptake was observed at lowest concentration 5 nM. 
The binding started at 20 nM showing minimal Cy3 signal concentration non-uniformly 
distributed in the cytoplasm, however, aptamer started accumulating in the cytoplasm 
with the increase in the aptamer concentration after 20 nM. Maximum Cy3 fluorescence 
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signal was observed starting from 80 nM and from 40 nM in the cytoplasm for aptamers 
SA44 and SA43 RNA (figures 4.4 and 4.5), and SA56 RNA (figure 4.6), respectively. 
The 100 nM aptamer concentration showed the best contrast between unstained nucleus 
and stained cell cytoplasm, suggesting that the aptamers were mainly localised in cell 
cytoplasm. The data from sections 4.2.1 and 4.2.2 led to further study of the shortened 
aptamers for their binding selectivity on other cell types. 
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Figure 4.4 Concentration dependent uptake and cellular localisation of SA44 RNA 
aptamer. Cy3 labelled SA44 RNA was incubated separately at varying concentrations 
ranging from 5 nM to 100 nM on live U87MG cells (red) and fixed using 4 % PFA. The 
nuclei were counterstained with DAPI (blue) and mounted. U87MG cells with no 
aptamer were used as control. Z-stacks were acquired under 40x magnifications at an 
excitation of 543 nm and emission of 560 nm under 1047-camera resolution (amplifier 
gain: 1; detector gain: 927; amplifier offset: - 0.06). Data are representative of three 
independent experiments with single plane images of a middle section of Z- axis. In 
each section, 1
st 
column represents image of nucleus stained with DAPI; 2
nd
 column 
represents Cy3 aptamer and 3
rd
 column represents the merge of DAPI and Cy3 image. 
Uptake was observed in a concentration dependent manner and mainly localised in 
cytoplasm. A Untreated cells (control); B 5 nM, SA44 RNA; C 20 nM, SA44 RNA; D 
40 nM, SA44 RNA; E 80 nM, SA44 RNA; F 100 nM, SA44 RNA   ar = 20 μm   
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Figure 4.5 Concentration dependent uptake and cellular localisation of SA43 RNA 
aptamer. Cy3 labelled SA43 RNA was incubated separately at varying concentrations 
ranging from 5 nM to 100 nM on live U87MG cells (red) and fixed using 4 % PFA. The 
nuclei were counterstained with DAPI (blue) and mounted. U87MG cells with no 
aptamer were used as control. Z-stacks were acquired under 40x magnifications at an 
excitation of 543 nm and emission of 560 nm under 1047-camera resolution (amplifier 
gain: 1; detector gain: 927; amplifier offset: - 0.06). Data are representative of three 
independent experiments with single plane images of a middle section of Z- axis. In 
each section, 1
st
 column represents image of nucleus stained with DAPI; 2
nd
 column 
represents Cy3 aptamer and 3
rd
 column represents the merge of DAPI and Cy3 image. 
Uptake was observed in a concentration dependent manner and mainly localised in 
cytoplasm. A Untreated cells (control); B 5 nM, SA43 RNA; C 20 nM, SA43 RNA; D 
40 nM, SA43 RNA; E 80 nM, SA43 RNA; F 100 nM, SA43 RNA. Bar = 20 μm  
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Figure 4.6 Concentration dependent uptake and cellular localisation of SA56 RNA 
aptamer. Cy3 labelled SA56 RNA was incubated separately at varying concentrations 
ranging from 5 nM to 100 nM on live U87MG cells (red) and fixed using 4 % PFA. The 
nuclei were counterstained with DAPI (blue) and mounted. U87MG cells with no 
aptamer were used as control. Z-stacks were acquired under 40x magnifications at an 
excitation of 543 nm and emission of 560 nm under 1047-camera resolution (amplifier 
gain: 1; detector gain: 927; amplifier offset: - 0.06). Data are representative of three 
independent experiments with single plane images of a middle section of Z- axis. In 
each section, 1
st 
column represents image of nucleus stained with DAPI; 2
nd
 column 
represents Cy3 aptamer and 3
rd
 column represents the merge of DAPI and Cy3 image. 
Uptake was observed in a concentration dependent manner and mainly localised in 
cytoplasm. A Untreated cells (control); B 5 nM, SA56 RNA; C 20 nM, SA56 RNA; D 
40 nM, SA56 RNA; E 80 nM, SA56 RNA; F 100 nM, SA56 RNA. Bar = 20 μm.  
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4.2.3 Selective uptake of shortened RNA aptamers in live cell lines 
The identification of a small set of aptamers SA44 RNA, SA43 RNA and SA56 RNA 
which showed high affinity for U87MG glioma cells raised an obvious question of 
whether these aptamers may bind as well to other cell types and whether they were able 
to discriminate cancerous from non-cancerous cells. To this aim, the cell type selectivity 
was determined by measuring the uptake of each aptamer at the same concentration, 
100 nM, on a panel of unrelated cell lines. Glioma cells 1321N1 and U87MG (grade IV, 
tumorigenic in vivo), T98G (grade IV, non-tumorigenic in vivo) and non-cancerous 
foetal astrocytes SVGP12, including non-glioma cells MCF-7 (breast cancer) and T24 
(bladder cancer) were utilised for the study. Aptamer uptake was assessed using 
confocal microscopy and further confirmed by flow cytometry.  
4.2.3.1 Selective uptake of aptamers SA44 RNA, SA43 RNA and SA56 RNA by 
confocal microscopy 
The cells were treated with 100 nM of SA44 RNA, SA43 RNA and SA56 RNA aptamer 
for 90 minutes at 37 °C and then analysed using confocal microscopy. Z-stacks and 3D 
projections were obtained to determine the level of fluorescence obtained for each 
aptamer on each cell lines (Section 2.6). The presence of a more intense Cy3-
fluorescence signal compared to the untreated control (no aptamer) indicated aptamer 
uptake and therefore the binding selectivity of the aptamers on various cell lines. 
Figures 4.7 and 4.8 indicated that tumorigenic cell lines U87MG and 1321N1 exhibited 
detectable Cy3-fluorescence (binding) in their cytoplasm for SA44 and SA43 RNA 
aptamers, when compared to the respective untreated controls. No detectable 
fluorescence was observed in SVGP12, T98G, T24, and MCF-7 cells compared to the 
untreated control. Similarly, SA56 RNA aptamer exhibited detectable Cy3-fluorescence 
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for U87MG and 1321N1 in the cytoplasm; however, it also showed moderate detectable 
Cy3 fluorescence in SVGP12, T98G, and T24 cells (Figure 4.9). The data suggested 
that SA44 RNA and SA43 RNA had increased uptake towards U87MG and 1321N1 
compared to other cell lines. SA56 RNA, on the other hand showed no selective uptake 
on glioma cells, as the staining was prominent for other cells types too.  
Chapter 4                                                 Binding analysis of shortened RNA and DNA aptamers 
 
 
 
109 
 
Figure 4.7 Selective uptake of SA44 RNA on live cell lines assessed by confocal 
microscopy. Cy3 labelled SA44 RNA (red) was incubated separately at a concentration 
of 100 nM on live 1321N1, U87MG, T98G, SVGP12, MCF-7, and T24 cells for 90 
minutes at 37 °C and fixed using 4 % PFA. The nuclei were counterstained with DAPI 
(blue). Cells with no aptamer and media alone were used as control. Z-stacks were 
acquired under 40x magnifications at an excitation of 543 nm and emission of 560 nm 
under 1047-camera resolution (amplifier gain: 1; detector gain: 927; amplifier offset: - 
0.06). Data are representative of at least three independent experiments with single 
plane images of middle section of Z-axis. The Cy3 fluorescence signal of the aptamer 
for each cell line was compared to their respective untreated controls. A and C High 
uptake of SA44 RNA in U87MG and 1321N1 cells respectively. A’ and C’ Merged 
DAPI image of SA44 RNA localised in the cytoplasm of U87MG cells and 1321N1 
cells respectively. E, G, I, and K Negligible uptake of SA44 RNA in SVGP12, T98G, 
T24, and MCF-7 cells, respectively. E’, G’, I’, and K’ Merged DAPI image of SA44 
RNA in SVGP12, T98G, T24, and MCF-7 cells, respectively. B, D, F, H, J, and L No 
detectable Cy3 fluorescence signal in untreated U87MG, 1321N1, SVGP12, T98G, 
T24, and MCF-7, respectively. B’, D’, F’, H‟, J’, and L‟ Merged DAPI image of 
untreated U87MG, 1321N1, SVGP12, T98G, T24, and MCF-7 cells, respectively. Bar = 
20μm.  
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Figure 4.8 Selective uptake of SA43 RNA on live cell lines assessed by confocal 
microscopy. Cy3 labelled SA43 RNA (red) was incubated separately at a concentration 
of 100 nM on live 1321N1, U87MG, T98G, SVGP12, MCF-7, and T24 cells for 90 
minutes at 37 °C and fixed using 4 % PFA. The nuclei were counterstained with DAPI 
(blue). Cells with no aptamer and media alone were used as control. Z-stacks were 
acquired under 40x magnifications at an excitation of 543 nm and emission of 560 nm 
under 1047-camera resolution (amplifier gain: 1; detector gain: 927; amplifier offset: - 
0.06). Data are representative of at least three independent experiments with single 
plane images of middle section of Z- axis. The Cy3 fluorescence signal of the aptamer 
on each cell lines were compared to their respective untreated controls. A and C High 
uptake of SA43 RNA in U87MG and 1321N1 cells respectively. A’ and C’ Merged 
DAPI image of SA43 RNA localised in the cytoplasm of U87MG cells and 1321N1 
cells respectively. E, G, I, and K Negligible uptake of SA43 RNA in SVGP12, T98G, 
T24, and MCF-7 cells, respectively. E’, G’, I’, and K’ Merged DAPI image of SA43 
RNA in SVGP12, T98G, T24, and MCF-7 cells, respectively. B, D, F, H, J, and L No 
detectable Cy3 fluoresccence signal in untreated U87MG, 1321N1, SVGP12, T98G, 
T24, and MCF-7, respectively. B’, D’, F’, H’, J’, and L’ Merged DAPI image of 
untreated U87MG, 1321N1, SVGP12, T98G, T24, and MCF-7 cells, respectively. Bar = 
20 μm  
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Figure 4.9 Selective uptake of SA56 RNA on live cell lines assessed by confocal 
microscopy. Cy3 labelled SA56 RNA (red) was incubated separately at a concentration 
of 100 nM on live 1321N1, U87MG, T98G, SVGP12, MCF-7, and T24 cells for 90 
minutes at 37 °C and fixed using 4 % PFA. The nuclei were counterstained with DAPI 
(blue) and mounted. Cells with no aptamer and media alone were used as control. Z-
stacks were acquired under 40x magnifications at an excitation of 543 nm and emission 
of 560 nm under 1047-camera resolution (amplifier gain: 1; detector gain: 927; 
amplifier offset: - 0.06). Data are representative of at least three independent 
experiments with single plane images of middle section of Z- axis. The Cy3 
fluorescence signal of the aptamer on each cell lines were compared to their respective 
untreated controls. A and C High uptake of SA56 RNA in U87MG and 1321N1 cells 
respectively. A’ and C’ Merged DAPI image of SA56 RNA localised in the cytoplasm 
of U87MG and 1321N1 cells respectively. E, G, and I Moderate uptake of SA56 RNA 
in SVGP12, T98G, and T24 cells, respectively. E’, G’, and I’ Merged DAPI image of 
SA56 RNA showing moderate Cy3 fluorescence signal localised in the cytoplasm in 
SVGP12, T98G, and T24, respectively. K Negligible uptake of SA56 RNA in MCF-7 
cells. K’ Merged DAPI image of SA56 RNA in MCF-7 cells.B, D, F, H, J, and L No 
detectable Cy3 fluorescence signal in untreated U87MG, 1321N1, SVGP12, T98G, 
T24, and MCF-7, respectively. B’, D’, F’, H’, J’, and L’ Merged DAPI image of 
untreated U87MG, 1321N1, SVGP12, T98G, T24 and MCF-7 cells, respectively. Bar = 
20 μm  
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4.2.3.2 Confirmation of selective uptake of the aptamers SA44 RNA, SA43 RNA and SA56 RNA 
by flow cytomtery. 
Glioma and glial cells (1321N1, U87MG, T98G and SVGP12), breast cancer cells 
(MCF-7) and bladder cancer cells (T24) were used for the study. The binding selectivity 
and uptake of SA44, SA43, SA56 was determined by incubating live cells with 100 nM 
concentration of the aptamers at 37 °C (5 % CO2) for 90 minutes (Section 2.7.1). 
Aptamers SA44 RNA and SA43 RNA demonstrated an increase in uptake towards 
U87MG and 1321N1 cells compared to other cell types (Figures 4.10 and 4.11). SA56 
RNA showed increased uptake in 1321N1 and U87MG cells, however, non-specific 
uptake was also observed in SVGP12, T98G, T24, and MCF-7 cells (Figure 4.12).  
 
A Shapiro-Wilk‟s test  p > 0.05) showed that the sample data were normally distributed 
among the respected cell groups. One-way ANOVA test revealed that there was a 
significant difference in the means of average MFI values of each shortened RNA 
aptamer between cell groups (p < 0.05). A post hoc Bonferroni test was therefore 
performed, which revealed that SA44 RNA and SA43 RNA showed significant 
differences in MFI values generated from 1321N1 and U87MG cells compared to 
SVGP12, T98G, T24 and MCF-7 cells (p < 0.01) (Figure 4.13). There was no 
significant difference observed in MFI values between 1321N1 and U87MG cells, and 
between SVGP12, T98G, T24, and MCF-7 cells treated with the aptamers SA44 and 
SA43 RNA (p > 0.05). On the contrary, SA56 RNA showed no significant difference 
between the MFI values of U87MG, 1321N1, SVGP12 (p > 0.05) cells (Figure 4.14). 
There was however, a significant difference observed in MFI values of U87MG, 
1321N1 and SVGP12 compared to T98G, T24, and MCF-7 cells (p < 0.01), which 
suggested that aptamer SA56 RNA showed no significant selectivity for glioma cells 
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compared to the non-cancerous glial cells, yet the ability to distinguish tumorigenic 
glioma cells (U87MG and 1321N1) from non-tumorigenic (T98G) or non-glioma cells 
(MCF-7 and T24).  
Chapter 4                                                 Binding analysis of shortened RNA and DNA aptamers 
 
 
 
117 
 
Figure 4.10 Representative flow cytometry profiles and quantitative analysis of the 
uptake of SA44 RNA on various cell lines. Cy3 labelled SA44 RNA aptamer (100 
nM) was incubated with live U87MG, 1321N1, SVGP12, T98G, T24 and MCF-7 cells 
at 37 °C (5 % CO2) for 90 minutes. Untreated cells were incubated with complete 
growth medium alone. The blue curve represented the background mean fluorescence 
intensity (MFI) of the untreated cells (control) and the red curve represented the MFI 
(uptake) of the cells treated with SA44 RNA on U87MG (A), 1321N1 (B) SVGP12 (C), 
T98G (D), T24 (E), and MCF-7 cells (F).  
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Figure 4.11 Representative flow cytometry profiles and quantitative analysis of the 
uptake of SA43 RNA on various cell lines.  Cy3 labelled SA43 RNA aptamer (100 
nM) was incubated with live U87MG, 1321N1, SVGP12, T98G, T24 and MCF-7 cells 
at 37 °C (5 % CO2) for 90 minutes. Untreated cells were incubated with complete 
growth medium alone. The blue curve represented the background mean fluorescence 
intensity (MFI) of the untreated cells (control) and the red curve represented the MFI 
(uptake) of the cells treated with SA43 RNA aptamer on U87MG (A), 1321N1 (B) 
SVGP12 (C), T98G (D), T24 (E), and MCF-7 cells (F).  
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Figure 4.12 Representative flow cytometry profiles and quantitative analysis of the 
uptake of SA56 RNA on various cell lines.  Cy3 labelled SA56 RNA aptamer (100 
nM) was incubated with U87MG, 1321N1, SVGP12, T98G, T24 and MCF-7 cells at 37 
°C (5 % CO2) for 90 minutes. Untreated cells were incubated with complete growth 
medium alone. The blue curve represented the background mean fluorescence intensity 
(MFI) of the untreated cells (control) and the red curve represented the MFI (uptake) of 
the cells treated with SA56 RNA aptamer on U87MG (A), 1321N1 (B) SVGP12 (C), 
T98G (D), T24 (E), and MCF-7 cells (F). 
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Figure 4.13 Comparative binding selectivity of aptamers SA44 RNA and SA43 
RNA across various cell lines. Binding selectivity was measured using 100 nM 
concentration of SA44 RNA (A) and SA43 RNA (B) aptamers. The background MFI 
values for the untreated corresponding cells were subtracted. Statistical significance of 
the differences in MFI values of SA44 RNA referred to its high binding selectivity for 
U87MG and 1321N1 cells compared to SVGP12, T98G, T24, and MCF-7 cells (** = p 
< 0.01; n=3). 
 
 
 
Figure 4.14 Comparative binding selectivity of aptamer SA56 RNA across various 
cell lines. Binding selectivity was measured using 100 nM concentration of SA56 RNA 
aptamer. The background MFI values for the untreated corresponding cells were 
subtracted. There was no significant difference in the uptake of SA56 RNA aptamer in 
U87MG, 1321N1 and SVGP12 cells, and between T98G, T24 and MCF-7 cells (p > 
0.05). Statistical significance of the differences in MFI values of SA56 RNA referred to 
higher uptake in U87MG, 1321N1 and SVGP12 cells compared to T98G, T24 and 
MCF-7 cells (** = p < 0.01; n = 3). 
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4.2.4 Comparison of binding affinity of the shortened RNA aptamers with the 
DNA homologs. 
An experiment was performed to compare the binding affinities of DNA and RNA 
homologues of the aptamers used in the study. As previously shown, SA44 RNA and 
SA43 RNA showed more uptake and binding selectivity towards glioma than SA56 
RNA (Section 4.2.3), therefore, only the DNA homologues of these two aptamers 
(SA44 DNA and SA43 DNA) were further studied. The binding assay for the detection 
of Cy3 labelled aptamers bound to cells was measured by flow cytometry. The detected 
MFI showed that these DNA aptamers can also bind strongly bind to U87MG cells in 
nanomolar range. Moreover, like the RNA versions (section 4.2.1), similar binding 
affinity was observed for SA44 DNA (Kd, 21.11 ± 3.30 nM) and SA43 DNA (Kd, 21.56 
± 4.60 nM) for U87MG cells (Figure 4.15).  
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Figure 4.15 Determination of binding affinity (Kd) of aptamers SA44 DNA and 
SA43 DNA towards the target U87MG cells. Aptamers were incubated with live 
U87MG cells and analysed by flow cytometry. The average mean fluorescence intensity 
(MFI) of the cells was plotted against varying concentrations of the Cy3 labeled 
aptamers (0.5 – 200 nM) and analysed using non-linear regression analysis (A) Binding 
curve of aptamer SA44 DNA on U87MG cells. (B) Binding curve of aptamer SA43 
DNA on U87MG cells.  
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4.2.5 Selective uptake of the lead DNA aptamers on various cell types  
The uptake and binding selectivity of the DNA aptamers measured by confocal 
microscopy (Section 2.6.2) was further confirmed by flow cytometry (Section 2.7.1) 
under similar conditions to that of RNA aptamers. Before, performing the binding 
studies of the lead DNA aptamers (SA44 and SA43 DNA), a pilot study was performed 
to determine the uptake and binding selectivity of the random DNA aptamers (SAN1 
and SAN2 DNA) by confocal microscopy (Section 2.6.2). No detectable Cy3 
fluorescence was observed on all cells with SAN1 DNA and SAN2 DNA aptamer 
(Figure 4.16), which indicated that the aptames was non-selective for any cell types. 
This suggested that both random sequence aptamers could act as a negative control for 
the study and either will be referred to as „random aptamer‟ from here on in   
 
Figures 4.17 and 4.18 indicated that tumorigenic cell lines U87MG and 1321N1 
exhibited detectable Cy3-fluorescence (binding) in the cytoplasm for SA44 and SA43 
DNA aptamers, when compared to the respective untreated controls and the random 
aptamer as measured by confocal microscopy. No detectable fluorescence was observed 
on SVGP12, T98G, T24, and MCF-7 cells. The data suggested that SA44 DNA and 
SA43 DNA reflected the binding characteristics of RNA counterparts with increased 
cytoplasmic uptake and selectivity towards tumorigenic glioma compared to non-
tumorigenic glioma, non- cancerous, and non-glioma cell types (Section 4.2.3).  
 
Aptamers SA44 DNA and SA43 DNA further demonstrated an increase in uptake 
towards U87MG and 1321N1 cells as compared to other cell types as measured by flow 
cytometry (Figures 4.19 and 4.20). A one-way ANOVA revealed that there was a 
significant difference in the MFI values of each shortened aptamer between individual 
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cell groups (Figure 4.21). Post hoc Bonferroni test revealed that SA44 DNA and SA43 
DNA showed significant differences in their MFI values generated from 1321N1 and 
U87MG compared to SVGP12, T98G, T24, and MCF-7 cells (p < 0.05). There was no 
significant difference observed in MFI values between SVGP12, T98G, T24, and MCF-
7 cells (p > 0.05). This confirmed that DNA aptamers SA44 and SA43 demonstrated 
significant binding selectivity for U87MG and 1321N1 cells compared to other cell 
lines. Overall, this data suggested that both shortened DNA and RNA aptamers were 
highly selective for tumorigenic glioma cells.  
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Figure 4.16 Uptake of random aptamers SAN1 and SAN2 DNA on various cell 
lines by confocal microscopy. Cy3 labelled SAN1 and SAN2 DNA (red) were 
incubated separately at a concentration of 100 nM on live 1321N1, U87MG, T98G, 
SVGP12, MCF-7, and T24 cells for 90 minutes at 37 °C and fixed using 4 % PFA. The 
nuclei were counterstained with DAPI (blue) and mounted. Cells with no aptamer and 
media alone were used as control. Z-stacks images were acquired under 40x 
magnifications at an excitation of 543 nm and emission of 560 nm under 1047-camera 
resolution (amplifier gain: 1; detector gain: 927; amplifier offset: - 0.06). Data are 
representative of three independent experiments with single plane images of middle 
section of Z- axis. The Cy3 fluorescence signal of the aptamer on each cells were 
compared to their respective untreated controls. A, B, C, D, E, and F represent merged 
Cy3 and DAPI image with no detectable Cy3 fluorescence on untreated U87MG, 
1321N1, SVGP12, T98G, T24 and MCF-7, respectively. G, H, I, J, K, and L represent 
merged Cy3 and DAPI image with no detectable Cy3 fluorescence with SAN1 DNA 
treated U87MG, 1321N1, SVGP12, T98G, T24 and MCF-7 cells, respectively 
compared to the respective untreated cells. Similarly, M, N, O, P, Q, and R represent 
merged Cy3 and DAPI image with no detectable Cy3 fluorescence with SAN2 DNA 
treated U87MG, 1321N1, SVGP12, T98G, T24 and MCF-7 cells, respectively 
compared to the respective untreated cells. Scale bar = 20μm.  
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Figure 4.17 Selective uptake of SA44 DNA on various cell lines using confocal 
microscopy. Cy3 labelled SA44 DNA (red) and random aptamer (RA) were 
incubated separately at a concentration of 100 nM on live 1321N1, U87MG, T98G, 
SVGP12, MCF-7, and T24 cells for 90 minutes at 37 °C and fixed using 4 % PFA. 
The nuclei were counterstained with DAPI (blue). Cells with random aptamer and 
media alone were used as control. Z-stacks were acquired under 40x magnifications 
at an excitation of 543 nm and emission of 560 nm under 1047-camera resolution 
(amplifier gain: 1; detector gain: 927; amplifier offset: - 0.06). Data are 
representative of three independent experiments with single plane images of middle 
section of Z- axis. The Cy3 fluorescence signal of the SA44 DNA aptamer on each 
cells were compared to the random aptamer and respective untreated controls. A, B, 
C, D, E, and F represent merged Cy3 and DAPI image of untreated U87MG, 
1321N1, SVGP12, T98G, T24, and MCF-7 cells, respectively. G, H, I, J, K, and L 
represent merged Cy3 and DAPI image of random aptamer (RA) showing 
negligible uptake and binding on U87MG, 1321N1, SVGP12, T98G, T24, and 
MCF-7 cells, respectively. M (M’) and N (N’) represents Cy3 and merged DAPI 
image showing high uptake and cytoplasmic binding of SA44 DNA in U87MG 
cells and 1321N1 cells respectively. O (O’), P (P’), Q (Q’), and R (R’) represent 
Cy3 and merged DAPI image of SA44 DNA showing negligible uptake in 
SVGP12, T98G, T24, and MCF-7 cells, respectively. Bar = 20 μm. 
Chapter 4                                                 Binding analysis of shortened RNA and DNA aptamers 
 
 
 
128 
 
 
 
 
Chapter 4                                                 Binding analysis of shortened RNA and DNA aptamers 
 
 
 
129 
Figure 4.18 Selective uptake of SA43 DNA on various cell types using confocal 
microscopy. Cy3 labelled SA43 DNA (red) and random aptamer (RA) were incubated 
separately at a concentration of 100 nM on live 1321N1, U87MG, T98G, SVGP12, 
MCF-7, and T24 cells for 90 minutes at 37 °C and fixed using 4 % PFA. The nuclei 
were counterstained with DAPI (blue). Cells with random aptamer and media alone 
were used as control. Z-stacks were acquired under 40x magnifications at an excitation 
of 543 nm and emission of 560 nm under 1047-camera resolution (amplifier gain: 1; 
detector gain: 927; amplifier offset: - 0.06). Data are representative of three independent 
experiments with single plane images of middle section of Z- axis. The Cy3 
fluorescence signal of the SA43 DNA aptamer on each cells were compared to the 
random aptamer and respective untreated controls. A, B, C, D, E, and F represent 
merged Cy3 and DAPI image of untreated U87MG, 1321N1, SVGP12, T98G, T24, and 
MCF-7 cells, respectively. G, H, I, J, K, and L represent merged Cy3 and DAPI image 
of random aptamer (RA) showing negligible uptake and binding on U87MG, 1321N1, 
SVGP12, T98G, T24, and MCF-7 cells, respectively. M (M’) and N (N’) represents 
Cy3 and merged DAPI image showing high uptake and cytoplasmic binding of SA43 
DNA in U87MG cells and 1321N1 cells respectively. O (O’), P (P’), Q (Q’), and R 
(R’) represent Cy3 and merged DAPI image of SA43 DNA showing negligible uptake 
in SVGP12, T98G, T24, and MCF-7 cells, respectively. Bar = 20 μm. 
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Figure 4.19 Representative flow cytometry profiles of the uptake of SA44 DNA on 
various cell lines. Cy3 labelled SA44 DNA aptamer and random aptamer (100 nM) 
were incubated separately with live U87MG, 1321N1, SVGP12, T98G, T24 and MCF-7 
cells at 37 °C (5 % CO2) for 90 minutes. Untreated cells were incubated with complete 
growth medium alone. The blue curve represents the background mean fluorescence 
intensity (MFI) of the untreated cells (control). The green and red curve represents the 
MFI (uptake) of the cells treated with random aptamer and SA44 DNA aptamer 
repectively, on U87MG (A), 1321N1 (B) SVGP12 (C), T98G (D), T24 (E), and MCF-7 
cells (F). 
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Figure 4.20 Representative flow cytometry profiles of the uptake of SA43 DNA on 
various cell lines. Cy3 labelled SA43 DNA aptamer and random aptamer (100 nM) 
were incubated separately with live U87MG, 1321N1, SVGP12, T98G, T24 and MCF-7 
cells at 37 °C (5 % CO2) for 90 minutes. Untreated cells were incubated with complete 
growth medium alone. The blue curve represents the background mean fluorescence 
intensity (MFI) of the untreated cells (control). The green and red curve represents the 
MFI (uptake) of the cells treated with random aptamer and SA43 DNA aptamer 
repectively, on U87MG (A), 1321N1 (B) SVGP12 (C), T98G (D), T24 (E), and MCF-7 
cells (F). 
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Figure 4.21 Comparative binding selectivity of aptamer SA44 DNA and SA43 DNA 
across various cell types. Binding selectivity was measured using 100 nM 
concentration of SA43 DNA (A) and SA43 DNA (B) aptamer. The background MFI 
values for the random aptamer treated cells were subtracted. Statistical significance of 
the differences in MFI values of SA44 DNA and SA43 DNA between U87MG and 
1321N1 versus SVGP12, T98G, T24, and MCF-7 referred to its high binding selectivity 
for U87MG and 1321N1 cells (** = p < 0.01). No statistical difference was observed 
between U87MG and 1321N1 cells for both the aptamers (p > 0.05; n = 3).  
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4.2.6 Summary of results for the binding selectivity of DNA and RNA aptamers 
Following analysis of the images obtained from the confocal microscopy and 
quantitative data obtained from flow cytomtery, a comparative summary of all aptamers 
on all cell lines was performed. The overall results were expressed by addition of data 
from confocal (strong binding) and flow cytometry (significant selectivity with high 
uptake) analysis (Table 4.1). 
  
Table 4.1 Summary of uptake and binding selectivity of aptamers on various cell 
types. 
 
 
The overall data suggested that the shortened aptamers SA44 RNA and SA43 RNA and 
the DNA homologs showed similar and high binding selectivity to U87MG and 1321N1 
cells compared to the other cell types. This indicated they were highly specific for 
tumorigenic glioma cells. SA56 RNA showed strong binding selectivity to tumorigenic 
glioma cells, however, binding was also observed in non-cancerous SVGP12 cells. This 
indicated that SA56 RNA was non-specific to glioma.  
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4.3 Discussion 
It has previously been hypothesised that aptamers can be utilised for cancer detection 
(Shangguan et al., 2008; Cerchia et al., 2009; Bayrac et al., 2012; Kang et al., 2012; 
Jimenez et al., 2012; Li et al., 2014). The main aim of this chapter was to analyse the 
binding affinity and selectivity of the shortened aptamers to glioma cells. All three full 
length aptamers (GL44, GL43 and GL56) adopted from Cerchia et al., (2009) showed 
complex 2D secondary structures, including four defined conserved stem-loop 
structures and negative ΔG as predicted by the M-Fold program, which indicated that 
these stem-loop structures may be crucial for binding with higher stability and affinity 
(in nano-molar concentrations) to their target tumorigenic glioma cells. Shortened 
aptamers SA44 RNA, SA43 RNA and SA56 RNA were shown to have two stem-loop 
structures and negative ΔG as predicted by M-Fold program, which indicated that the 
aptamers were capable of folding into complex tertiary structure with higher stability 
that is necessary for binding to the target molecule. It has been established that the 
lower the Kd, the higher the binding affinity of the aptamers to the targets (Cerchia et 
al., 2009; Kang et al., 2012). This was demonstrated by higher binding affinity of SA44 
RNA and SA43 RNA towards U87MG cells with almost three times decrease in their 
Kd values as compared to the original full-length aptamers GL44 RNA and GL43 RNA. 
The increase in the binding affinity could be due to differences in secondary structures 
with nucleotides present in the stem-loops regions of shortened aptamers capable of 
binding to target sites with high affinity compared to those of original full-length 
aptamers. For example, the two stem-loop nucleotide regions in the shortened aptamers 
(SA) may be involved in binding to the targets on U87MG cells with more affinity than 
the nucleotides in four stem loop regions within the full length aptamers (GL) as 
predicted from the secondary structures. SA56 RNA (Kd, 41.48 ± 16.95 nM), however, 
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retained the same binding affinity as the full-length aptamer GL56 RNA (63 ± 3 nM), 
which indicated that the deletion of primer sequence of this aptamer did not alter the 
binding affinity to the target U87MG cells  Moreover, nucleotides “UAU” shared 
common regions within the stem-loops of secondary structures of GL56 and SA56 RNA 
aptamers, which indicated that these nucleotides might be involved in targeting U87MG 
cells. The results suggested that the shortened aptamers would be widely applicable, as 
they tightly bind to the target U87MG cells. In addition, because of the relatively small 
size, shortened aptamers may exhibit superior cell penetration (Hicke et al., 2001). 
 
One of the major challenges for in vitro targeting is the ability to direct the binding of 
the targeting aptamers to tumour cells instead of non-cancerous healthy cells (Bayrac et 
al., 2011, Gao et al., 2012). The aptamer specific for glioma cells compared to the other 
cell types can allow the specific identification of glioma without prior knowledge of any 
biomarkers or proteins present in the cells (Cerhcia et al., 2009; Keefe et al., 2010). 
U87MG and 1321N1 (wild-type p53, tumorigenic in vivo), T98G (mutant p53, non-
tumorigenic in vivo), SVGP12 (non-cancerous foetal astrocytes), T24 (bladder cancer), 
and MCF-7 (breast cancer) cells were chosen to be the best model to analyse the 
binding selectivity of the shortened aptamers because of the well-defined origin and 
defined proliferative growth rate of the cells (chapter 3).  
 
The tumour cell recognition was demonstrated by both confocal imaging and flow 
cytometry using Cy3 labelled aptamers at 100 nM concentration (Kd values reached 
saturation point). U87MG and 1321N1 cells exhibited intense Cy3-fluorescence 
staining in the cytoplasm after incubation with SA44 RNA and SA43 RNA aptamers, 
while the SVGP12 cells displayed no detectable fluorescence. Interestingly, T98G also 
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showed negligible uptake indicating the aptamers were specific to highly tumorigenic 
glioma cells and this was consistent with the GL44 and GL43 counterparts in Cerchia et 
al., (2009). This indicated, although there is a difference in the binding affinity between 
the full length (GL44 and GL43) and shortened aptamers (SA44 and SA43), the similar 
cell type selectivity for U87MG and not for T98G demonstrates that the targets could be 
the same for both the aptamers (Cerchia et al., 2009). Moreover, SA44 and SA43 RNA 
showed negligible uptake on bladder cancer and breast cancer cells, again, indicating 
selectivity towards tumorigenic glioma cells. Together, these results showed that the 
shortened aptamers SA44 RNA and SA43 RNA showed preferential binding to 
tumorigenic glioma cells. Similarly, SA56 RNA showed higher uptake on U87MG and 
1321N1; however, it also showed moderate uptake in the cytoplasm of SVGP12, T98G 
and T24 cells and negligible uptake in MCF-7 cells. The overall confocal data 
suggested that either the binding of these aptamers could depend on the target present in 
cancer cells, or that malignant tumours from different origins have different malignant-
related molecular determinants which are not recognised by the aptamers used in the 
study. 
 
Further exploration of specific cell recognition by the selected aptamers was 
demonstrated by flow cytometry, which offered significant advantage in terms of 
quantification and statistical power compared to confocal microscopy. Similar to the 
findings observed in confocal microscopy, the flow cytometry results overall 
demonstrated that aptamers SA44 RNA and SA43 RNA showed higher uptake and 
significant binding selectivity (p < 0.05) to tumorigenic glioma cells compared to the 
non-cancerous and non-glial cells. SA56 RNA aptamer however, showed no such 
selectivity for glioma cells U87MG and 1321N1 compared to the non-cancerous cells 
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SVGP12 (p > 0.05). This quantitative data established that aptamers SA44 and SA43 
only recognised targets presented on the 1321N1 and U87MG cells and therefore, 
showed potential as specific molecular probes for glioma tumour analysis. The results 
were comparable with other related studies, where aptamers have been selected using 
live cells as their target with selectivity for certain cell types. These aptamers were able 
to interact with particular molecules over-expressed on the cell surface of tumour cells 
(Pestourie et al., 2005; Chu et al., 2006; Shangguan et al., 2008; Jimenez et al., 2012; 
Kang et al., 2012).  
 
Similar binding affinity was observed for SA44 DNA (Kd, 21.11 ± 3.30 nM) and SA43 
DNA (Kd, 21.56 ± 4.60 nM) for U87MG cells compared to the RNA versions. 
Moreover, SA44 DNA and SA43 DNA were highly selective for tumorigenic glioma 
cells. The study also proved that there was no difference between the RNA aptamers 
and the DNA homologs in terms of their selectivity for glioma. Previous analyses have 
reported that there is very little difference between RNA and DNA aptamers in terms of 
affinity and specificity (Gold, 1995). Some studies however, reported major differences 
in their affinity and specificity. For example, Lauhon and Szostak demonstrated that the 
DNA form of an RNA aptamer for riboflavin could still bind its target, albeit with lower 
affinity than RNA (Lauhon and Szostak, 1995). Similarly, in the study by Travascio et 
al., (1999) a hemin-binding deoxyribozyme was converted to a ribozyme with a 30-fold 
loss of binding affinity to its targets. In another experiment, binding was abolished in 
the DNA homolog of the RNA aptamer for ATP (Dieckmann et al., 1999). DNA and 
RNA vary based on their individual nucleotides: uracil being associated with RNA and 
thymine with DNA  Furthermore, the presence of the 2‟-hydroxyl in RNA leading to α-
form structure in double helical regions, whereas, the absence of 2‟- hydroxyl in DNA 
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leading to β-form structure can affect the major and minor groove widths, the rise per 
base pair, the average axial diameter, and the twist angel in the final structure (Walsh 
and DeRosa, 2009). This in turn could affect the overall binding of the RNA and DNA 
aptamers to the targets. This could be the reason why single stranded DNA aptamers 
exhibits a propensity for forming intricate tertiary structures that is not comparable to 
that of RNA when binding to its target even though they are similar in basic structure. 
In this study, both RNA and their DNA homologues showed similar affinity and 
selectivity for tumorigenic glioma cells indicating that the putative target could be 
similar and highly accessible for both the types. DNA aptamers have shown greater 
stability than RNA aptamers and therefore are less susceptible to degradation because of 
the absence of the hydroxyl (OH) group in DNA (Min et al., 2008; Dupont et al., 2010). 
Given the ease of synthesis, reduced cost, potentially increased stability of DNA 
aptamer compared to its RNA homologue, and similar binding selectivity towards 
glioma, DNA versions of the shortened RNA aptamers were selected for further 
experiments.  
 
From the study, it can be concluded that the shortened aptamers SA44 RNA and SA43 
RNA and the DNA homologs were highly selective for glioma cells, presumably due to 
selective affinity between the aptamers and their targets for glioma. The aptamers could 
have been taken up by the tumorigenic glioma cells via active transport because of the 
saturation of Cy3 fluorescence intensity (MFI) in U87MG cells at higher concentrations 
indicating an active process. If the uptake was through passive transport then MFI 
values would increase linearly. The saturable activity, selective binding and cytoplasmic 
localisation of the aptamers to tumorigenic glioma cells at physiological temperature 
together supported the hypothesis that the aptamers were actively transported and may 
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target the cell surface receptors that are overexpressed in glioma which allowed 
aptamers to internalise via an unknown endocytic pathway. In addition, the cells after 
incubation with aptamers, were challenged with protease trypsin to collect the cells for 
flow cytometry which could potentially degrade all aptamers bound to the cell surface 
receptors. Therefore, the signal (MFI) was from the cells that allowed the aptamers to 
internalise. In addition, internalisation of the aptamers also highlighted a question if the 
aptamers have had any effect on the cell viability. All of these inferences have been 
addressed in next chapter. 
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CHAPTER 5 GLIOMA SPECIFIC INTERNALISATION STUDY OF 
THE DNA APTAMERS 
5.1 Introduction 
Aptamers which bind to cell-surface proteins such as cancer epitopes can be used for 
imaging applications and can differentiate between closely related cell types, such as 
non-cancerous and tumour cells (Hicke et al., 2001; Hicke et al., 2006; Cerchia et al., 
2009). Aptamers have been shown to inhibit cell growth on their own (Eugene et al., 
2006) or by conjugation with other moieties such as drug loaded nanoparticles (Li et al., 
2014). In addition, aptamers with cell-internalising properties can be developed for 
delivery of therapeutic agents such as small molecule drugs, radioisotopes, toxins, 
miRNAs and siRNAs into target cells (Dhar et al., 2008; Cao et al., 2009; Keefe et al., 
2010; Rocky et al., 2011). The latter strategy is likely to increase efficacy as well as 
reduce the potential unwanted toxic effects of the therapy because the aptamers would 
deliver the drug selectively to the cancerous cells while sparing the non-cancerous 
healthy cells.  
 
Several inherent factors such as the charge and size of the aptamer present potential 
barriers for cellular uptake. The presence of the negatively charged phosphate backbone 
in nucleic acid molecules could result in electrostatic repulsion from the negatively 
charged cell surface, which could be the primary cause of inadequate uptake into the 
cells. Moreover, aptamers longer than 25 bases have shown difficulty crossing the cell 
membrane because of the tendency to self hybridise thereby affecting the cellular 
uptake (Patil et al., 2005). It would be highly desirable to develop aptamers that can be 
internalised directly into the cells in order to further explore the in vivo applications.  
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The previous chapter demonstrated that SA44 and SA43 DNA aptamers significantly 
bound to tumorigenic glioma cells with high affinity and selectivity compared to the 
control cells. Binding with high selectivity to U87MG and 1321N1 suggested a possible 
common cell surface target that is present in these two cell lines. Confocal data also 
demonstrated that these aptamers were localised in the cytoplasm of the target cells, 
suggesting that the aptamers had internalised into the cells. All of these experiments 
were performed with aptamers incubated on live cells under similar conditions such as 
physiological temperature (37 °C) for 90 minutes and before exposing the cells to 
protease (trypsin). To elucidate and confirm the uptake process, there was a need to 
investigate the uptake at 4 °C. If the rate of uptake was slower compared to the rate of 
uptake at 37 °C this would be highly indicative of an active transport process. This 
finding would also support the data obtained from concentration dependent saturation 
process and glioma cell selectivity of the aptamers, which indicated active transport 
from the previous chapter.  
 
In addition, pre-trypsinisation treatment to cells was performed to distinguish whether 
the aptamer bound to a cell surface target ligand and follow internalisation by receptor-
mediated pathway or an intracellular target ligand which could then follow distinct 
endocytic pathway other than receptor mediated. The aim of this chapter was therefore, 
to obtain more information underlying the uptake mechanism of the lead aptamers 
SA44 and SA43 DNA. In addition, the potential for the shortened aptamers to inhibit 
cell proliferation was assessed by performing a viability assay.  
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5.2 Results 
5.2.1 Effect of temperature on aptamer binding to cells 
A flow cytometry based assay was performed to monitor the uptake of aptamers that 
bound to the glioma cells (Section 2.7.2). Aptamers were added to live cells either at 37 
°C (optimal for active transport) or at 4 °C (where active uptake is dormant) (Zueva et 
al., 2010; Kang et al., 2012) and were incubated for 90 minutes. A two-way ANOVA 
test revealed that both aptamers SA44 DNA and SA43 DNA showed significantly 
higher uptake in U87MG and 1321N1 cells compared to SVGP12 cells at 37 °C (p < 
0.01) (Figures 5.1 and 5.2). Cells treated at 4 °C showed no uptake in all the cell lines. 
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Figure 5.1 Representative flow cytometry profiles showing temperature dependent 
uptake of SA44 DNA and SA43 DNA. Cy3 labelled SA44 DNA and SA43 DNA 
aptamers (100 nM) were incubated separately with live U87MG, 1321N1 and SVGP12 
cells at 37 °C (5 % CO2) or 4°C for 90 minutes. The blue curve represents the 
background mean fluorescence intensity (MFI) of the random aptamer. The black and 
red curve represents the MFI (uptake) of the cells treated with SA44 DNA and SA43 
DNA aptamer, respectively. A, B, and C Uptake of SA44 DNA and SA43 DNA on 
U87MG, 1321N1, and SVGP12 cells, respectively at 37 °C. D, E and F Negligible 
uptake of SA44 DNA and SA43 DNA on U87MG, 1321N1 and SVGP12 cells, 
respectively at 4 °C. 
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Figure 5.2 Temperature dependent uptake of aptamer SA43 DNA and SA44 DNA. 
Uptake was measured using 100 nM concentration of SA43 DNA and SA44 DNA 
aptamer. The background MFI values for the random aptamer (control) on 
corresponding cells were subtracted. Statistical significance of the differences in MFI 
values of SA43 DNA and SA44 DNA referred to its high uptake for U87MG and 
1321N1 cells at 37 °C compared to 4 °C by a two way ANOVA test (**= p < 0.01). All 
experiments were repeated at least three times. Data are mean of three independent 
samples; bars, SEM.  
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5.2.2 Effect of trypsin protease digestion on aptamers binding to cells 
To test whether the targets of the aptamers were mainly cell surface receptors, which are 
membrane bound or whether the targets were intracellular, the cells were treated with 
protease (0.25 % trypsin) for 10 mins before adding the aptamer to the cells (Section 
2.7.3). Only those aptamers that had been internalised without the receptor-mediated 
process remained after trypsin treatment and were detected by flow cytometry. As a 
control for internalisation, SVGP12 cells were used for negative binding. As shown in 
figures 5.3 and 5.4 the uptake of the aptamers SA44 and SA43 was not affected before 
or after trypsin treatment on U87MG, 1321N1, and SVGP12 cells. There was a 
statistical difference in the uptake of SA44 and SA43 DNA on U87MG, 1321N1 
compared to SVGP12 both before and after trypsin treatment (**p < 0.01). 
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Figure 5.3 Representative flow cytometry profiles showing the effect of trypsin 
protease digestion on aptamers binding to cells. Cy3 labelled SA44 DNA and SA43 
DNA (100 nM) were incubated with live U87MG, 1321N1 and SVGP12 cells at 37 °C 
(5 % CO2) for 90 minutes before or after treatment with 0.25 % trypsin (10 mins). The 
blue curve represented the background mean fluorescence intensity (MFI) of the 
random aptamer. The red and green curve represented the MFI (uptake) of the cells 
incubated with SA44 DNA aptamer before and after trypsin treatment, respectively. A, 
B, and C No difference in SA44 DNA uptake before and after trypsin treatment on 
U87MG, 1321N1, and SVGP12 cells respectively. D, E, and F No difference in SA43 
DNA uptake before and after trypsin treatment on U87MG, 1321N1, and SVGP12 cells 
respectively. 
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Figure 5.4 Comparative effect of trypsin treatment on internalisation potential of 
SA44 DNA and SA43 DNA on U87MG, 1321N1, and SVGP12 cells. Uptake was 
measured using 100 nM concentration of SA43 DNA and SA44 DNA aptamer. The 
background MFI values of random aptamer (control) on corresponding cells were 
subtracted. ANOVA test revealed no statistical significance of the differences in MFI 
values of SA43 DNA (A), and SA44 DNA (B) when incubated before and after trypsin 
treatment on U87MG, 1321N1 and SVGP12 cells (p > 0.05). Statistical difference was 
observed in the internalisation of SA44 and SA43 DNA on before and after trypsin 
treated U87MG, 1321N1 compared to SVGP12 cells (**p < 0.01). All experiments 
were repeated at least three times. Data are mean of three independent samples; bars, 
SEM.
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5.2.3 Effect of aptamers on cell viability 
After establishing the internalisation properties of aptamers, it was important to assess 
the function of SA44 DNA and SA43 DNA aptamers in terms of their effect on cell 
viability. Cells were incubated with 20 nM, 100 nM, 500 nM and 1000 nM of each 
aptamer and monitored for 24, 48 and 72 hours for cell viability using the presto blue 
assay (Section 2.8). To investigate the role of the DNA aptamers on cell viability, cells 
were treated with aptamers and viability was compared to the known cytotoxic cisplatin 
as a positive control. SA44 DNA and SA43 DNA showed the highest cell viability 
(approximately 100 %) and no significant change in viability was observed throughout 
the 3-day period (Figures 5.5 and 5.6). Microscopic observations also revealed that all 
cells appeared healthy after aptamer treatments without noticeable morphological 
changes (data not shown). Cells treated with cisplatin, 10 μM  positive control  showed 
significant decrease in cell viability at 72 hours.  
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Figure 5.5 Effect of SA44 DNA on cell viability using Presto blue assay. Live cells 
U87MG, 1321N1 and SVGP12 were incubated with biotin tagged SA44 DNA aptamer 
at different concentrations such as 20 nM, 100 nM, 500 nM and 1000 nM at 37 °C (5 % 
CO2) and monitored for 24, 48 and 72 hours for cell viability using presto blue assay. 
Cisplatin at 10 μM concentration was used as positive control. A two-way ANOVA test 
was performed to analyse the difference in the percentage cell viability of the SA44 
DNA against cisplatin and untreated controls. A, B, and C No statistical difference was 
observed between the percentage cell viability of SA44 DNA and untreated controls for 
U87MG, 1321N1 and SVGP12 cells, respectively (p > 0.05). Cisplatin showed a 
significant decrease in the percentage cell viability at 72 hours when compared to SA44 
DNA and untreated control (* p < 0.05). All experiments were repeated at least three 
times. Data are mean of three independent samples; bars, SD. 
Chapter 5                                             Glioma specific internalisation study of the DNA aptamers 
 
 
 
152 
 
Figure 5.6 Effect of SA43 DNA on cell viability using Presto blue assay. Live cells 
U87MG, 1321N1 and SVGP12 were incubated with biotin tagged SA44 DNA aptamer 
at different concentrations such as 20 nM, 100 nM, 500 nM and 1000 nM at 37 °C (5 % 
CO2) and monitored for 24, 48 and 72 hours for cell viability using presto blue assay. 
Cisplatin at 10 μM concentration was used as positive control. A two-way ANOVA test 
was performed to analyse the difference in the percentage cell viability of the SA43 
DNA against cisplatin and untreated controls. A, B, and C No statistical difference was 
observed between the percentage cell viability of SA43 DNA and untreated controls for 
U87MG, 1321N1 and SVGP12 cells, respectively (p > 0.05). Cisplatin showed a 
significant decrease in the percentage cell viability at 72 hours when compared to SA43 
DNA and untreated control (* = p < 0.05). All experiments were repeated at least three 
times. Data are mean of three independent samples; bars, SD. 
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5.3 Discussion 
By assessing the cellular distribution of aptamers by confocal microscopy in the 
previous chapter, there was a strong association with the cytoplasm, suggesting 
intracellular uptake. The objective of this chapter was to better understand the 
mechanism of cell uptake of the aptamers and to highlight the potential of 
oligonucleotides to serve as intracellular delivery agents to tumour cells. This was 
achieved by a flow cytometry quantitative method that allowed accurate measurement 
of aptamer internalisation. To explore this mechanism further, the influence of low 
temperature and protease activity on cellular uptake of the aptamers was determined.  
 
Active and passive transport of any test molecule or drug by the cells have been 
assessed with commonly used method of parallel incubations at 37 °C and 4 °C, as 
active transport proteins are highly temperature dependent (Komai et al., 1992; Thomas 
et al., 2004). Although active transport is inhibited at low temperatures, passive 
processes might also be altered to some degree as membrane fluidity decreases 
(Neuhoff et al., 2005). Preferably, temperature dependence studies should be combined 
with a concentration dependent study to assess whether transport is saturated at higher 
concentration of the test molecule or drug (Poirier et al., 2008; Pang et al., 2010). The 
study initially suggested that the uptake of aptamers could be via active transport by 
showing the saturation process and selectivity of aptamers to glioma cells at 
physiological temperature (37 °C) (Chapter 4, section 4.2.1). In order to confirm the 
active uptake, aptamers were incubated at 4 °C because active transport is inhibited at 
this temperature. As expected from an energy driven process, no internalisation was 
observed while the cells incubated at 4 °C; on the contrary, aptamers were rapidly 
internalised at 37 °C. Both SA44 and SA43 DNA aptamers retained specificity for 
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tumorigenic glioma cells at 37 °C. The results provided strong evidence that the uptake 
of aptamers depended on a cellular process related to active transport assisted by 
enzymes requiring energy.  
 
Methods for assessing cell specific internalisation of aptamers have been crucial to the 
development of powerful reagents capable of delivering therapeutics such as siRNAs or 
small molecule drugs to the target cells. In previous studies to confirm internalisation, 
trypsin treatment has shown to be a convenient and straightforward method to achieve 
this goal (Huang et al., 2009; Orava et al., 2010; Van Simaeys et al., 2010; Kang et al., 
2012; Zhang et al., 2012
a
; Wu et al., 2014). Cell trypsinisation causes a loss of 
extracellular components of membrane proteins, which are then restored after several 
hours after the cells have been replated at lower density (Huang et al., 2010). This was 
in agreement with other related studies where expression of cell membrane proteins 
such as HSP 60, HSP 90 beta, protein disulphide isomerase, and integrins reduced 
drastically after trypsinisation which were recovered within 24 hours after replating 
cells (Cruz et al., 1997; Huang et al., 2010; Sutradhar et al., 2010).  
 
Using trypsin treatment, numerous aptamers have shown to be selective for cell surface 
targets (Hicke et al., 2001; Hicke et al., 2006; Kang et al., 2012; Xiao et al., 2008; Zhou 
and Rossi, 2009; Zhang et al., 2012). The confirmation of aptamer internalisation 
requires that aptamers bound to the cell surface be removed. Previous chapter have 
detailed experiments whereby aptamer was incubated with live cells and then 
trypsinised (for flow cytometry) to remove any cell surface bound aptamers. Only those 
aptamers that have been internalized remained and were detected by flow cytometry 
(Figure 5.7, A). The study initially hypothesised that the SA44 and SA43 DNA aptamer 
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may be binding to cell surface receptors, which may help the aptamer to internalize via 
a receptor-mediated endocytic pathway when considered with the saturation process 
data (Chapter 4, section 4.2.4). The question arose whether the cell surface receptors 
were involved in the internalisation of the aptamers or whether the aptamers entered the 
cells without the assistance of cell-surface receptors. Prior cleavage with trypsin would 
abrogate internalisation of the aptamers if the cell-surface receptors were involved. The 
internalisation potential of SA44 and SA43 DNA even after the cell-surface receptors 
were cleaved by trypsin (aptamer incubation after trypsin treatment) suggested that the 
aptamer may have internalised via some distinct pathway other than receptor mediated 
endocytic pathway and the target was mainly intracellular (Figure 5.7, B), however, 
further studies warrant to confirm the mechanism (discussed in chapter 8).  
 
 
Figure 5.7 Internalisation property of the aptamer SA43 DNA in glioma cells. A 
Trypsin treatment after aptamer incubation suggesting aptamer may internalise the cells 
via receptor-mediated endocytosis. B Trypsin treatment before aptamer incubation 
confirmed that aptamer internalise the glioma cells via different pathway other than 
receptor-mediated endocytic process. 
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Currently, the lack of cellular selectivity of cancer chemotherapeutic drugs results in a 
poor toxicity profile (Lee and Nan, 2012). Studies based on aptamers have provided a 
proof of concept that aptamers with minimal cytotoxicity can mediate cell type-specific 
delivery through conjugation with toxins, chemotherapeutic drugs, imaging agents and 
siRNAs (Dassie et al., 2009; Kim et al., 2010; Li et al., 2010; Kotula et al., 2012). 
Following the internalisation of the DNA aptamers, the influence on cell viability was 
yet to be observed. Short-term toxicity of SA44 DNA and SA43 DNA aptamer was 
assessed using presto blue cell viability assay. The known cytotoxic cancer drug 
cisplatin has been previously shown to be taken up by cells via passive transport 
because of linear and non-saturable activity indicating reduced drug uptake (Eastman, 
1990; Sedlestska et al., 2005), however some past studies have postulated the 
involvement of several transporters such as Na
+
, K
+
 - ATPase and members of solute 
carriers involved indicating some type of active facilitated transport (Arnesano et al., 
2013). Studies, however, have shown the cytotoxicity effect (IC
50
) of cisplatin to occur 
in a concentration dependent manner for glioma cells (Carminati et al., 2010; Taghavi et 
al., 2013). A short pilot study was therefore performed to determine the concentration 
dependent cytotoxicity of cisplatin on glioma cells over three days (data not shown). 
The results showed significant reduction in cell viability following 10 μM cisplatin 
treatment at 72 hours which was chosen to be ideal concentration to compare the effect 
of aptamer on cell viability. Cells treated with aptamers SA44 DNA and SA43 DNA 
showed the highest cell viability (approximately 100 %) even at high aptamer 
concentrations compared to the cisplatin and throughout the same incubation period. 
This suggested that the DNA aptamers showed no grow inhibitory effect on cells 
suggesting them to be non-cytotoxic at the concentrations tested and are therefore ideal 
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candidates for delivery of therapeutic payloads. 
In summary, the selected aptamers not only showed high affinity to the target glioma 
cells with nanomolar dissociation constants as described in the previous chapter, but 
also were able to internalise into cells actively without influencing the cell viability. 
Although the cells had been treated with trypsin before and after aptamer application at 
37 °C, an evident increase in cellular fluorescence intensity in tumour cells was shown 
compared to the experiments carried out at 4 °C, whereby active transport was inhibited 
and cellular uptake was completely eliminated. No internalisation was detected for 
SVGP12 cells. Together these data confirmed that the shortened aptamers are non-toxic 
and retained target specific cell internalisation properties and thus, can be developed 
into effective targeted delivery agents for glioma (Further discussed in chapter 8) 
(Rockey et al., 2011). A definitive conclusion to confirm selective targeting of aptamers 
(SA44 and SA43 DNA) to glioma cells compared to non-cancerous cells by mere 
studying on selected cell lines is not enough because glioma as whole disease is 
heterogeneous, hence the study needed to be extended to glioma tissues. Clinical tissue 
sections are more representative of diseased state and therefore, there was a question 
highlighted whether these shortened aptamers could recognise and differentiate between 
different grades of glioma and non-cancerous brain tissues. Combining the selectivity of 
aptamers on live glioma cells and fixed glioma tissues will be the main highlight of the 
study and would prove the specificity of shortened aptamers for glioma, which will be 
addressed in next chapter. 
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CHAPTER 6 HISTOCHEMICAL ANALYSIS OF DNA APTAMERS 
6.1 Introduction 
Data in the previous two chapters suggested that SA44 and SA43 DNA aptamers were 
more selective to tumorigenic glioma cells compared to the other cell types (Chapter 4 
and 5). While aptamers show great promise in targeting glioma cells, there have been 
very limited reports of clinical applications as probes for histochemistry in studying 
glioma (Blank et al., 2001; Kang et al., 2012). This chapter explored the potential of 
aptamers to function clinically as a glioma-selective targeting molecule. Using 
histochemistry, the selected biotin conjugated aptamers were studied on various grades 
of glioma, meningioma, and non-cancerous patient tissue sections.  
6.2 Results  
6.2.1 Binding analysis of aptamers on fixed cells.  
Prior to assessing the potential of aptamers recognising targets in the fixed histological 
clinical tissues, binding was assessed in fixed cells. To this aim, a pilot study was 
initially performed to determine the binding capability of the selected biotin labelled 
aptamers under fixed conditions. Cells 1321N1, U87MG and SVGP12 were fixed with 
4 % PFA prior to the incubation with biotin labelled aptamers (Section 2.9). As shown 
in figure 6.1, SA44 and SA43 DNA showed higher binding selectivity to fixed and 
permeabilised 1321N1 and U87MG cells compared to non-cancerous SVGP12. The 
binding was localised mainly in the nucleus with some cytoplasmic staining of the 
target glioma cells. SA56 showed no binding selectivity as nuclear staining was 
observed on both 1321N1 and SVGP12 cells. Random aptamer (RA) on the other hand 
showed negligible staining on both 1321N1 and SVGP12 cells. This indicated that the 
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aptamers SA44 and SA43 DNA could selectively bind to the targets on tumour cells 
even under fixed conditions. These results strongly suggested that the aptamers SA44 
and SA43 DNA would have the potential to be used as glioma recognition molecules in 
clinical samples compared to SA56 DNA. 
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Figure 6.1 Binding analysis of DNA aptamers on fixed cells. The left panel shows 
1321N1 tumour cells treated with no aptamer (A), SA44 DNA (C), SA43 DNA (E), 
SA56 DNA (G), and random aptamer (RA) (I). The right panel shows the non-
cancerous SVGP12 cells treated with no aptamer (B), SA44 DNA (D), SA43 DNA (F), 
SA56 DNA (H), and RA (J). All scale bars, 200 μm  
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6.2.2 Binding analysis of aptamers on fixed clinical tissues 
To determine if aptamers could be used as probes for histochemical analysis on specific 
grade of glioma, histochemistry (HC) was performed on fixed cancerous and non-
cancerous tissue sections. The study involved screening of the biotin labelled DNA 
aptamers SA44, SA43, SA56, and random aptamer (RA) on serial tissue sections from 
the BTNW tissue bank including non-cancerous brain, grade I, grade II, grade III, grade 
IV glioma, and meningioma from a total of 61 patients (Section 2.10). Overall, the main 
aim was to identify and discriminate aptamers binding to tumour tissues and not to 
healthy non-cancerous tissue. Figures 6.2 – 6.4 shows representative images of tissue 
sections from non-cancerous and different pathological grades of glioma and 
meningioma tissues stained with the biotinylated DNA aptamers. A defined protocol 
was applied to analyse and count the cells stained with each DNA aptamer in the tissue 
sections (Section 2.10.4). The stained tissue sections were blindly scored without 
knowing the grade of the tissue using an established quantitative scoring system, which 
showed remarkable and distinctive staining intensities and proportion rate for all the 
aptamers (Appendices 4,5,6,7,8 and 9) (Harvey et al., 1997; Leake et al., 2000; Rhodes 
et al., 2010). RA showed comparatively negligible binding to the non-cancerous and 
tumour tissues and therefore served as the best negative control for the experiment. 
SA44 DNA showed moderate to strong nuclear staining in glioma tissues with an 
average mean score ranging from 5.3 - 6.5, however, most of the non-cancerous tissues 
also showed strong nuclear staining with the SA44 DNA aptamer with an average score 
of 4.5. SA56 DNA showed strong nuclear staining on most tumour tissues including the 
non-cancerous sections with an average mean score ranging from 5.7 - 7.25. With 
regards to SA43 DNA aptamer, there was a differential staining on tumour tissues when 
compared to non-cancerous tissues. The aptamer showed moderate to strong nuclear 
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staining in tumour tissues with a mean score ranging from 4 – 6.6, whereas, in non-
cancerous tissues, the average score was only 2.9. This indicated that, SA43 DNA could 
potentially discriminate tumour tissues from the non-cancerous tissues. To confirm 
these findings, further data analysis was performed as described below. 
 
To identify a clinically meaningful cut off point for defining positive binding of 
aptamers to the cells on tissue sections, the results were examined on a scatter plot 
(Figure 6.5). A statistical test using one-way ANOVA followed by Bonfferoni post hoc 
test was applied to compare the overall mean binding scores for each aptamer on all 
glioma and meningioma tissues compared to the non-cancerous tissues. SA44 DNA and 
SA56 DNA showed no significant difference in mean binding score between all glioma 
grades, including meningioma and non-cancerous brain. SA43 DNA, on the contrary, 
showed significant difference in binding score between all grades of glioma and non-
cancerous brain. The cut off value of 3 as analysed from the blind study was found to be 
more precise, as scores of 2 or 3 did match non-cancerous tissue samples which 
included patients with less than 1 % or 10 % cells weakly or moderately stained. 
Moreover, it could be inappropriate to include patients with less than 1 % to 10 % 
weakly stained cells to be included with the groups showing more than 10 % staining 
because it would provide false positive results. Each tissue section was therefore 
defined as positive aptamer binding if the total HC score was greater than 3 and 
negative aptamer binding if the total score was less than or equal to 3.  
 
Comparison between the control (non-cancerous) group and tumour groups (grade I, 
grade II, grade III, grade IV, and meningioma  were then analysed using Fishers‟ exact 
test (Table 6.1). A significant difference in binding selectivity between non-cancerous 
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group and tumour groups with grade I, II, III, and IV was observed with SA43 DNA 
aptamer (p < 0.05), however, no significant difference was observed for meningiomas 
(p > 0.05). SA44, SA56 and random aptamer showed no significant difference in 
binding selectivity between non-cancerous and all grades of glioma, including 
meningioma. This indicated that SA43 DNA could potentially discriminate between all 
glioma grades and non-cancerous tissues.  
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Figure 6.2 Representative images of tissue sections from non-cancerous (BTNW 
no. 596) and different pathological grade glioma (BTNW no 814, grade I; 726, 
grade II; 738, grade III; and 1077, grade IV) patients stained with a biotinylated 
random sequence aptamer. Biotin labeled aptamers were incubated with the tissue 
sections for 60 min followed by incubation with AB reagent for 30 min. DAB substrate 
was then added which resulted in brown colour product upon reacting with avidin biotin 
complex. The nuclei were counterstained with haematoxylin. A-E untreated tissues (no 
aptamer); F-J Random aptamer treated. With mean scores greater than 3, random 
aptamer showed negligible staining in all non-cancerous, grade I, and grade II tissues; 
however, showed moderate nuclear staining in 2/12 grade III, and 3/10 grade IV tissues. 
All scale bars, 200 μm  
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Figure 6.3 Representative images of tissue sections from non-cancerous (BTNW 
no. 596) and different pathological grade glioma (BTNW no 814, grade I; 726, 
grade II; 738, grade III; and 1077, grade IV) patients stained with biotinylated 
SA44, SA43 and SA56 DNA aptamers. Biotin labeled aptamers were incubated with 
the tissue sections for 60 min followed by incubation with AB reagent for 30 min. DAB 
substrate reagent was then added which resulted in brown colour product upon reacting 
with avidin biotin complex. The nuclei were counterstained with haematoxylin. A-E 
SA44 DNA treated; F-J SA43 DNA treated; K-O SA56 DNA treated. With mean 
scores greater than 3, SA44 DNA showed moderate to strong nuclear staining in 9/13 
non-cancerous, 7/7 grade I, 12/14 grade II, 10/12 grade III, and 8/10 grade IV tissues. 
SA43 DNA showed weak to moderate nuclear staining in 3/13 non-cancerous tissues. 
Strong nuclear staining was observed in 6/7 grade I, 11/14 grade II, 11/12 grade III, and 
8/10 grade IV tissues with SA43 DNA aptamer. SA56 DNA showed strong nuclear 
staining in 12/13 non-cancerous tissues, 6/7 grade I, 11/14 grade II, 11/12 grade III, and 
9/10 grade IV tissues  All scale bars, 200 μm  
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Figure 6.4 Representative images of tissue sections from different pathological 
grade meningioma grade I (BTNW no. 75   , and meningioma grade II (BTNW no. 
760) patients stained with biotinylated random aptamer, SA44, SA43 and SA56 
DNA aptamers. Biotin labeled aptamers were incubated with the tissue sections for 60 
min followed by incubation with AB reagent for 30 min. DAB substrate reagent was 
then added which resulted in brown colour product upon reacting with avidin biotin 
complex. The nuclei were counterstained with haematoxylin. A, F, K untreated tissues 
(no aptamer); B, G, L Random aptamer treated; C, H, M SA44 DNA DNA treated; D, 
I, N SA43 DNA treated; and E, J, O SA56 DNA treated. With mean scores greater than 
3, random aptamer showed moderate staining on 1/3 grade I, and no staining on any of 
grade II/III (0/2) meningioma tissues. SA44 DNA and SA56 DNA showed strong 
nuclear staining on all 3/3 grade I, and 1/2 grade II meningioma. SA43 DNA showed 
moderate nuclear staining on 2/3 grade I, and 1/2 grade II meningioma tissues. All scale 
bars, 200 μm  
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Figure 6.5 Scatter plot showing the mean and the distribution of average scores for each 
aptamer on patients tissue sections. Using ANOVA and post hoc Bonferroni test, 
SA44 DNA, SA56 DNA and random aptamer showed no statistical difference in 
the average binding scores between tumour and non-cancerous tissues. SA43 DNA 
showed statistical difference in the average binding scores between all pathological 
grades (I, II, III, IV) of glioma tissues compared to the non-cancerous tissues (*, p 
< 0.05; **, p < 0.01). 
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Table 6.1 Comparison of each DNA aptamer binding on non-cancerous tissues 
against various glioma grade and meningioma tissues using Fishers exact test.  
Grade Random 
aptamer 
SA44 SA43 SA56 
Non-
Cancerous 
0/13 9/13 3/13 12/13 
I 0/7  
(p = 1.000) 
7/7  
(p = 0.2487) 
6/7  
(p = 0.0166) 
6/7  
(p = 1.000) 
II 1/14  
(p = 1.000) 
11/14  
(p = 0.6776) 
11/14 
(p = 0.0070) 
11/14  
(p = 1.000) 
III 2/12 
(p = 0.2200) 
10/12   
(p = 0.6447) 
11/12 
(p = 0.0010) 
11/12 
(p = 1.000) 
IV 3/10  
(p = 0.0678) 
8/10  
(p = 0.6600) 
8/10  
(p = 0.0123) 
9/10  
(p = 1.000) 
Meningioma 1/5 
(p = 0.2778) 
4/5 
(p = 1.000) 
3/5 
(p = 0.2682) 
4/5 
(p = 0.4902) 
  
6.2.3 Detailed histological analysis of SA43 DNA aptamer (exceptional cases).  
SA43 DNA showed significant binding selectivity to glioma tumour tissues compared 
to the non-cancerous tissues (Table 6.1), therefore, detailed histological analysis was 
performed on the tissues stained with SA43 DNA aptamer, to determine cellular 
localisation and cell type selectivity with the help of an experienced pathologist from 
Royal Preston Hospital (RPH). SA43 DNA showed moderate staining on three of the 
non-cancerous tissues studied (Figure 6.6). Tissue section from patient no. 713, a non-
cancerous brain sample adjacent to breast metastasis in cerebellum showed staining 
with all test aptamers including SA43 DNA. This initially suggested that metastasised 
breast tumour cells present in the cerebellar part could be recognised selectively by the 
aptamer, and that this biopsy was not a suitable non-cancerous control. The cerebellar 
tissue however, was stated to be hyper cellular (particularly granule cells) in nature and 
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non-cancerous by the pathologist upon closer inspection. This suggested that tumour in 
the cerebellar part could not be selectively recognised by the aptamer SA43 DNA. Upon 
closer inspection, there was selectivity between the cells on the tissue (no.713) with this 
particular aptamer (SA43). The aptamer showed binding to granular cells of the 
cerebellum, but not molecular cells (Figure 6.6) and Purkinje cells (Figure 6.7). Patient 
tissue no. 1085 and 1039 from the non-cancerous category was excised from around a 
grade I trigeminal schwannomas (tumours of Schwann cell origin) and from around a 
frontal carcinoma of unknown origin and showed staining with all test aptamers. This 
initially suggested that, there could be some cells infiltrated from the tumour part which 
might have shown binding to the aptamers, however, the tissues were stated to be non-
cancerous by the pathologist (Further discussed in section 6.3).  
 
SA43 DNA was more selective to glioma tissues, however, three high-grade tissue 
samples showed negligible staining with the aptamer (Figure 6.8). These tissues were in 
the category of necrotic glial tumour with pleomorphism, microvascular proliferation, 
and thrombosed vessels, however, other tissues showing staining also had similar 
peculiarities. Glioma tissues consist of heterogeneous cells; hence, the tissue sample 
may contain cell populations that do not express the aptamer target.  
 
Another noteworthy observation was that the aptamer showed negligible binding to 
endothelial cells of all of the glioma tissues from all the pathological grades including 
meningioma a representative image showing absence of binding to the endothelial cells 
is shown in figure 6.9. The overall findings for the study showed that SA43 DNA is an 
aptamer, which can be utilised for HC to potentially discriminate between glioma 
tissues and non-cancerous brain tissues. 
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Figure 6.6 SA43 DNA aptamer showing moderate staining in three non-cancerous 
tissues. A B and C Non-cancerous tissues showing negligible staining with random 
aptamer. D E and F Non-cancerous tissues showing moderate nuclear staining with 
SA43 DNA aptamer. All scale bars, 200 μm  
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Figure 6.7 SA43 DNA selectivity within the cells of the cerebellar tissue. SA43 
DNA aptamer showed binding on granular cells (region highlighted in blue arrow), 
molecular layer cells (red arrow), and negligible binding to Purkinje cells (black arrow). 
Scale bar, 200 μm.  
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Figure 6.8 SA43 DNA aptamer showing weak to no staining in three high-grade 
glioma tissues. A B and C High-grade glioma tissues showing negligible staining with 
random aptamer. D E and F High-grade glioma tissues showing weak to negligible 
staining with SA43 DNA aptamer. All scale bars, 200 μm. 
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Figure 6.9 Representative images from various glioma pathological grades 
including meningiomas showing negligible binding to endothelial cells with SA43 
DNA aptamer.  Arrows indicate absence of SA43 DNA binding to endothelial cells in 
grade I glioma (A), grade II glioma (B), grade III glioma (C), grade IV GBM (D), grade 
I meningioma (E), and grade II meningioma (F). All scale bars, 200 μm  
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6.3 Discussion 
An important tool in cancer diagnosis is immunostaining, in which freshly dissected 
clinical tissues are fixed prior to the treatment with probes, such as antibodies and 
aptamers, specifically for tumour markers. In research, clinical tissue specimens are 
more representative of disease than cultured cell lines, in that the former are separated 
and preserved in the disease state while the latter may be influenced by in vitro factors 
as discussed in chapter 3 (Li et al., 2009). The ultimate usefulness of aptamer binding 
assessment by histochemistry (HC) as a diagnostic tool resides in the ability of aptamers 
to distinguish cancerous from non-cancerous cells.  
 
Initial binding studies were conducted on the fixed cells to determine if the DNA 
aptamers were capable to bind to their cell targets under chemical fixation using 
standard avidin-biotin complex staining technique (de Matos et al., 2010). SA44 and 
SA43 DNA both retained binding capability to fixed and permeabilised 1321N1 glioma 
cells compared to the non-cancerous SVGP12 cells. The binding was mainly localised 
in the nucleus along with some cytoplasmic staining indicating that the target was 
localised in both cytoplasm and nucleus of the tumour cells. SA56 DNA showed no 
selectivity, which was also supoorted the live cells data (Chapter 4). 
 
To elucidate the application of aptamers in HC, analysis was performed on glioma 
tissues of various pathological grades including non-cancerous brain tissues as a 
control. An established scoring system was used as previously it has been found to be 
highly reproducible, correlated with established biochemical assays and provided 
equally significant predictive and prognostic information regarding patient samples 
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(Harvey et al., 1999; Leake et al., 2000). The optimal cut off point in the study was a 
total HC score of greater than 3, which considered more than 10 % cells positively 
stained with the aptamers. This was in agreement with many clinical and commercial 
laboratories choosing 10 % or even 20 % positive tumour cells as the cut off value for 
defining estrogen receptor (ER), progesterone receptors (PR), and HER2 positivity 
(Harvey et al., 1999; Leake et al., 2000; Wolf et al., 2007). Using this scoring system 
and through physical observation, the present study showed differential binding with 
SA43 aptamer on tumour tissues compared to the non-cancerous tissues. Moreover, the 
binding was localised in the nucleus and selective for a certain cell type. This proved 
that the results achieved were not an artefact or non-specific staining but were in 
accordance with the fact that the aptamers can be used for staining specific targets on 
cells within the tissue sections.  
 
SA43 DNA showed significant binding to glioma tumour tissues compared to the non-
cancerous tissues. SA44 DNA mimicked SA43 DNA in binding to glioma tissues; 
however, it also showed binding to most of the non-cancerous tissues. SA44 DNA 
differed in the presence of nucleotide bases „CC‟ compared to SA43 DNA, however, the 
absence of nucleotides did not alter the secondary structure. Whether the binding to the 
non-cancerous tissues is because of the presence of nucleotides bases CC in SA44 DNA 
aptamer, still remains an unsolved question. Structural studies with aptamer-target 
interactions have however demonstrated diversity in tertiary structures of aptamers 
associated with folding upon binding to the target (Gold et al., 1995). If this is the case 
for SA44 and SA43 aptamers, the deletion of the two cytosines from the SA44 sequence 
might then adopt a different 3-dimensional (3D) conformation more preferable for 
targeting tumour cells. This suggested that aptamer 3D conformation might play an 
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important role in its specific tumour targeting and also suggested for further studies on 
aptamer-target interactions to provide a conclusive remark. The binding characterisitcs 
of SA56 DNA to tissues mimicked the live cells data, as it also showed binding to both 
glioma and non-cancerous tissues. This could be explained by its binding to targets that 
may be equally expressed in glioma and non-cancerous cells. The project therefore 
focussed on SA43 DNA aptamer, as it undoubtedly showed similar binding 
characterstics on both live cells, fixed cells and fixed clinical tissues, therefore, further 
in-depth analysis was performed on the data obtained with this aptamer.  
 
An in depth analysis of SA43 DNA aptamer binding to three non-cancerous tissues 
showed some distinct observations. One of the tissues was non-cancerous cerebellar 
tissue around metastatic breast tissue. The layers of cerebellum are indicated as internal 
granular layer, Purkinje cell layer, and molecular layer (outer layer of the cortex of the 
cerebellum) (Moncalero et al., 2011). The aptamer showed distinctive binding to 
granular cells and molecular cells, but showed no binding to Purkinje cells. This 
observation initially suggested that tumours in the cerebellar region could not be able to 
be recognised selectively by the aptamer, if such indiscriminate binding to granular and 
molecular layer cells was present. Furneaux et al., (1990), however, reported that 
Purkinje cells antigen namely, Purkinje neuronal protein termed cdr2 was highly 
expressed in tumours from tissues with paraneoplastic cerebellar degeneration (PCD) 
but was absent in normal tissues. PCD is one of the several immune-mediated 
paraneoplastic neurologic disorder that develop as a remote effect of systemic cancers 
 Darnell and Posner, 2006; O‟Donovan et al., 2010). This suggested that further studies 
warrant identifying if the aptamer can bind to purkinje cells in PCD, which could assist 
in identifying and discriminating the PCD from normal tissues. The other two non-
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cancerous tissues were excised around a grade I trigeminal schwannoma and a frontal 
carcinoma of unknown origin. These tissues showed highest total binding score (7) with 
SA43 along with aptamers SA44 and SA56. Grade I trigeminal schwannoma are very 
rare arising from Schwann cells, which function as supporting cells in peripheral 
nervous system (PNS) similarly to how glial cells act as supporting cells in CNS. The 
question was raised whether the aptamer SA43 DNA would be able to show selectivity 
in tumour tissues within PNS as it also binds to the non-cancerous tissue. Analysis from 
one such tissue would not provide such conclusive remark and therefore, further studies 
are needed to confirm aptamer selectivity within the cells of PNS. The non-cancerous 
tissue of the brain biopsy around frontal carcinoma of unknown origin also showed 
binding to SA43 DNA including SA44, and SA56, however, as the origin of the tumour 
was unknown, it was difficult to comment on the binding with the aptamers, whether it 
was on the non-cancerous tissue excised or possibly to the infiltrative cells from the 
surrounding tumour tissue.  
 
A number of aptamers have been reported to bind targets on endothelial cells of brain 
tumour with a view to distinguish them from the endothelial cells in non-cancerous 
brain (Blank et al., 2001; Mann et al., 2010). Nucleolin, a well establish target for the 
AS1411 aptamer is also highly expressed in the plasma membrane of both cancer cells 
and endothelial cells in the angiogenic blood vessels (Christian et al., 2003). Another 
study by Blank et al. used endothelial cells as targets and selected DNA aptamers that 
could be used as histological markers of microvessles in brain tumours (Blank et al., 
2001). These papers demonstrated that aptamers binding to endothelial cells is an 
advantage in diagnostic and therapeutic purposes, in such a way that aptamers can 
internalise via endothelial cells and can easily pass through blood brain barrier (BBB). 
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The study here however showed negligible binding of SA43 DNA to the endothelial 
cells, which was therefore, initially thought to be a hindrance, considering its entry into 
BBB. The BBB, mediated by endothelial tight junctions, however, has been reported to 
be defective and leaky in malignant gliomas, resulting in cerebral oedema as visualised 
by immunohistochemistry of plasma proteins using biopsy specimens (Seitz and 
Wechsler, 1987) and contrast enhancement upon neuro-radiological examination 
(Roberts et al., 2000). Moreover, Schneider et al. including few other researchers have 
reported that malignant gliomas have acquired the ability to actively degrade tight 
junctions by secreting soluble factors, eventually leading to BBB disruption within 
invaded brain tissue (Schneider et al., 2004; Wolburg et al., 2012; Agarwal et al., 
2013). Moreover, immunohistochemical studies have revealed that some abnormal 
function of the transmembrane tight junction components are mostly down regulated in 
malignant gliomas and has therefore been associated with loosening of the BBB 
(Liebner et al., 2000; Papadopoulous et al., 2001; Nitta et al., 2003).  
 
The enhanced permeability and retention (EPR) effect describes the intrinsic ability of 
macromolecules and particles of a certain size to accumulate in solid tumour tissues 
(Iyer et al., 2006; Yang et al., 2013). Features that have been identified as EPR 
mediators include vascular permeability enhancing and vasodilating factors such as 
vascular endothelial growth factor, bradykinin, prostaglandins, and nitric oxide that are 
upregulated or present in large quantities in tumour compared to normal tissue (Iyer et 
al., 2006). Anatomical differences in tumour vasculature also contribute, such as the 
lack of a smooth muscle layer surrounding the vessels that leads to increased blood flow 
volume to tumours during hypertension and hence more leakage of macromolecules into 
the surrounding tissue (Iyer et al., 2006). SA43 DNA aptamer showed negligible 
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binding to endothelial cells, the study therefore proposes this to be an advantage 
because the aptamer can potentially gain entry into malignant glioma tissue by the EPR 
effect (increased potential entry when conjugated with nano-particles, discussed in 
chapter 8) and through the leaky vasculature without any non-specific binding to the 
surrounding endothelial cells.  
 
Overall, a substantial amount of data proves the potential of SA43 DNA aptamer being 
more selective for glioma when compared to the non-cancerous tissue. The study has 
opened many new horizons and avenues to further explore the applications of aptamers 
in targeting tumour cells and tissues. There was however, a point to be noted that the 
aptamer SA43 DNA showed strong binding in the nucleus of the fixed cells and tissues, 
whereas, the binding was shown to be localised in the cytoplasm on live tumorigenic 
glioma cells at 90 min incubation time. The question was raised whether the aptamer 
still resided in cytoplasm after 90 min or did it reach the nucleus over time. Performing 
longer time over 24 hours would provide an answer to the question, which will be 
addressed in next chapter. 
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CHAPTER 7 DETERMINING THE FATE OF SA43 DNA 
APTAMER IN TUMOUR CELLS 
7.1 Introduction 
The previous chapters gathered a considerable amount of data stating SA43 DNA was 
able to recognise the targets on both live and fixed tumour cells and tissues compared to 
the non-cancerous cells and tissues. The localisation of aptamer SA43 DNA in the 
cytoplasm and around the periphery of the nucleus in the live tumour cells at 90 minutes 
was however, distinct to the localisation in nucleus of fixed tumour cells and tissues. 
Considering the current scenario of both live cytoplasmic and fixed nuclear localisation, 
a longer time course study was performed to understand if the aptamer entered the 
nucleus of live cells over 24 hours. Confocal microscopy was used to track the 
localisation and internalisation potential of the aptamer on live tumour and non-
cancerous cells at specific time points.  
7.2 Results 
SA43 DNA uptake was detectable as early as 60 minutes in 1321N1 and U87MG cells, 
whereas the uptake started from 6 hours in SVGP12 cells, which was minimal 
compared to the 1321N1 and U87MG cells (Figures 7.1, Appendix 3). Moreover, there 
was no obvious difference between the distributions of SA43 DNA aptamer at 2 hours 
and 24 hours in tumour cells 1321N1 and U87MG as the fluorescence remained 
localised in the cytoplasm even at 24 hours, which suggested that the aptamer was 
unable to reach the nucleus.  
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Figure 7.1 Time dependent uptake and cellular localisation of SA43 DNA by 
U87MG, 1321N1 and SVGP12 cells. Cy3 labelled SA44 DNA was incubated 
separately at a concentration of 100 nM on live U87MG, 1321N1 and SVGP12 cells 
(red) which were then fixed using 4 % PFA. The nuclei were counterstained with DAPI 
(blue) and mounted. Cells with no aptamer were used as control. Z-stacks images were 
acquired under 40x and 63x magnifications at an excitation of 543 nm and emission of 
560 nm under 1047-camera resolution (amplifier gain: 1; detector gain: 927; amplifier 
offset: - 0.06). Data are representative of three independent experiments with single 
plane images of middle section of Z- axis. The Cy3 fluorescence signal of the aptamer 
on each cells were compared to their respective untreated controls. A, B and C represent 
time dependent uptake of SA43 in live U87MG, 1321N1 and SVGP12 cells. Scale bar = 
20 μm  
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7.3 Discussion 
A longer time course assay was performed in order to assess whether the different 
binding localisation events on live cells observed will lead to same localisation of 
binding as fixed cells. The aptamer resided in the cytoplasm of live tumour cells even at 
24 hours incubation suggesting that the aptamer was unable to penetrate through the 
nuclear membrane even after 24 hours of incubation. With such observations, the study 
proposed that aptamers would internalise into the tumour cells rapidly by unknown 
endocytosis mechanism and culminate to lysosomes for degradation and hence, unable 
to reach the nucleus. The entrapment of internalised aptamer in endocytic compartments 
may have then prevented further intracellular transport towards the nucleus, because of 
degradation of aptamer. This was in agreement with a few studies where the aptamer 
was shown to internalise through an endocytosis mechanism, which leaded to 
endosomal and cytoplasmic localisation in live cells (McNamara et al., 2006; Dassie et 
al., 2009; Li et al., 2010). Moreover, if SA43 DNA managed endosomal escape, the 
aptamer must have traversed the cytosol to access the nucleus, which could be then 
challenged by the complex environment of the cytosol, containing cytosolic nucleases, 
which can further degrade the aptamer. To date, only one aptamer AS1411, which 
targets nucleolin, has been identified which internalises though macropinocytosis 
(Reyes Reyes et al., 2010) allowing nuclear localisation and the apparent ability to 
escape the endosomal or lysosomal pathway (Kotula et al., 2012). The method 
employed in this study, however, utilised Cy3 dye as a probe, which would accumulate 
in the cytoplasm with or without degradation of the aptamer used, herein. Therefore, a 
mere observation of fluorescence in the cytoplasm does not necessarily represent intact 
DNA aptamer as the Cy3 dye will fluoresce independent of its attachment to the 
aptamer, full-length or otherwise.  
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Uptake was observed in non-cancerous SVGP12 cells from 6 hours indicating longer 
incubation time could enhance non-specific uptake of SA43 DNA in vitro and reduce 
the binding specificity. The staining was however minimal compared to tumour cells 
even at 24 hours, and therefore SA43 DNA would be able to still differentiate the 
aptamer binding between the tumour and non-cancerous cells. Such observations 
warrant further studies understanding the exact mechanism of the uptake and the 
localisation of the aptamer within the sub-cellular compartments over time (Discussed 
in chapter 8).  
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CHAPTER 8 GENERAL DISCUSSIONS AND FUTURE WORK 
8.1 Challenges for glioma targeted therapy and overall summary 
The overall aim of this project was to examine the potential of RNA and DNA aptamers 
as a targeting agent for targeting tumour cells. Taking into account the available 
literature, it was hypothesised that aptamers can be applied for cancer diagnosis and 
treatment (Cerchia et al., 2009; Bayrac et al., 2012; Kang et al., 2012; Nicol et al., 
2013; Li et al., 2014). Glioma cells and tissues were chosen as a model for tumour 
targeting because they are the most common primary central nervous system tumours 
with a dismal prognosis, and are widely incurable. Surgery followed by radiotherapy 
and/or chemotherapy has been the standard treatment; however, due to the infiltrative 
growth of gliomas, it is hard to completely resect the tumour. Most of the 
chemotherapies have also failed because of the blood brain barrier (BBB) resistance and 
poor glioma targeting of the chemotherapeutics (Pardridge, 2007; Serwer and James, 
2012). For example, temozolomide has poor efficacy in the treatment of glioma, 
however, the mean survival time of the glioma patient is only extended by 
approximately 6 months (Serwer and James, 2012). Overall, as human gliomas are 
highly heterogeneous tumours, the sensitivity to therapeutic approaches has been 
difficult to predict.  
 
The ultimate aim for an aptamer to be successfully used for targeted drug delivery for 
glioma is the capability to distinguish tumour cells from non-cancerous cells in clinical 
samples for effective targeted delivery. Moreover, the aptamer should be able cross the 
BBB and internalise into the target tumour cells for successful drug delivery without 
influencing the cell viability of surrounding non-cancerous cells. An effective approach 
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was adopted to identify a molecular probe to recognise and target glioma cells and 
tissues. The project here reported a preliminary study focussed on selecting RNA and 
DNA aptamers for targeting glioma cells assessed by powerful approaches such as 
confocal laser imaging and flow cytometry. Shortened aptamers SA44 RNA and SA43 
RNA were shown to target live glioma cells with high affinity and specificity compared 
to the non-cancerous glial cells, breast cancer, and bladder cancer cells. The DNA 
homologs of the RNA aptamers also showed similar binding tendency to glioma cells. 
 
One of the major challenges for in vitro targeting is to be able to direct the binding of 
the targeting aptamers to tumour cells instead of healthy non-cancerous cells. Confocal 
imaging and flow cytometry on live cells at 90 minutes incubation with both the DNA 
aptamers (SA44 and SA43) showed that the aptamers internalised rapidly in the target 
glioma cells, however, from the data obtained from studying pathological glioma 
tissues, SA43 DNA showed significant binding selectivity for glioma tissues compared 
to non-cancerous tissues. This data obtained from the tissue sections is novel because 
few studies have investigated aptamer binding in glioma tissue (Blank et al., 2001; 
Kang et al., 2012). Considering both the live cells and pathological tissue data, SA43 
DNA was selected as a promising aptamer for targeting glioma. 
8.2 Internalisation property of SA43 DNA aptamer and its implication 
on targeted drug delivery   
Targeted aptamer-drug delivery has been shown to have great potential for cancer 
therapy, as aptamers provide enhanced delivery and hence increased efficacy and 
reduced side effects (Huang et al., 2009; Keefe et al., 2010; Rockey et al., 2011). 
Although aptamers can specifically bind to various molecular targets, the contact and 
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internalising property may produce the best possible results if the aim is to deliver 
conjugated chemotherapeutics that act internally on the cells. Indeed, intracellular 
delivery of aptamer-drug conjugates results in higher drug concentration inside the 
cells, and thus its efficacy is more than non-internalised aptamer therapeutics or by 
using standard chemotherapeutic agents alone (Orava et al., 2010; Esposito et al., 
2011). The study showed that SA43 DNA aptamer not only showed high affinity to the 
target glioma cells with nanomolar dissociation constants as described in chapter 4, but 
also was able to actively internalise rapidly into live tumour cells compared to the non-
cancerous and non-glioma cells (Chapter 4 and 5).  
 
The ability of the aptamer SA43 DNA to selectively bind and rapidly internalise into the 
glioma cells was comparable over the other published aptamers such as GM128 and 
GM131 (Kang et al., 2012), which showed higher binding affinity and selectivity to 
U118-MG glioma cells, however, also lost binding efficiency after trypsin treatment 
(Kang et al., 2012). Zhang et al., (2012
a
) reported the development of cancer-cell-
specific DNA aptamer probe, KMF2 – 1a, that successfully internalised to the 
endosomes of the targets on breast cancer cells, however, the internalisation failed after 
trypsin treatment. Moreover, other aptamers targeting glioma and other cancer cell types 
lost their binding efficiency after trypsin protease treatment, and unable to internalise 
thereby suggesting their most likely target could be proteins on cell surface (Shangguan 
et al., 2008; Sefah et al., 2010; Ara et al., 2012; Jimenez et al., 2012; Meyer et al., 
2012; Zhang et al., 2012
a
; Hernandez et al., 2013; Wu et al., 2014). These aptamers 
have been shown to internalise via receptor-mediated endocytosis, due to the 
involvement of cell surface receptors in aptamer uptake. The ability of the aptamer 
SA43 DNA to bind and internalise in the tumourigenic glioma cells even after trypsin 
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treatment hypothesised that either the aptamer entered the cells via some other 
endocytic process other than receptor mediated pathway or the target could be resistant 
to trypsin cleavage if it was present on the cell surface (Further discussed in section 
8.4). Such selective internalisation property of the aptamer (irrespective of trypsin 
treatment) would be of great relevance in designing strategies for targeted therapy of 
glioma. This is because internalisation of the aptamer may occur via an endocytic 
pathway, thereby improving drug accumulation in targeted glioma cells and tissues thus 
enhancing the targeted therapy.  
8.3 Putative target for SA43 DNA aptamer (in relation to the parallel 
study)  
Considering the nanomolar affinity of SA43 DNA aptamer and selective targeting to 
glioma cells and tissues, it could be possible that the aptamer may bind to an essential 
protein, which is overexpressed in glioma cells. A parallel project for determining the 
target for SA43 DNA aptamer was carried out simultaneously based on 
immunoprecipitation (IP) analysis in our laboratory, but subsequently termed 
aptoprecipitation (AP). The results revealed that more than 30 % pull down was only to 
Ku heterodimer (Ku 70/80) proteins on 1321N1 and U87MG cells including primary 
glioblastoma cells (BTNW 914) by the aptamer SA43 DNA (unpublished data). The 
remaining 70 % pull down was distributed among cytoplasmic and nuclear proteins 
such as mitochondrial proteins and nucleolin, however, very few surface proteins were 
present.  
 
Ku 70/80 is a DNA-repair protein involved in the repair of double stranded breaks 
required for non-homologous end joining (NHEJ) pathway and is ubiquitously 
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expressed in the nucleus of most untransformed cells, however, it has been reported to 
be expressed on the cell surface, cytoplasm or nucleus in various tumour cells (Muller et 
al., 2005; Fransson and Borrebaeck, 2006; Persson et al., 2010). With regards to 
glioma, this antigen has been reported to be highly expressed in U87MG cells (Canazza 
et al., 2011) and glioma tissues (Persson et al., 2010). Such observation was in 
agreement with the parallel study, where the SA43 aptamer target was found to be 
expressed in both the cytoplasm and nucleus of fixed 1321N1 and U87MG cells 
compared to non-cancerous SVGP12 cells and normal human astrocytes (NHA cells; 
unpublished data). The localisation of Ku heterodimer outside of the nucleus in tumours 
suggests that this protein is serving additional roles besides its main function in DNA 
repair such as, cell adhesion, migration, and invasion, however, they are yet poorly 
understood (Fransson and Borrebaeck, 2006). Considering the fact that Ku 70/80 is also 
expressed predominantly in the nucleus of non-cancerous cells, the absence of binding 
to non-cancerous cells and tissues with SA43 DNA aptamer demonstrated aptamer 
sensitivity to detect the target in glioma and hence could be utilised in histological 
glioma diagnosis.  
 
Overall, the parallel aptoprecipitation analysis on the aptamers strongly supported that 
the SA43 DNA aptamer targeted Ku heterodimer proteins, which was overexpressed in 
the tumour cells, compared to the non-cancerous cells. Moreover, the selectivity of 
SA43 DNA on glioma tissue sections highly supported the parallel study demonstrating 
aptamer SA43 DNA sensitivity to the target in tumour cells by showing least binding to 
the non-cancerous tissues, as Ku 70/80 was also shown to be expressed in non-
cancerous cells. In addition, strong cytoplasmic and nuclear binding of SA43 on live 
cells, and fixed tumour cells and tissues respectively (present study), and both 
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cytoplasmic and nuclear binding of Ku 70/80 on fixed cells (parallel study) again 
demonstrates the sensitivity of the aptamer to the target and warrants further study to 
understand the aptamer-target interaction.  
8.4 Predicting the mechanism of the uptake of SA43 DNA aptamer  
Confocal imaging with Z-stacks showed intracellular distribution of SA43 DNA in the 
cytoplasm and towards one edge of the periphery of the nucleus of some tumour cells, 
possibly suggesting that the aptamer entered the cells via endocytosis and was deposited 
in or near the endoplasmic reticulum. This was supported by a reduction in cellular 
uptake of the aptamer at 4 °C when energy dependent processes, including endocytosis, 
are reduced. Although it is recognised that passive diffusion is also reduced at 4 °C, it is 
unlikely the aptamer is uptaken by a passive process because of the saturable activity of 
the aptamer as discussed in chapter 5. Moreover, the parallel study (section 8.3) further 
supported the transport to be active and highly restrictive; as non-cancerous cells would 
have also showed binding to the aptamer considering Ku 70/80 is present in the non-
cancer cells too. The experiments where aptamers were incubated for increased duration 
(24 hours) also suggested that the aptamer was able to follow the endosomal and 
lysosomal pathway, leading to deposition of aptamer throughout the cell cytoplasm and 
enabling their interaction with other cellular components including lysosomes which 
potentially would have degraded the aptamer and hence was unable to reach the nucleus 
(Holt et al., 2010).  
 
Most of the aptamers showing active uptake and sensitivity to trypsin treatment have 
been shown to internalise via receptor-mediated endocytosis as mentioned in section 
8.2. Most of the recent work have also shown that internalisation of DNA can be 
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mediated through macropinocytosis, an actin-driven, ligand independent mechanism 
(Wittrup et al., 2007; Fumoto et al., 2009). The AS1411 aptamer which targets 
nucleolin with an active process, has been shown to be internalised into cancer cells 
(DU145, MCF7 and MDA-MB-321) by macropinocytosis (Reyes-Reyes et al., 2010). It 
was therefore difficult to predict the exact mechanism of the aptamer SA43 DNA to 
tumour cells as it showed active uptake and also entered the cells independent of trypsin 
treatment. If the aptamer was taken up by receptor mediated transport, then there could 
be some cell surface protein or any other moiety involved (including Ku 70/80, if it was 
present on the cell surface too), which could be resistant to trypsin cleavage and may 
have help the aptamer to internalise into the target cells. With respect to Ku 70/80, the 
protein consists of total 560 amino acids and the number of cleavages with trypsin has 
shown to be 82 (14.6 %) with arginine and lysine as the targets for cleavage (Expasy 
peptide cutter tool by Gasteiger et al., 2005). The small percentage of amino acids 
involved in trypsin cleavage could therefore suggest a possibility of Ku 70/80 being 
resistant to a 10-minute trypsin treatment if Ku 70/80 was present on cell surface along 
with its localisation in cytoplasm and nucleus, as the aptamer showed internalisation 
even after trypsin treatment. The antibody INCA-X binding to Ku 70/80 has shown to 
internalise in the tumour cells (pancreatic carcinoma) undergoing receptor-mediated 
endocytosis involving clathrin - mediated endocytosis after binding to the antigen 
(Fransson and Borrebaeck, 2006). In addition, different antibodies directed against Ku 
70/80 have shown different abilities to target the antigen, in relation to its presentation 
of the cell surface or intracellular localisation (Persson et al., 2010). Such cellular 
internalisation may also proceed by a number of other different mechanisms including 
phagocytosis, macropinocytosis, or clathrin and caveolae-independent endocytosis (Liu 
and Shapiro, 2003; Xin et al., 2011). Cargo entering via these different routes is 
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transported to a series of intracellular compartments from where it is either recycled or 
directed to degradative compartments such as late endosomes and lysosomes. Clathrin 
mediated endocytosis, used by all eukaryotic cells to internalise nutrients and degrade or 
recycle substances is well known for its role for selective uptake of molecules through 
specific receptors (Mahmoudi et al., 2011). Usually, the particles ingested via clathrin – 
mediated pathway and macropinocytosis initially reside in endosomes and 
macropinosomes respectively, which are acidified and fused with lysosomes afterwards.  
Understanding the exact mechanism of the uptake of the aptamer SA43 DNA would 
provide an idea of aptamer-target interaction and the role of Ku 70/80 in harbouring the 
entry of aptamer in the cytoplasm. Moreover, silencing of Ku 70/80 will further confirm 
and verify whether this is indeed the target. The study did not examine the specific 
pathway of endocytosis relevant for the aptamer uptake, which could be further clarified 
using individual pathway inhibitors. Sucrose and chlorpromazine, blocking agents for 
clathrin- coated pit formation; filipin, a special inhibitor of calveolae associated 
endocytosis, nocodazole, an inhibitor of macropinocytosis and cytochalasin D, a 
microtubule-disrupting agent could be used to confirm the actual mechanism of aptamer 
uptake by the cells. Understanding the uptake and trafficking within the cells will 
undoubtedly facilitate design improvements in aptamer therapeutics. In the context of 
drug delivery, the endosomal compartment is usually acidic, and many internalised 
molecules change their structures at low pH to release their bound substance. As such, 
the internalised aptamer SA43 DNA could potentially respond to these conditions to 
release their drug payloads. For example, one such acid – labile linkage was used by 
Huang et al. for sgc8c (aptamer)- Dox (drug) conjugate, where it was found that the 
aptamer – drug conjugate was cleaved inside the acidic endosomal environment, 
resulting in Dox release (Huang et al., 2009).  
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Advances in microscope have increased resolution to a point where sub-cellular 
compartments can be visualised. In addition, because of the wide range of different 
fluorescent labels, multiple fluorescent labels can be used in a single sample allowing 
co-localisation studies. Using these approaches, it will be interesting to observe and 
identify aptamer internalisation, tracking the sub-cellular localisation, and identify the 
transport pathway of aptamers into the cells. 
8.5 Aptamer and its entry through BBB  
The large molecular weight of the SA43 DNA aptamer (14 kDa) may preclude its 
crossing blood brain barrier (BBB) through paracellular transport (unless specific 
transporters are present). As discussed in chapter 6, aptamer SA43 DNA may have a 
high chance for crossing the blood brain barrier through paracellular transport without 
any non-specific binding to endothelial cells in the case of glioma (Section 6.3). Parallel 
studies in the laboratory have also shown that the aptamer can cross artificial tumour 
BBB culture systems (unpublished data), however, further studies are required to be 
performed in vivo to confirm these findings.  
 
A recent study by Cheng et al., found that an aptamer A15 was capable of crossing the 
BBB in vivo, suggesting that, BBB in situ could be the optimal platform compared to 
the artificial BBB culture systems for selecting aptamers that could afford central 
nervous system delivery through BBB (Cheng et al., 2013
a
). While the exact 
mechanism of the brain uptake of the BBB penetrating aptamer (A15) was unclear, 
given the large molecular weight of the aptamer (23 kDa), the study proposed the most 
likely mechanism could be through absorptive-mediated transcytosis or fluid-phase 
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pinocytosis. The small size of the aptamer SA43 DNA compared to the A15 aptamer 
including its non-toxicity for the cells and active binding selectivity for glioma tumour 
tissues can enable the aptamer to cross the blood brain barrier and hence can hold a 
powerful promise in animal model systems to dynamically visualise and target the 
tumour tissues in vivo. Moreover, strategies combining aptamer with nanoparticles 
(further discussed in section 8.6) has also shown to increase the efficacy of their entry to 
blood brain barrier (Yu et al., 2012; Liu et al., 2014).  
8.6 The bigger picture: Future perspectives of combined strategies for 
cancer therapy using aptamer–nanoparticle–drug conjugate model for 
controlled drug release  
The major challenges of recent research include finding ways to maximise the tolerated 
dose of chemotherapeutic drug given whilst balancing this with an acceptable toxicity 
profile by increasing selectivity to cancerous cells (Markman, 2008; Yallapu et al., 
2010; Li et al., 2014). The study here already succeeded in demonstrating SA43 DNA 
aptamer as an excellent targeting ligand for the sensitive and selective recognition of 
particular cancer cell populations in glioma cell lines and tissues. The identification of 
the potential aptamer SA43 DNA targeting glioma will allow the possibility of coupling 
therapeutic agents directly to the aptamer for targeting glioma cells. Overall, the rapid 
uptake and tumour cell internalisation of the aptamer SA43 DNA in the cytoplasm will 
be advantageous, for quick release and action of the drug to the tumour cells (Li et al., 
2010; Kotula et al., 2012). This could lower the therapeutic doses of the drugs required 
and would therefore reduce any harmful side effects resulting from the use of high 
doses of chemotherapeutics (Kim et al., 2010; Li et al., 2010; Kotula et al., 2012). 
These findings will further support the hypothesis that aptamer SA43 DNA can serve as 
promising agent for cell type specific intracellular delivery with both diagnostic and 
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therapeutic implications.  
 
The development of material science, however, must also satisfy the need for aptamers 
to have chemical properties that allow long circulation in the blood, maintain 
biocompatibility and exhibit control release. Aptamer distribution throughout the blood 
plasma compartment may be subjected to degradation by nucleases present in the blood 
(Chung et al., 2013). In addition, some unmodified aptamers have half-lives in the 
blood that can be as short as 2 minutes because of their small size (Griffin et al., 1993). 
The smaller molecular mass for most of the aptamers (5-15 kDa) including SA43 DNA 
(14 kDa) could be susceptible to renal filtration even if they are resistant to nuclease 
degradation  To overcome such difficulties, pyrimidine modifications at the 2‟-fluorine 
position or chemical modifications with PEG have been used to enhance the 
bioavailability and pharmacokinetics properties (Bouchard et al., 2010). The best-
characterised aptamers for targeted delivery are 2‟-fluoro-pyridine aptamers generated 
against the extracellular domain of prostrate-specific membrane antigen (PSMA) 
(Lupold et al., 2002). These aptamers have been used to deliver, self – assembled 
polymeric nanoparticles (Kolishetti et al., 2010; Farokhzad et al., 2006), and QDs 
(Bagalkot et al., 2007) with increased efficacy for their targets.  
 
Table 8.1 shows the strengths and weaknesses of small molecules (drugs), aptamers and 
nanoparticles. The aptamer SA43 DNA can also overcome the challenges of being 
degraded in blood and quick renal filtration by designing a model consisting of drug 
encapsulated high polymeric nanoparticle – aptamer bioconjugates as an effective 
targeting delivery systems (Figure 8.1).  
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Taking the advantage of the enhanced permeability and retention (EPR) effect strategy, 
nanoparticles can enter the interstitium and be entrapped in the tumour, and have higher 
retention times than normal tissues (Gao et al., 2013; Zhou et al., 2014). Cancer 
targeting entirely based on EPR (passive targeting mechanism) however, has 
undesirable systemic effects and suboptimal antitumour efficacy (White et al., 2006; 
Woo et al., 2008), which can be improved significantly by delivery vehicles with active 
tumour-targeting capability (Cao et al., 2009). The excellent property of SA43 DNA 
showing rapid active tumour targeting will enhance the NPs loaded drug uptake into 
tumour cells.  
 
Table 8.1 Strengths and weaknesses of drugs, aptamers and nanoparticles during 
targeted tumour therapy. 
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Drugs whether hydrophilic or hydrophobic, could be encapsulated into and protected by 
these delivery systems. The controlled release of chemotherapeutic drugs providing the 
optimum dosage for long periods will increase the efficacy of the drug, maximising 
patient compliance and enhance the ability to use highly toxic, poorly soluble, or 
relatively unstable drugs. A very recent study developed a curcumin (CUR)-
encapsulated nano-particle (NP) tri-conjugate consisting of RNA aptamer (Apt-CUR-
NPs) against epithelial cell adhesion molecule (EpCAM) and lipid polymer lecithin 
hybrid nanoparticles encapsulating curcumin for targeted delivery to colorectal 
adenocarcinoma cells. The tri-conjugates exhibited enhanced uptake and increased 
binding to HT29 colon cancer cells compared to CUR-NPs conjugated with a control 
aptamer, as measured by confocal microscopy and flow cytomtery (p < 0.01). In 
addition, a substantial improvement in cytotoxicity towards target HT29 cells was 
achieved along with increased bioavailability of delivered CUR was observed in vivo 
over a period of 24 hours compared to that of free CUR (Li et al., 2014).  
 
There have also been reports where uptake of ligand functionalised nano-particles 
conjugates can occur via an endocytic mechanism (mostly macropinocytosis related) 
other than receptor mediated pathway (Iversen et al., 2012). In addition, the increased 
endosomal escape with nanoparticles has been demonstrated by few other studies, and 
therefore, combining the strategies of aptamer, nano-particle and drug delivery to target 
tumour cells will be potentially effective in glioma treatment (Pittella et al., 2011; 
Gilleron et al., 2013). Moreover, such combination of targeted drug delivery and 
controlled release technology may pave the road to more effective yet safe 
chemotherapeutic options for glioma therapy. Thus, further studies need to be carried 
out to elucidate the interaction between aptamer-nanoparticle drug conjugate for 
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optimising the drug delivery system, however, the interaction between aptamers and the 
target still needs to be understood, which will facilitate the action of these tri-
conjugates. In addition, much work remains to be done before these conjugated 
materials can be used in clinical practice such as understanding the transport of 
aptamers to the cancer locale, the interactions between aptamers and cancer cells, the 
intracellular trafficking of aptamers within cancer cells and the subcellular density. The 
study utilised paraffin-embedded formalin fixed tissue samples for determining the 
potential of aptamers in histological diagnosis of glioma. Use of such fixed tissues 
however, may have a possibility of altering the composition or structure of epitopes 
during the tissue processing methods. Use of unfixed frozen tumour tissues over fixed 
waxed tissues can minimize tissue processing and preserve the natural presentation of 
epitopes. Treating aptamers on frozen tissues will further assist to acquire clearer 
conclusions and support the current findings on aptamer targeting to tumour tissues.  
 
In conclusion, the results of the study have laid the foundation for future work that will 
demonstrate the therapeutic value of targeted drug delivery through the conjugation of 
aptamer – nanoparticle - drug. It is indicated that the aptamer target molecules may also 
provide useful information for explaining the mechanism of oncogenesis. Meanwhile, 
although the study has produced abundance of in vitro data stating that the reported 
aptamer SA43 DNA have more binding selectivity for glioma cells and tissues 
compared to the control cells and tissues, it is of paramount importance to fill the gaps 
of the current knowledge by understanding the exact mechanism, stability, and aptamer-
target interaction. 
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Figure 8.1 Predicted mechanisms for targeted drug release through the use of 
aptamer-nanoparticle-drug conjugate. A Model consisting of aptamer-nanoparticle 
drug conjugate, B Tri-conjugate showing cellular association (1), internalisation via 
endocytosis, endosomal escape of the tri-conjugate, lysosomal degradation of tri-
conjugate, therapeutic drug freely diffuses into cytoplasm leading to controlled drug 
release, cytoplasmic transport of therapeutic drug to the target organelle; (2), 
Internalisation via macropinocytosis or phagocytosis; (3), cellular internalisation and 
releasing the drug without any association with endosomes or lysosomes, (4) recycling 
and exocytosis of nano-particles.  
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8.6 Summary 
In summary, the results provided a proof-of-concept for the use of RNA and DNA 
aptamers in targeting glioma cells. The assays described in the study provided a 
powerful tool for assessing and confirming the internalisation potential and cellular 
localisation of the selected aptamers. The selective binding capability of aptamers 
studied, suggested that the interaction of the aptamer and target largely depends on the 
nature of the aptamer sequence. From the shortened aptamers studied, SA43 DNA 
exhibited selective in vitro targeting on tumour targets on both live and fixed glioma 
cells, and most importantly glioma tissues. The key consequence of the internalising 
property of the aptamer SA43 DNA is the ability to accumulate inside the tumour cells, 
thus routing their therapeutic cargoes to intracellular sites relevant to their action. The 
current approach will hold particular promise in aptamer – nanoparticle – drug delivery 
for studying targeted therapeutics. The selective binding capability of aptamer SA43 
DNA and the sensitivity to glioma tissues will hold promise in histochemical diagnosis 
of glioma. Moreover, the small size of the aptamer, non-toxicity to cells, and negligible 
binding to endothelial cells will potentially allow the aptamer to cross BBB via EPR 
effect. This will further allow testing the potential of aptamer-nanoparticle-drug 
conjugate for their enhanced efficacy in targeting tumour cells in vivo. Importantly, 
these efforts promise to expedite the development of the aptamer- based approaches for 
delivering therapeutic drugs to the cytoplasm of the target cells and possibly facilitate a 
more rapid translation for therapeutics to humans. 
Appendices 
 
 
 
204 
APPENDICES 
 
Appendix 1. Description and specifications of the cell lines and their media. 
 
Cell lines Description Culture Medium (Lonza, 
UK) 
Media constituents 
1321N1  Astrocytoma 
WHO grade II 
Dulbecco’s Modified Eagle 
Medium (DMEM), 
10 % FBS and L-glutamine 
(2 mM) 
1 mM sodium bicarbonate 
1.0 g/l glucose 
25 mM Hepes 
0.0011 g/l phenol red 
 
T24  Highly malignant  
grade III human 
urinary bladder 
carcinoma 
U87MG Glioblastoma 
WHO grade IV 
Eagle’s Minimum Essential 
Medium (EMEM), 10% FBS, 
L-glutamine (2 mM), Sodium 
pyruvate (5 mM) and  NEAA 
(5 mM) 
2.2 g/l sodium bicarbonate 
4.5 g/l glucose 
10 mM Hepes 
0.0053 g/l phenol red 
 
T98G Grade IV 
glioblastoma 
SVGP12 Non-cancerous 
foetal astrocytes 
MCF-7  Human mammary 
gland 
adenocarcinoma 
cell line 
  
 
Appendix 2. Formulation and storage conditions of reagents used in cell culture. 
 
Reagent Storage Constituents Supplier 
Fetal Bovine 
serum (FBS) 
-20°C Heat inactivated FBS Lonza, UK 
L-glutamine -20°C 200 mM L-glutamine Lonza, UK 
Non essential 
amino acid 
2-8°C 100x non essential amino acid Lonza, UK 
Phosphate buffer 
saline (PBS, 1x) 
Room 
temperature 
8 g/l NaCl, 0.2 g/l KCl,  
1.44 g/l Na2PO4 
0.24 g/l KH2PO4, pH 7.4. 
Fisher scientific, 
UK 
Trypsin EDTA -20°C 0.5 g Porcine trypsin 
0.2 g EDTA 
Lonza, UK 
Dimethyl-
sulfoxide (DMSO) 
Room 
temperature 
99.5% dimethyl sulfoxide, 
0.81% sodium chloride 
Lonza, UK 
Trypan blue  
 
Room 
temperature 
0.81% (w/v) sodium chloride 
0.06% (w/v) potassium 
phosphate dibasic  
Sigma, UK 
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Appendix 3. DVD inserted showing Z stacks and merged Cy3 and DAPI image of 
SA43 DNA on U87MG, 1321N1 and SVGP12 at various time points as measured by 
confocal microscopy.  
 
  Appendix 4. Patient’s demographics 
 
BTNW no. Diagnosis Bx site Age Gender 
625 Normal brain R frontal 51 F 
713 Normal brain R posterior fossa 39 F 
596 Normal brain L frontal 60 M 
7 Normal brain R temporal 66 M 
106 Normal brain R temporal 42 F 
136 Normal brain R temporal 51 F 
678 Normal brain R frontal 48 F 
713 Normal brain R posterior fossa 39 F 
8 Normal brain R frontal 38 F 
83 Normal brain L temporal 57 M 
225 Normal brain R temporal 26 F 
321 Normal brain L parietal 72 M 
356 pilocytic astrocytoma I Posterior fossa 25 M 
720 pilocytic astrocytoma I Posterior fossa 65 F 
814 pilocytic astrocytoma I L cerebellar 
pontine angle 
23 F 
1043 Ganglioglioma I R frontal 16 M 
422 Pilocytic astrocytoma I L posterior fossa 25 M 
632 Ganglioglioma I L temporal 38 F 
801 Subependymona I 4th ventricle 52 M 
680 astrocytoma II R temporal 59 M 
726 oligoastrocytoma II R occipital 45 M 
736 astrocytoma II L temporal 63 F 
740 astrocytoma II L frontal 46 M 
761 astrocytoma II L temporal 24 M 
934 Diffusely infiltrating LGG II L frontal 30 M 
1005 Mixed glioma / Glioneuronal 
II 
R occipital 43 F 
1028 Gemistocytic astrocytoma II Not stated 40 M 
1044 Infiltrating LGG II R frontal 27 M 
1047 Ependymona II L occipital 52 F 
681 astrocytoma III L occipital 75 M 
629 astrocytoma III R parietal 39 F 
686 oligoastrocytoma III R parietal 56 M 
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703 oligoastrocytoma III R frontal 46 M 
738 oligodendroglioma III L frontal 66 M 
883 Oligodendroglioma III L frontal 59 F 
925 Astrocytoma III R parietal 78 M 
962 Astrocytoma III L parietal 66 F 
1021 Astrocytoma III L frontal 56 F 
1051 Astrocytoma III L occipital 34 M 
1066 Oligodendroglioma III R temporal 59 M 
933 Cavernoma high grade  R frontal 41 M 
693 GBM IV L frontal 74 M 
748 GBM IV L frontal 49 M 
749 GBM IV L frontal 45 F 
758 GBM IV L frontal 49 M 
769 GBM IV L frontal 70 M 
789 GBM IV L frontal 41 M 
794 GBM IV R parietal 77 M 
806 GBM IV R parafalcine 66 F 
807 GBM IV L frontal 79 M 
1054 GBM IV R frontal 42 M 
1077 GBM IV R frontal 65 M 
1078 GBM IV R parieto-occipital 79 M 
1086 GBM IV R frontotemporal 41 M 
1088 GBM IV L frontal 74 M 
1090 GBM IV L parietal 73 F 
1094 No tumour biopsy R frontal 32 M 
13 Oligoastrocytoma II R temporal 52 F 
20 Astrocytoma II L frontal 26 M 
62 Ependymoma II 4th ventricle 34 F 
65 Diffuse astrocytoma II L frontal 25 M 
158 Diffuse astrocytoma II L temporal 74 M 
160 Astrocytoma II L tempero-frontal 35 M 
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Appendix 4. Total binding scores for each aptamer treated on non-cancerous tissues.  
 
 
 
Appendix 5. Total binding scores for each aptamer treated on Grade I patients tissues 
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Appendix 6. Total binding scores for each aptamer treated on Grade II patients tissues  
 
 
 
 
Appendix 7. Total binding scores for each aptamer treated on Grade III patients tissues  
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Appendix 8. Total binding scores for each aptamer treated on Grade IV tissues 
 
 
 
Appendix 8. Total binding scores for each aptamer treated on meningioma tissues 
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